Credible Source of Information / Benefits Campaign - Results

4/10/2007 page 1

AGENDA Corporate Circle/Corporate Visionary Molecular Imaging Campaign Meeting

April 6, 2007 Hyatt Hotel (Rm: Reston Suite A) - Reston, Virginia

Objectives of the Meeting:

Report on Campaign Fundraising Progress Review and Solicit Input on Strategic Plan Progress Review and Solicit Input on Future Plans

Topic Time Discussion Leader

Continental Breakfast

8:00-8:30

1.Welcome and Introductions Orientation

8:30-9:00 Martin Sandler, M.D. SNM President

2. Campaign Report – Fundraising Progress

9:00-9:15 Katy Bates Director of Development

3. Molecular Imaging Center of Excellence –An Overview Strategic Plan & Task Force Overview Year 1 Update Advocacy Program at SNM’s Annual

Meeting Rebranding Financial Report Feedback/Question & Answer

9:15-10:00 Marty Pomper, M.D. .

Coffee Break

10:00-10:15

4. Plan Moving Forward Strategic Plan for Years 2-3 Feedback/Question & Answer

10:15-11:15 Marty Pomper, M.D.

5. Other Issues Industry Expert Summit Meeting frequency Feedback mechanisms Other items from audience

11:15-12:00 Virginia Pappas, CAE

Adjournment

12:00

MI Campaign Corporate Circle & Corporate Visionary Attendee List

SNM Leadership

Martin P. Sandler, M.D. SNM President Vanderbilt University Medical Center Department of Radiology and Radiological Sciences Nashville TN 37232-2675 Assistant: Janet Staley Phone: 615-322-0860 Fax: 615-343-2330 E-mail: [email protected] E-mail: [email protected]

Alexander J. McEwan, M.D. SNM President-Elect Department of Oncologic Imaging 11560 University Avenue Edmonton AB T6G 1Z2 Canada Assistant: Cheryl Loeffler Phone: 780-432-8524 Fax: 780-432-8483 E-mail: [email protected] E-mail: [email protected]

Robert W. Atcher, Ph.D., M.B.A. SNM Vice President-Elect UNM/LANL Professor of Pharmacy Program Manager, HHS Programs Mailstop M888 Bioscience Div. Los Alamos National Laboratory Los Alamos, NM 87545 Phone: 505-667-0585 Fax: 505 667 8339 Pager: 505 996 1956 E-mail 1: [email protected] E-mail 2: [email protected]

Peter S. Conti, M.D., Ph.D. SNM Immediate Past President (Bench to Bedside Co-Chair) Professor University Southern California 1510 San Pablo Street Suite 350 Los Angeles, CA 90033 Phone: (323) 442-5940 Fax: (323) 442-5778 E-mail: [email protected]

MI Center Leadership

Martin G. Pomper, MD, Ph.D. President SNM Molecular Imaging Center of Excellence Johns Hopkins University Department of Radiology 600 N. Wolfe Street Phipps B-100 Baltimore, MD 21287-2182 Phone: 410-955-2789 Fax: 410-614-1213 E-mail: [email protected]

Henry F. VanBrocklin, Ph.D. Vice President SNM Molecular Imaging Center of Excellence University of California San Francisco Dept of Radiology, UCSF 185 Berry Street, Suite 350 San Francisco, CA 94107 Phone: 415-353-4569 Fax: 415-353-9421 E-mail: [email protected]

Carolyn J. Anderson, Ph.D. Secretary/Treasurer SNM Molecular Imaging Center of Excellence Washington Univ. Med. School 510 S. Kings Hwy Blvd Box 8225 St. Louis, MO 63110 Phone: 314-362-8427 Fax: 314-362-9940 E-mail: [email protected]

Michael D. Devous, Sr., Ph.D. Bench to Bedside Co-Chair University of TX SW Medical Center Nuclear Medicine Center 5323 Harry Hines Boulevard Dallas, TX 75390-9061 Phone: 214-648-3315 Fax: 214-648-5641 E-mail: [email protected]

Corporate Circle / Corporate Visionary

Hadi Moufarrej GM Global Molecular ImagingGE Healthcare 3000 N Grandview Blvd., W1250Waukesha, WI 53188Phone: 262-312-7334 Fax: 262-548-5197 E-mail: [email protected] Assistant: Carla Palmer E-mail: [email protected]

Richard A Frank, M.D., Ph.D., FFPM Vice President, Medical Affairs and Clinical Strategy GE Healthcare 105 Carnegie Center Princeton, NJ Phone: 609-936-6028 *211 6028 Dialcomm Mobile: 609-933-0007e E-mail: [email protected] Assistant: Lerina Forster Phone: 609-936-6029 E-mail: [email protected]

Tom Burnett Global Marketing Director, SPECT Portfolio MDS Nordion 447 March Road Kanata, Ontario Canada K2K 1X8 Phone: 613-592-3400 x1443 Mobile: 613-286-1844 E-mail: [email protected]

Phil Larabie MDS Nordion 447 March Road Kanata, Ontario Canada K2K 1X8 Phone: 613-592-3400 E-mail: [email protected]

Susan L. Wallace, Ph.D. Vice President, Sales and Marketing Cardinal Health PET Services 2004 Tallgrass Circle Waukesha, WI 53188 Phone: 262-542-2118 Fax: 262-542-2146 E-mail: [email protected]

Anwer Rizvi Vice President, Sales IBA Molecular 100 Executive Drive Suite 100 Sterling, VA 20166 Phone: 703-787-7900 E-mail: [email protected]

Matt Shah Director, Strategic Planning Siemens Medical Solutions USA, Inc. Molecular Imaging 2501 North Barrington Road Hoffman Estates, IL 60195 Phone: 847-304-7370 Fax: 847-304-7707 E-mail: [email protected]

Thomas H. Tulip, Ph.D. Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road Building 600-1 N. Billerica, MA 01862 Phone: 978-671-8048 E-mail: [email protected]

Peter Martin, Ph.D. Director Business Development, Molecular Imaging Philips Medical Systems 595 Miner Road Zone 3, B:4 Cleveland, OH 44143-2131 Tel: +1 440.483.2558 Fax: +1 440.483.4379 Cell: +1 440.220.2375 E-mail: [email protected]

SNM Staff

Virginia M. Pappas, CAE Chief Executive Officer SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1241 Fax: (703) 708-9020 E-mail: [email protected]

Michael S. Nelson, CAE Chief Operating Officer SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1024 Fax: (703) 708-9020 E-mail: [email protected]

Megan Schagrin Associate Director, Industry & International Relations SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1214 E-mail: [email protected]

Pandora C. Rivera Program Manager, Leadership SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1027 Fax: (703) 708-9020 E-mail: [email protected]

Kathleen Bates Director, Development SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1028 Fax: (703) 708-9020 E-mail: [email protected]

Marybeth Howlett Director, Molecular Imaging Center of Excellence SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1026 Fax: (703) 708-9020 E-mail: [email protected]

Fundraising Progress Report

MI Campaign MeetingCorporate and Visionary Members

April 6, 2007

Current Status• Campaign is chaired by Peter Conti, MD/PhD (corporate),

Michael Devous, PhD (individual) and Hadi Mouffarej, GE Healthcare.

• Fundraising strategies are based on sequential solicitation, with key industry and SNM leaders having been solicited first.

Corporate Fundraising• Current corporate donations total $3,275,000. • Current donors include

– Corporate Circle:GE Healthcare, Bristol-Myers Squibb Medical Imaging, IBA Molecular, Siemens Medical Solutions USA

– Corporate Visionaries: Cardinal Health, Philips and MDS Nordion

– Corporate Friend: FlouroPharma. • Decisions are pending with 4 companies.• 130 companies have been contacted by mail and will be called• Contacts with major pharmaceutical companies are planned

Individual Fundraising• The Education and Research Foundation for the SNM (ERF) is responsible for

seeking individual support for the campaign.• The fundraising goal is $500,000 over five years.• $105,580 has been raised as of April 3, 2007. 89 donors have contributed.• The ERF Board is meeting with individual major gift prospects.• A campaign solicitation has been incorporated into the ERF Annual Report for

FY 2006, which is being sent to all members with the April JNM. Other all member solicitation mailings will go out periodically.

• Other fundraising strategies include:o Making presentations at chapter meetingso Seeking matching gifts wherever possibleo Targeting imaging practices o Holding fundraising events

BENCH TO BEDSIDE MOLECULAR IMAGING CAMPAIGN PROGRESS REPORT

MARCH 2007

Summary The Bench to Bedside Molecular Imaging Campaign—a $5 million, five-year fundraising initiative—was officially launched at the SNM annual meeting in June 2006. Campaign funds raised will support initiatives that advance molecular imaging to the forefront of patient care. These include: Outreach activities to referring physician and patient groups Support for translational clinical studies and small innovative trials Research grants and fellowships to advance new medical developments Expanded advocacy efforts Communications activities, including a new molecular imaging web site

Fundraising Progress To date, SNM has secured financial commitments of over $3.3 million from key corporate supporters and leaders in molecular imaging. Corporate commitments have been received from GE Healthcare Bristol-Myers Squibb Medical Imaging IBA Molecular Siemens Medical USA MDS Nordion Philips Cardinal Health FlouroPharma

In addition to corporate support, 88 SNM and SNMTS members have donated or pledged $100,580 toward the $500,000 SNM membership fundraising goal. The society and foundation leadership are continuing to reach out to the pharmaceutical industry, other companies that have a relationship with the SNM, and to all members of the society. Strategic Initiatives-First Year The Molecular Imaging Center of Excellence (MICoE) is the SNM entity responsible for carrying out the activities that will be financed by the Bench to Bedside campaign. Under the leadership of center chairman Martin G. Pomper, MD/PhD and staff director Marybeth Howlett, MEM the center has formed task force teams with medical and scientific experts in various core areas who are providing guidance in the creation of education and professional development programs, new grants and awards, and protocols and standards in the field. The task forces have reached out to include leaders from the MICoE, other SNM Councils and Committees, and individuals from the wider molecular imaging community.

1

Task Forces include: • Advocacy • Communications • Education • Grants and Awards • Leading Technologies and Assessment • Future Tracers • Membership • Standard Definitions

Task Forces’ Progress Advocacy-Activities The task force is reaching out to key medical and patient groups to identify areas of common interest and identify future collaborative educational/outreach activities. It is also developing a plan for strengthening relationships with federal agencies that support molecular imaging research. To facilitate these goals, the task force is developing an advocacy database of organizations. One of the major purposes is to determine collaborative and mutually beneficial activities that will advance molecular imaging and therapy research. A major advocacy initiative is planned to coincide with the Annual Meeting, including scheduled visits to Capitol Hill and a declaration of “Molecular Imaging Week”. Communications-Activities The task force is developing a plan for the creation of a molecular imaging web site that will serve as a central repository and provide on line information, education and training for various audiences. The website will serve to increase understanding about the benefits and applications of molecular imaging, create an interest in utilizing molecular imaging to advance patient care, and generate interest in utilizing molecular imaging to advance research in relevant areas. Concurrently underway is the planning for a major public relations campaign to communicate the new messages about SNM and molecular imaging. The task force is also developing a plan for brochures, case studies and other resources for physicians and researchers in basic biological sciences that illustrate the practical significance of molecular imaging. The MICoE Editorial Board is also responsible for several important communications activities. It will oversee the publication of a quarterly newsletter—MI Gateway—and monthly email blasts that contain molecular imaging references and news. The first issue of the newsletter will be published in the spring and sent to all donors to the Campaign. This newsletter will provide updates on campaign activities and feature articles on molecular imaging. The Editorial Board also provides monthly articles and references to Newsline and has submitted suggestions for molecular imaging topics and authors to the JNM Editor. A molecular imaging supplement to the Journal is planned for late 2007. Education-Activities

• The SNM midwinter meeting was held February 16-18, and it featured Advances in Cardiovascular Imaging, Advances in Molecular Imaging of the Brain, and several presentations on hybrid imaging.

• A “Molecular Imaging Gateway” has been created for the 2007 SNM annual meeting that will include posters and booths from academic and government molecular imaging centers and other societies. In addition, molecular imaging papers and sessions with be flagged with a special icon.

• The development of a molecular imaging speakers and experts bureau that can be accessed by SNM chapters, patient organizations and others has begun.

2

• The task force has begin the development of a curriculum outline for fellows and residents in molecular imaging.

Grants and Awards- Activities The task force has begun to identify specific grants and awards in molecular imaging that will advance research and support for professionals. The task force expects to recommend a list of grants and awards for approval by the SNM Board in June. Funding for the grants and awards will be provided in part by the Education and Research Foundation for the SNM. Leading Technologies and Assessments and Future Tracers – Activities These two task forces will coordinate a series of retreats and workshops in 2007 and early 2008. The first retreat, “Bringing Molecular Imaging from Bench to Bedside,” will focus on what can be done in the short term (< 5 years) to realize molecular imaging benefits in the clinical environment. The second workshop will be a working retreat that will broadly review molecular imaging leading-edge technologies and evaluate issues associated with each. Using the results of the first two meetings, a third workshop will evaluate future molecular imaging agents to determine what is needed to validate them for clinical use. Lastly, a Leading Technologies Advancement workshop will bring together the ideas generated in the first three workshops to examine the pathways for gaining acceptance of new molecular imaging technologies and identify key barriers to moving them from the research environment to the bedside. Membership- Activities This newly created task force will be focusing on developing a recruitment plan to increase membership of professionals involved in molecular imaging and therapy. Standard Definitions-Activities The task force developed a definition of molecular imaging that was approved by the SNM BOD and further terminology will be developed. This activity is critical to the foundation of all communications, education and advocacy activities. For additional information on support for the Campaign contact: Kathleen Bates, Director of Development Voice: 703-326-1194; email: [email protected] For additional information on strategic initiatives and their implementation: Marybeth Howlett, Director, Molecular Imaging Center of Excellence Voice: 703-652-6798; email: [email protected]

3

The Education and Research Foundation for the SNM thanks the donors listed below for their generous support of the MI Campaign.

MI Leadership Circle Terence Beven, MD♦Robert F. Carretta, MD♦Michael D. Devous, Sr., PhD♦Gary L. Dillehay, MD♦Frederic H. Fahey, D.Sc ♦Peter T. Kirchner, MD♦Sandy McEwan, MD♦Nuclear Medicine Division, Radiological Associates of Sacramento♦Heinrich R. Schelbert, MD, PhD♦Daniel Skovronsky, MD, PhD♦SNM Pacific Southwest Technologist Section MI Visionaries Naomi Alazraki, MD and Andrew Taylor, Jr., MD♦Kathleen Bates♦Roy W. Brown♦ Nanci A. Burchell, CNMT, FSNMTS♦ Peter S. Conti, MD, PhD♦Valerie R. Cronin, CNMT, FSNMTS♦Michael M. Graham, PhD, MD♦Warren R. Janowitz, MD, JD♦Frances K. Keech, MBA, RT (N), FSNMTS♦Joe C. Leonard, MD♦Warren H. Moore, MD♦Conrad E. Nagle, MD♦Richard B. Noto, MD♦Virginia Pappas, CAE♦Lynne T. Roy, CNMT, FSNMTS, MBA♦Henry Royal, MD♦Martin P. Sandler, MD♦Henry Van Brocklin, PhD♦Susan C. Weiss, CNMT, FSNMTS♦Louis Zeiger, MD MI Partners Robert W. Atcher, PhD, MBA♦ Danny A. Basso, CNMT, NCT, FSNMTS ♦Chaitanya R. Divgi, MD♦Kevin J. Donohoe, MD♦Mark T. Madsen, PhD♦Cindi-Luckett-Gilbert, BHS, CNMT, PET, RT(N)♦April Mann, CNMT, FSNMTS, RT(N) ♦Raymond Marty, MD♦Alan H. Maurer, MD♦Paul H. Murphy, PhD♦David C. Sager ♦Edward B. Silberstein, MD♦Mathew and Lalita Thakur♦Kathy S. Thomas, CNMT, FSNMTS♦Michael J. Welch, PhD♦George Zubal, PhD MI Contributors Anonymous♦Hussein M. Abdel-Dayem, MD♦Carolyn J. Anderson, PhD ♦Carol Bonanno, CNMT♦Deborah Barnes, CPA♦Rebecca S. Bock, CNMT♦Barbara Y. Croft, PhD♦Simin Dadparvar, MD♦Dominique Delbeke, MD, PhD♦Jesus Diaz, MD♦Kent P. Friedman, MD♦James R. Galt, PhD♦Michael and Janelle Gelfand♦Stephen K. Gerard, MD♦David Gilmore, MS, CNMT, NCT, RT (R) (N)♦Dilip Gohil, CNMT♦Leonie L. Gordon, MD♦Bennett S. Greenspan, MD♦Art J. Hall, CNMT, FSNMTS♦Peter Herscovitch, MD♦D. Scott Holbrook, BS, CNMT, FSNMTS♦Marybeth Howlett, MEM ♦R. Bruce Jordan, MD♦K.C. Karvelis, MD♦William Ladd, MD♦David H. Lewis, MD ♦Edward L. Lyons, Jr., RT(R), CNMT♦Darlene F. Metter, MD♦Mary Anne Own, MHE, RT(N)♦Alan B. Packard, PhD♦J. Anthony Parker, MD, PhD♦Martha W. Pickett, CNMT, FSNMTS♦Nancy A. Price, CNMT♦Patrick F. Rossitto, CNMT♦Eileen O. Smith, MBA, CNMT♦Nancy M. Swanston, CNMT, RT(N)♦Amol M. Takalkar, MD♦Mark Tulchinsky, MD♦Harish Vaidya, CNMT, NCT MI Friends Leonard M. Freeman, MD♦Lynnette A. Fulk, CNMT, FSNMTS♦Karen A. Kurdziel, MD Legend: MI Leadership Circle ($5,000-$24,999); MI Visionaries ($1,000-$4,999); MI Partners ($500-$999); MI Contributors ($100-$499); MI Friends ($10-$99) List as of April 2, 2007

1

Companies in receipt of March 2007 Campaign Solicitation Letter ABX Advanced Biochemical Compounds Academy of Molecular Imaging AccSys Technology, Inc. Accusync Medical Research Advanced Cyclotron Systems, Inc. AHRA AirNet Amici, Inc. Anazao Health Corporation Anzai Medical Company, Ltd. Applied Radiology Associates In Medical Physics, LLC Astellas Pharma US, Inc. Aureus Medical Group BC Technical, Inc. Becquerel & Sievert Co., Ltd. Best Medical International Biodex Medical Systems, Inc. Biodose Bio-Imaging Technologies, Inc. Bioscan, Inc. Calutech Mobile Solutions Cambridge Isotope Laboratories CardiArc, Inc. Cardiovascular Imaging Technologies Care Wise Medical Products Charles River Laboratories CIS-US, Inc. CNMTstore Codonics Comecer SRL Creatv Microtech, Inc. Cyclomedica Australia Pty Ltd. Cyclomedical Applications Group LLC Cytogen Corporation Data Spectrum Corporation Daxor Corporation Diagnostic Imaging Digirad Dilion Technologies DMS Health Group DraxImage, Inc. echelon Encore Global Imaging Frontier Imaging, LLC Gamma Medica-Ideas Genzyme Corporation

Gravatom Engineering Systems Ltd. GVI Medical Devices Health Imaging Media Huayi Isotope Co. Imaging Economics/Medical Imaging Imaging Technology News Immunomedics, Inc. IN/US Systems - NeuroPhysics Informa Healthcare InSight Health Corporation INVIA IS2 Medical Systems IsoRx, Inc. ISOTEC Iso-Tex Diagnostics, Inc. Isotope Products Laboratories ITT Information Solutions Ivy Biomedical Systems, Inc. JML Biopharm Inc. Laboratory Impex Systems Ltd Lemer Pax Lippincott, Williams & Wilkins M & O Perry Industries Macrocyclics, Inc. MarCal Medical, Inc. Marshall Isotopes Ltd. Maxim Travel Allied Med Travelers Medi/Nuclear Corporation, Inc. Medical Coaches Incorporated Medical Imaging Resources, Inc. MedImage, Inc. Medi-Nuclear Corporation Mediso Medical Imaging Systems MEDX, Inc. Mid-Atlantic Imaging Services MiE America, Inc. MILABS MIMvista Naviscan PET Systems NMTCB North American Scientific Nuclear Diagnostic Products Nuclear Fields NUKEM NukeMed Numa

-Continued on Reverse Side-

NuView Radiopharmaceuticals, Inc. Pinestar Technology, Inc. PMOD Technologies QSA-Global Inc. (formerly AEA Technology) R.W. Wiesener, Inc. Radiation Products Design, Inc. Radiology Today Radqual, LLC Raytest, USA Resources On Call Rotem Inc. Saint-Gobain Crystals Sam Young Unitech Co., LTD Schering AG Segami Corporation Shang Hai Siccas high Technology Corporation Shell-USA, Division of SAI Sirtex Medical, Inc. Sony Electronics Inc. Spectrum Dynamics Ltd Springer SynterMed, Inc. Taiyo Nippon Sanso Corporation Tema Sinergie SRL TeraRecon, Inc. The Gollman Group, Inc. Thinking Systems Corporation ThyCa Thyroid Cancer Survivors tis-Technology Imaging Services Tomographix IP Ltd. Trace Sciences International Corporation Trionix, Inc. UltraSPECT United Pharmacy Partners, Inc. Universal Medical Resources, Inc. Von Gahlen International, Inc. Vulcan Global Manufacturing Solutions W.B. Saunders/Mosby Wako Chemicals USA, Inc., LAL Division

5 Year Strategic Plan Pg. 2

Overview• A strategic planning group consisting of SNM leadership, senior staff

and the Molecular Imaging Center Board members met at various times between April and September 2006 to develop SNM’s long-range strategic direction and create a strategic plan for the Molecular Imaging Campaign. This planning document defines SNM’s clear strategic direction for the campaign. It is the planning group’s consensus on what will constitute its future success.

Strategic Approach:• The approach in defining the new strategic direction was not to identify

what SNM is doing today, but to determine what is not being done today, and must be done in the future to be successful. This strategic direction is not about business as usual — it is about change!


Long Range Strategic Planning Horizon10-30 Year Envisioned Future

• The new core purpose describes SNM’s very reason for being or existing — why the Society will or should exist for a long time (10 to 30 years). SNM leadership decided to refocus SNM on the future needs of the profession.

SNM’s New Core PurposeTo improve health care by advancing molecular imaging and therapy.

• Core values are a small set of timeless, guiding principles that do not require external justification. They only have intrinsic value and importance to SNM and its members. Core values are so fundamental that they seldom change — if at all. They define the behavior required in order for the organization to achieve its core purpose. Core values are so deep-seated and valid that the Society would preserve the core valueseven if it were admonished for having these values.

Core ValuesHighly principled, ethical behavior

IntegrityA reputation for honesty

Respect for allFoster inquiry and reflection

Courage and leadership in the face of changeCamaraderie

Commitment to excellence


Big Audacious Goal

The B.A.G. is a huge challenge and its achievement will require SNM to move outside of its comfort zone. The goal can be accomplished and has a clear finish line, but will require a heroic effort and luck. The goal will stimulate membership activity, commitment, and participation beyond SNM 's present leadership. It sets the direction for the succession of future three to five year strategic plans.

Big Audacious Goal

SNM will be the leader in unifying and advancing molecular imaging and therapy.


Vivid Description

This vivid description shows what the world would be like if SNM should complete its Big Audacious Goal. SNM plans to complete the goal through the MI Campaign activities.

SNM will have:• increased visibility in the medical community as the recognized leader for advancing molecular imaging and therapy.• developed the capability and strategic position that enables it to be the advocate and unified voice for molecular medicine, including imaging and therapy.• significantly increased both the visibility and understanding of molecular imaging and therapy within the medical community, key stakeholders and targeted public audiences.• achieved significant success in educating and promoting collaboration with referring physician and patient groups.• developed a number of interactive and collaborative relationships with a variety of for-profit, public and private organizations.•become branded for providing leading edge programs, knowledge and networking forums that contribute to member’s ability to advance molecular imaging and therapy.• become a powerful supporter of translational research.


Three to Five-Year Envisioned Future

• strong financial viability and capability.• a number of new educational programs,

services and networking opportunities that are highly valued by members.

• increased its staff’s resources, expertise and capabilities.

• made use of the latest technology at the staff level, in communication with all audiences, and in providing education and knowledge to members.

• increased membership and membership retention.

• increased non-dues revenue.

By 2010, SNM will have:• increased awareness, recognition and visibility

(branding) with all key stakeholder audiences.• developed a number of strategic partnerships,

collaborative relationships and coalitions with a wide variety of organizations.

• become a powerful advocate for molecular imaging and therapy in the legislative arena.

• created increased awareness, understanding and use of molecular imaging and therapy in the medical community.

• developed increased support for critical translational research.

• provided additional resources to members for education and knowledge.

• a world class website that is highly used by members and the outside world.

An envisioned future is a simple and concise picture of an ideal, desired future for the organization three to five years. The envisioning process is the leadership team-reaching consensus on what future success will look like. By engaging in an envisioning process, the Society is already beginning to create its own future. It sets direction and helps to focus SNM’s strategic planning efforts. The envisioned future does not supplant the 3 to 5 year strategic plan, it comes before it. The envisioned future sets the tone and direction for the strategic planning process.


The following represents SNM’s long-range goals for the Molecular Imaging Campaign that encompass its three to five year direction. These goals are outcome-oriented statements that lead towards its envisioned future. These goals are not in any order of priority. All of the goals will need to be accomplished, if SNM is to fully achieve its three to five year quest.

In 2010:

• Goal A) SNM will be members’ indispensable resource for education, knowledge exchange, training and networking.

• Goal B) SNM will be the powerful advocate for molecular medicine, including imaging and therapy.

• Goal C) SNM will be the leader in educating and promoting collaboration with referring physician and patient groups.

• Goal D) SNM will be a significant supporter of innovations in translational research.• Goal E) SNM will be recognized as the society, which positions molecular medicine as

an essential tool in providing the highest standards of patient care around the world.

Long-Range Goals


Goal A SNM will be member’s indispensable resource for education, knowledge

exchange, training and networking

Train the current workforce and help educate future generations of practitioners in molecular imaging.

–Educate core members about principles, and concepts on molecular imaging–Design in training and CE education activities/programs for core members and other professionals in molecular imaging

• Restructure Annual and Midwinter meetings to accommodate more molecular imaging. 2 years

• Create new molecular imaging track at the Annual Meeting• Molecular imaging workshops of the kind formerly supported

by DOE. • Molecular imaging road show “101” at SNM regional chapters

and other like venues. • Expand LLSAP for other member groups and MI practitioners. • Web-based programs and printed materials.• Video production of road shows and other educational

meetings to be used for online education and training.• Develop JNM Supplement and increased articles concerning

molecular imaging topics in the journal.

Organize and lead industry and professional society summits, international cooperative groups and workshops in Molecular Imaging to promote exchange of ideas, protocols and scientific date for molecular imaging and establish a foundation for networking. 5 years.

• Foster education and information dissemination in developing countries.

• Provide grants to academic institutions to host small workshops on molecular imaging topics.

• Develop curriculum for other member groups.• Conduct symposia to bring together experts in the field of

molecular imaging in an effort share research results, diagnostic protocols and therapy innovations.

• Maintain and improve journal standing as the best in medical imaging

–Identify further efforts to include molecular imaging research and information in JNM.–Define what measures are needed to increase references and influence of journals.

• Become the resource for molecular imaging books.–Create a comprehensive book resource within SNM to improve value for members and reinforce centrality of society to molecular imaging.–Create publishing plan for new SNM books on essential molecular imaging topics.

Objectives & Strategies:A1 Position SNM as a central education repository for molecular imaging.




Objectives & Strategies:A2. Create and award grants and fellowships for individuals interested in

molecular imaging.• Work with funding agencies to identify additional resources to host workshops for trainees. • Include molecular imaging as an area of interest in all current research grants and

awards designated by SNM. • Identify University training sites and develop cooperative agreements to host trainees;

make/track awards. Include molecular imaging as an area of interest in all current research grants and awards designated by SNM.

• Molecular imaging fellowships for MD/PhDs and PhD to support training in interdisciplinary research.

• Competitive grants for institutions to sponsor intensive training workshops on molecular imaging topics.

• Fellowships and grants for students pursuing MD/PhDs and PhD degrees in molecular imaging.




Objectives & Strategies:A3. Develop fellowship and residency curriculum.• Non-ACGME Fellowship in basic science and translational research. • ACGME Residency and Fellowship programs accepted by ABNM and ABR. • Develop curriculum on molecular imaging for residents, technologists and other professional

groups.

A4. Attract and address diversified needs of nuclear medicine and molecular imaging practitioner.

• Create membership campaign to attract molecular imaging professionals.• Develop workshops, symposia and forums to meet the diverse educational needs and inter-

disciplinary nature of the SNM membership and molecular imaging community.




Objectives & Strategies:A5. Meet the needs for all relevant audiences in continuing professional development.• Meet the needs for all relevant audience for maintenance of certification and pay-for-performance

requirements of nuclear medicine and molecular imaging.• Identify, define and demonstrate the standards in nuclear medicine and molecular imaging such as

competencies, core curriculum, and guidelines.• Determine how SNM will take the lead role in certification and credentialing for molecular imaging.

A6. Perform clinical trials in nuclear medicine and molecular imaging.• Formulate the key questions that are needed to design appropriate clinical trials in nuclear medicine and

molecular imaging.• Support small, innovative trials in diagnostic and therapeutic radiopharmaceuticals through the SNM Clinical

Trials Group.

A7. Complete and implement an internal communications plan to communicate to members and member groups that the society is their indispensable resource for molecular imaging.

• Facilitate the movement/exchange of information along all channels within the society in order to achieve clear, coordinated and effective messaging to internal groups: members, chapters, councils, COEs.

• Review the Web site with the key messages in mind; ensure coherent Web presence; ensure ease of use and access.


Goal B SNM will be a powerful advocate for molecular medicine, including

imaging and therapy.

Objectives & Strategies:B1. Take a proactive role in lobbying for reimbursement and research

funding.• Intensify advocacy in Congress and cultivate relationships with relevant federal agencies

such as DOE, NSF, DHS, FDA and NIH. 2 years• Partner with medical association to conduct presentations to advise medical stakeholders

about molecular imaging technology. 2-5 years• Identify and address key legislative and regulatory issues for molecular imaging and

therapy.• Develop a common listserv of those involved in MI to facilitate exchanges of information,

such as announcements of funding opportunities.


Goal B SNM will be a powerful advocate for molecular medicine, including

imaging and therapy.

Objectives & Strategies:B2. Educate community on benefits of molecular imaging and emerging

technologies.• Develop a media plan to educate community.

– Identify targeted patient advocacy groups, drug companies and funding agencies. Develop a molecular imaging speaker’s bureau to provide lecturers to a variety of audiences on current and anticipated diagnostic and therapeutic methodologies.

• Collaborate with comparable medical organizations to seek consensus on major molecular imaging initiatives.

– Facilitate the collaboration of industry representatives, trade associations, medical societies, patient groups and others for the advocacy of molecular imaging and therapy, with a primary focus on legislative and regulatory priorities as well as general outreach.

– Develop a website that provides access to publications and ongoing research in the field. Establish joint molecular imaging events, workshops, and educational materials with like minded medical organizations, patient groups, government agencies and others.

– Organize symposia to educate the general public, legislators, and regulatory personnel on benefits of molecular imaging technology.


Goal C SNM will be the leader in educating and promoting collaboration with

referring physicians and patient groups

Objectives & Strategies:C1. Create outreach program aimed at referring physicians, patient

groups, federal agencies, regulators and general public.

• Develop standardized definitions and terminologies for molecular imaging outreach. 1 year• Organize a speaker’s bureau. 2 years• Launch series of primers on molecular imaging published by JNM as supplements. 2 years• Organize a series of joint symposia at non-imaging professional societies. 2-5 years.• Educate and solicit input from pharmaceutical companies about molecular imaging in drug development. 2-

5 years• Develop mechanism for in house technology evaluation and create position statements on how these

technologies can become viable. 5 years• Collaborate with other medical organizations focused on imaging to achieve rapid action toward expanding

the role of molecular imaging in research and in patient care.• Membership and participation in coalitions such as the National Coalition for Cancer Research.• Push patient informed link.• Hold a summit with patient groups and industry to identify issues and educational needs.• Further develop the existing information for patients on SNM’s website.• Create new/revise SNM patient pamphlets.• Attend and speak at referring physician and patient group meetings.


Goal D SNM will be a significant supporter of innovations in translational

research

Objectives & Strategies:D1. Define translational research from bench to bedside — research to

practice

D2. Institutional grants for training workshops on translating basic research into clinical application.

D3. Develop research programs to assist new investigators in the field of molecular imaging.

• Award and track pilot research grants for young investigators. • Provide bridge funding to investigators entering the field of MI and therapy.

D4. Identify new funding opportunities.• Solicit funding by agencies not traditionally associated with imaging research

(Howard Hughes, Gates Foundations). Work with NIH to organize workshops in MI and create funding opportunities for novel technology research and early phase clinical trials.



research

Objectives & Strategies:D5. Develop standardized imaging protocols, outcome measures and the

role of biomarkers in clinical trials• Work with FDA, NCI, ACR and other UPICT committee members to have standard protocols

for PET and PET/CT. 2 years• Have fully staffed clinical trials workgroup within SNM to conduct Phase I/II trials of MI

probes and devices. 5 years• Foster the development of multi-center clinical trials.

D6. Investigate the implications of molecular imaging in diagnosis, prediction of treatment response and monitoring of treatment response and individual treat plans.

D7. Assure the viability of MI through the development of techniques that meet a clinical need and that are reimbursable.



research

Objectives & Strategies:D8. Position SNM as a central repository for information on research in molecular

imaging.• Create web-based tools for communicating innovative research.

– MI research updates monthly.– MI innovations in research.– Protocol and standards development

• Develop distance learning forums and mini seminars, e.g., how to do small animal imaging, steps to obtaining IND grant money.

• Provide information on how to design protocols, and prepare grant/protocol to get started.– Provide central resources on how to design protocols.– Who, what are IRB issues?

• Create a voice for research.– Promote innovation through research symposia and specialized publications.– Work with FDA and other regulatory agencies on regulatory issues.– Work with NIH to develop RFAs.

D9. Partner with basic science organizations/IND to promote translational research –foster academic/IND partnerships.


Goal ESNM will be recognized as the society which positions molecular medicine as an

essential tool in providing the highest standards of patient care around the world.

Objectives & Strategies:E1. Develop an integrated strategic marketing plan to position the SNM as

the recognized leader in molecular imaging initiatives.

• Create segmented messages to be used in marketing materials for members, medical community, industry, regulatory and the general public.

• Develop a visual identity system including logo development, stationary suite, business cards, newsletter and publication design and template.

• Redesign to Web site to accurately reflect the new brand.• Redesign educational, membership and direct marketing materials to ensure visual, tonality

and emphasis reinforce the new brand.• Create an SNM tool kit explaining the new brand to staff and members.• Create a brand standards guideline to ensure consistency of future messaging and brand

identity.• Identify key internal brand behaviors; train staff to demonstrate those behaviors (customer

service).• Develop program evaluation criteria to ensure that future programs and services adhere to

the desired brand attributes.• Develop a plan to migrate the new brand into a name change over a 2-3 year period.




• Identify audience – industry, medical, science and regulatory.

• Establish credibility.• Develop key messages.

– SNM is changing.– Identify programs and services.– Vehicles to accomplish change, e.g., new

journal.– Integrated society.– Define molecular imaging.

• Disseminate the messages to the medical community and the public through article placements in trade and general press; direct outreach through the SNM Web site; speaking opportunities at meetings and conferences; events, publications and other outreach conducted and sponsored by SNM; partnerships with like-minded imaging associations.

• Conduct major market research to supplement the recommendations of this task force.

Objectives & Strategies:E2. Develop major media marketing plan to influence the introduction and acceptance of molecular imaging technology, diagnostic and therapeutic benefits.

• Identify and target multiple opinion leaders and organizations that will influence the introduction and acceptance of molecular imaging technology, diagnostic and therapeutic benefits.

• Implement major organizational marketing and re-branding initiatives to highlight the institutional commitment to Molecular Imaging.

• Identify major media initiatives to win coverage in national and trade media.

• SNM will redesign its web and Internet applications to showcase the institutional emphasis upon molecular imaging initiatives. Expand MI center website to create tools and information.




Objectives & Strategies:E3. Increase membership by those molecular imaging physicians,

scientists and technicians. • Develop a major membership recruitment campaign targeted at

molecular imaging physicians, scientists and technicians.• Engage the work of experts on molecular medicine in SNM through

forums or to conduct programs (e.g., biologists, geneticists, FDA, NIH).

Molecular Imaging Strategic Plan 2007

Vision: SNM will be the leader in advancing and unifying molecular imaging and therapy. Mission: To improve healthcare by advancing molecular imaging and therapy. Goals:

Provide resources for education, knowledge exchange, training, and networking.

Support advocacy for molecular medicine, including imaging and therapy. Educate and promote collaboration with referring physician and patient

groups. Train the current imaging workforce and educate future generations of

practitioners on the applications of molecular imaging. Foster innovations in translational research and seek research funding for

molecular imaging. SNM will be recognized as the society that positions molecular medicine as an


Objectives

Create a central repository for education and research information. Educate the community on the benefits of molecular imaging and therapy. Create awards, grants, and fellowships for individuals interested in molecular

imaging. Develop fellowship and residency curricula. Create communications programs for physicians, patient groups, federal

agency and legislative representatives, and general public. Proactively advocate for reimbursement and research funding. Identify new funding opportunities. Perform clinical trials in nuclear medicine and molecular imaging. Define and support translational research from bench to bedside. Develop standardized imaging protocols, outcome measures, and the role of

biomarkers in clinical trials. Attract researchers, technologists, and laboratory technicians involved with

molecular imaging and therapy as members. Legend: Red=Communications; Green=Education; Purple=Advocacy; Blue=Science/Research

Molecular Imaging Center of Excellence - Strategic Plan page 1

Goal A: SNM will be members' indispensable resource for education, knowledge exchange, training and networking. A1. Objective: Position SNM as a central education repository for molecular imaging and therapy. Deliverable: Expand the molecular imaging offerings at the 2007 SNM annual and midwinter meetings to inform, educate, and train SNM members and meeting participants about molecular imaging. March 2007 Update: A representative from the Molecular Imaging Center of Excellence (MICoE) Board of Directors (Dr. Robert Atcher) was appointed to the SNM Scientific Program Committee and will work with the committee to oversee plans for expanding molecular imaging offerings at the 2007 and 2008 SNM annual and mid winter meetings. The SNM Mid-Winter meeting was held February 16-18 and it featured Advances in Cardiovascular Imaging, Advances in Molecular Imaging of the Brain, and several presentations on hybrid imaging. For the Annual Meeting, June 2-6, many education initiatives will focus on molecular imaging, such as: MI Categorical Seminars Molecular Imaging and Cancer Therapy New Directions in Molecular Imaging of the Brain SPECT/CT – Quantitative SPECT for Molecular Imaging Molecular Biology

MI Continuing Education Sessions Advanced Molecular Imaging Cardiac Molecular Imaging Molecular Imaging and Therapy and the Public Policy Agenda Molecular Imaging 101 Molecular Imaging in Neuroendocrine Disorders Highlights in Molecular Imaging

Scientific Sessions Small Animal Multimodality Small Animal PET Small Animal SPECT

In addition, these sessions, along with molecular imaging posters, will be flagged with a special icon. Also, there will be a new “Molecular Imaging Gateway” section at the annual meeting that will include posters and/or booths from various academic and government molecular imaging centers and societies. (Please see Attachment A.)


Deliverable: Expand LLSAP for other member groups and molecular imaging and therapy practitioners. March 2007 Update: Several LLSAP and other on-line courses cover molecular imaging topics, such as: LLSAP Cardiovascular CT and Hybrid Imaging Clinical Applications of SPECT and PET Investigational and Clinical Applications of PET and SPECT Oncology PET and PET/CT

OED Hybrid Cardiac PET/CT Imaging New Molecular Imaging Agents for Oncology Molecular Imaging Course Services

Deliverable: Develop web-based programs and printed materials. March 2007 Update: Currently, molecular imaging information is being integrated into the existing SNM Web site and additional non-Nuclear molecular imaging information is being added to SNM “hot topics” and weekly email blasts. In addition, the Molecular Imaging Center of Excellence is continuously updating its Web site. Deliverable: Use video production of road shows and other educational sessions for online education and training. March 2007 Update: The molecular imaging sessions at the Mid-Winter Educational Symposium were filmed for the purpose of creating on-line training modules. Plans are in place to video the educational sessions during the Annual Meeting as well. Deliverable: Expand JNM content to include molecular imaging information that expands beyond nuclear techniques. Develop a JNM Supplement that focuses on molecular imaging topics. March 2007 Update: Dr. Heinz Schelbert, Editor in Chief of JNM, has instituted four new initiatives to increase the journal’s non-nuclear molecular imaging content. The Newsline section of JNM has been expanded to include a monthly update column from the MICoE and additional briefs on non-radionuclide molecular imaging papers in the Lit Briefs section. JNM will be doing a series of 4-page molecular imaging review articles, one per issue. The MICoE suggested a list of topics/authors for the series in late March; the first of the articles may appear in the December 2007 issue. In addition, Dr. Schelbert


plans a molecular imaging supplement in 2007, guest edited by Sam Gambhir, MD, PhD. (Please see Attachment B.) Deliverable: Foster education and information dissemination in developing countries. March 2007 Update: SNM has been very active with international nuclear medicine and molecular imaging societies. SNM gives free memberships to South Africa. JSMI is receiving free booth space at the annual meeting and several international molecular imaging groups have been invited to participate in the MI Gateway. MI Categorical SNM held a full day categorical focusing on molecular imaging on Sunday, October 22, 2006 at the WCNMB in Seoul, Korea. Topics included the following: Imaging Cell Death and Signaling Network Targeted Imaging and Drug Development Genomic and Proteomic Approaches to MI of Cancer The Evolving Role of Nanotechnology in MI of Cancer A Paradigm for the Development and Application of Optical-Nuclear Dual-Labeled

Imaging Agents Neuroimaging of Alzheimer’s Disease Translational MI with PET Tracers

MI Roundtable SNM also held a MI Summit roundtable on Sunday, October 22, 2006 at the WCNMB in Seoul, Korea. The purpose behind this summit was to discuss the future role of the World Federation in Molecular Imaging. Questions/Issues included: Status of MI and MI professional societies

--State of the art – clinical v. laboratory --Relationship between traditional imaging societies and new MI societies

What are the current needs of developing countries with respect to traditional nuclear

medicine and molecular imaging What is the role of industry in supporting traditional nuclear medicine and molecular

imaging in the developing countries and elsewhere What is the role of the World Federation with respect to molecular imaging:

--Educational venue/content/audience --Roundtable for MI societies to discuss issues/collaboration --Roundtable for MI luminaries for scientific exchange --MI global strategic planning (with industry)


IAEA Grant SNM also donated a $5,000 grant for 2007 IAEA sponsored programs. This grant is being used by IAEA to support meetings, educational activities, travel grants, etc., in the areas of nuclear medicine and molecular imaging and therapy. Deliverable: Conduct symposia to bring together experts in the field of molecular imaging in an effort to share research results, diagnostic protocols, and therapy innovations. March 2007 Update: Currently, MICoE is implementing a plan that involves a series of four or more retreats/workshops in 2007-2008 to examine emerging technologies and identify what can be done to realize benefits in the clinical environment. These workshops–the first of which is to be held in June 2007–will bring together leaders from industry, government, and academia.

Deliverable: Organize and lead industry and professional society summits, international cooperative groups and workshops in molecular imaging to promote exchange of ideas, protocols and scientific data for molecular imaging and establish a foundation for networking.

March 2007 Update: In July, SNM hosted an Expert/Industry Summit and the proceedings were published in Newsline in the December 2006 Journal of Nuclear Medicine. The new Board held its first meeting during the Summit and used the resulting recommendations in crafting a one-year strategic plan for the center. A working group is being assembled to develop topics and agenda for the next summit, targeted to coincide with the next Mid-Winter Meeting in February 2008 in Newport Beach, CA.

Deliverable: Maintain and improve journal standing as the best in medical imaging. Identify further efforts to include molecular imaging research and information in JNM. Define the necessary measures to increase references and influence of the journal. March 2007 Update: JNM mission statement has been updated to be in line with the new SNM purpose and submitted to the board for consideration: "The Journal of Nuclear Medicine advances the knowledge and practice of molecular imaging and therapy and nuclear medicine to improve patient care through publication of original basic science and clinical research. JNM is a monthly, peer-reviewed journal published both in print and online by SNM, an international, multidisciplinary professional organization for molecular imaging and therapy and nuclear medicine professionals.”


Deliverable: Create a comprehensive book resource within SNM to improve value for members and reinforce centrality of society to molecular imaging. Create a publishing plan for new SNM books on essential molecular imaging topics. March 2007 Update: SNM will release a new book in May: A Clinician’s Guide to Nuclear Oncology: Practical Molecular Imaging and Radionuclide Therapies, by Naomi Alazraki et al. The book provides balanced, relevant information about molecular and nuclear imaging and therapy for clinicians who take care of patients with cancer. Each chapter (by type of cancer) includes a description of the procedure, information on patient preparation, explanation of the resulting report, and an examination of the treatment and overall impact of the imaging on patient management—as well as a section addressing what is “On the Horizon” for diagnosis and/or therapy for this cancer. Furthermore, SNM is developing a comprehensive plan for a new book program, especially in relation to molecular imaging; the Publications Committee hopes to forward a recommendation to the board by the 2007 Annual Meeting. A2. Objective: Create awards, grants and fellowships for individuals interested in molecular imaging. Deliverable: Recommend new grant and award programs, including a funding mechanism, in the area of non-nuclear or multi-modality molecular imaging for SNM BOD approval. This will increase support for research and research careers in molecular imaging. March 2007 Update: A new Grants & Awards Task Force has been created under the leadership of Dr. Mathew Thakur. Several MI Center of Excellence members and others from the molecular imaging community are serving on the group. Several calls have been held and individual members are working on specific assignments. The Task Force is on schedule to recommend new grants and awards to further the field of molecular imaging at the SNM Board meeting in June. A3. Objective: Develop fellowship and residency curricula. Deliverable: Create an outline of a curriculum for a fellow/resident in molecular imaging. March 2007 Update: The Education Task Force, under the leadership of Dr. Carolyn Anderson, has been reviewing the current nuclear medicine curriculum for residents and is examining how to incorporate molecular imaging. During the past year, under the leadership of the SNM-member Chair, the Residency Review Committee (RRC) has been discussing the next major change to the curriculum to be in the area of molecular


imaging. As a result, we anticipate that they will be interested in our recommendations. The Task Force is working with this now-former RRC Chair to become knowledgeable about the processes involved in making changes to a curriculum. As part of this process, we are looking carefully at the RRC’s experience in incorporating PET into the curriculum to ensure that we approach it in a similar manner. The Task Force is planning to involve the current RRC Chair in its activities but the overall process is expected to take four years. The Task Force will be discussing a curriculum for fellows as well. A4. Objective: Attract and address diversified educational needs of nuclear medicine and molecular imaging practitioners. Deliverable: Develop tools to attract the diversified molecular imaging community and provide informational and educational resources for them. March 2007 Update: The MICoE created nine new Task Forces that are implementing many of the Campaign deliverables. (Please see Attachment C.) Each Task Force, led by a COE Board member, has reached out and engaged a diverse membership from the Center, other SNM committees and councils, and the wider molecular imaging community. All Task Force members who are not currently SNM members are receiving a complementary one-year free trial SNM membership to fully acquaint them with all of the available resources and programs. In addition, the MICoE web site is now open to all registered users as of March 2007. All users who register are eligible for a 90-day free trial membership to the MICoE and all of its resources. Furthermore, as mentioned above, MICoE is reaching out the molecular imaging community in developing its retreats and workshops. A6. Objective: Perform clinical trials in nuclear medicine and molecular imaging. Deliverable: There are four objectives for the clinical trials group:

1. Establish a clinical trials group. 2. Develop a project taking on the quantification and validation of a standard. 3. Open communication with cooperative groups and NIH. 4. Design and implement clinical protocols using non-standard tracers.

March 2007 Update: The clinical trials group is established and a process and structure have been developed. The first project on quantification and validation of a standard is underway. The phantom has been designed and delivered. It is now at its third site and the protocol is


being completed. By the annual meeting, there will be data presented from the three sites and it will be at the next site. Communication with cooperative groups and NIH has already started and will be followed up with a meeting in May with representatives from NCI. By the annual meeting, we will be identifying how to take the validated quantification methods into clinical trials. A7. Objective: Complete and implement an internal communications plan to communicate to members and member groups that the society is their indispensable resource for molecular imaging. Deliverable: Facilitate the movement/exchange of information along all channels within SNM in order to achieve clear, coordinated, and effective messaging to internal groups: members, chapters, councils, and Centers. Create a molecular imaging “road show”. March 2007 Update: SNM Staff developed a working draft of a “road show” that was presented at the SNM Mid-Winter meeting for review and input by the MI Board of Directors, SNM Board of Directors, and SNM House of Delegates. This slide presentation includes information on molecular imaging and therapy and communicates SNM’s new direction to the members. SNM Leadership is currently using this “road show” at all the Chapter meetings around the country this year, and it will continue to be a resource for members. The “road show” also will be used as the basis for advocacy and fundraising materials. (Please see Attachment D) As mentioned previously, the MICoE Task Forces have reached out to all of the SNM Councils and Committees for membership. In addition, SNM and SNMTS Leadership and the CEO have prepared updates on the purpose and progress of the Campaign in almost every issue of Newsline in JNM. Deliverable: Update the website with the key messages in mind; ensure coherent Web presence; ensure ease of use and access. March 2007 Update: Currently, molecular imaging information is being integrated into the existing SNM website and additional non-nuclear molecular imaging information is being added to SNM “hot topics” and weekly email blasts. In addition, the Molecular Imaging Center of Excellence is updating its web pages. New Task Force members will receive a complementary one-year membership to SNM and the MICoE and its web resources. In order to publicize SNM’s molecular imaging resources even further, a 90-day free trial membership to the MICoE is now available to all who register.


As mentioned previously, new Web sites are being developed for both SNM and the molecular imaging community. Goal B – SNM will be the powerful advocate for molecular medicine, including imaging and therapy. B1. Objective: Take a proactive role advocating for reimbursement and research funding. Deliverable: Maintain and strengthen relationships with HHS, CMS, NIH, FDA, DOE, NSF, NAS, DOD, and other federal agencies that support molecular imaging research to pursue increased support for molecular imaging initiatives. March 2007 Update: A new Advocacy Task Force, formed under the leadership of Dr. Robert Atcher, includes members of MICoE as well a diverse representation from the molecular imaging community. Several current and former government agency representatives have been invited to serve on this and other Task Forces. SNM has met with the various agencies listed above to inform them of SNM molecular imaging initiatives. SNM will continue to arrange meetings to inform the agencies of the nuclear medicine/molecular imaging community research goals and identify areas of mutual interest and collaboration. In addition, SNM will pursue a comprehensive and aggressive program during its Annual Meeting (May 31-June 6, 2007) in Washington, DC, to expand the visibility of SNM as the preeminent organization representing molecular imaging and therapy. Its activities will include: Have the first week in June declared “Molecular Imaging Week” Organize a “Hill Visit Day” where several hundred members visit their Senators and

Congressmen to promote molecular imaging Arrange meetings for SNM and MICoE leadership with targeted members of

Congress and Executive Branch officials Invite and recognize national figures at the Annual Meeting Sponsor a reception on Capitol Hill for Leadership with members of Congress who

have been and/or should be supportive of molecular imaging. SNM has reached out to Executive Branch agencies and, as a result, FDA, NRC and CMS will all be active participants in the Annual Meeting – each of them conducting educational sessions for attendees. (Please see Attachment E.)


Deliverable: Facilitate the collaboration of industry representatives, trade associations, medical associations, and patient groups for the advocacy of molecular imaging and therapy. March 2007 Update: SNM has established a “Molecular Imaging and Therapy Coalition” which provides a forum for discussion between federal agencies and legislators and the molecular imaging industry and professional and patient organizations. The Coalition meets twice a year. B2. Objective: Educate community on benefits of molecular imaging and emerging technologies. Deliverable: Develop an advocacy database of medical associations, pharmaceutical companies, patient advocacy groups and funding agencies for advocacy and outreach planning. Include information on any work done with each group to date, detailing the nature of the relationship and collaboration. March 2007 Update: Staff has developed a draft database and will finalize by June with input from various molecular imaging Task Forces. Deliverable: Develop new and strengthen existing relationships with five clinical, five research and five pharmaceutical organizations, providing targeted messages for each entity based on specific interests, such as reimbursement. Create interest in directing and expanding federal and private research support in critical areas and identify potential areas of collaboration. Advocate proper coding and reimbursement for molecular imaging procedures and drugs. March 2007 Update: Meetings have been held with several organizations in each category. We have reached the goal for clinical organizations, meeting with ASTRO, ASCO, RSNA, ACR, and AAPM. Leadership has met with Merck, Glaxo, and Novartis. Other meetings will be scheduled for the spring. In addition, SNM has worked with and provided suggestions for topics for a National Coalition for Cancer Research Hill Briefing in June. SNM has met with CMS and discussed the molecular imaging campaign, as well as the need for adequate reimbursement for molecular imaging agents, drugs, and procedures. SNM continues to work with other organizations (i.e., AMA, ACR, NEMA, CORAR, AMI, ASNC) to ensure collaboration and harmonization in seeking fair reimbursement. Deliverable: Creation of a molecular imaging Web site that will serve as a central repository and will provide on line information, education, and training in molecular


imaging for various audiences. The Web site will serve to increase understanding about the benefits and applications of molecular imaging, create an interest in utilizing molecular imaging to advance patient care, and generate interest in utilizing molecular imaging to advance research in relevant areas. March 2007 Update: A new Communications Task Force was formed under the leadership of Dr. Al Sinusas that includes members of the Molecular Imaging Center of Excellence and others from the molecular imaging community. The group has met by conference call and in person to review plans for the Web site and other communications vehicles, such as the new Molecular Imaging Center of Excellence Welcome Packet. SNM has retained the firm Erickson-Barnett to revamp the SNM Web site and design a new molecular imaging Web site. Design work has begun on both sites and they are expected to be delivered in June 2007. (Please see Attachment F.) Deliverable: Develop listserv with external constituencies to provide a forum for discussion of molecular imaging. The listserv will assist in the exchange of ideas, facilitate funding opportunities, and allow users to pursue shared interests. March 2007 Update: The “listserv” will be fully operational once the community Web site is developed. In the interim, the SNM Web site “community” will be expanded in April 2007 to accommodate additional “listserv” functionality.

Goal C: SNM will be the leader in educating and promoting collaboration with referring physician and patient groups. C1: Objective: Create outreach program aimed at referring physicians, patient groups, federal agencies, regulators and general public. Deliverable: Develop standardized definitions and terminology in molecular imaging that will be the foundation of all communications, advocacy, and education activities. Once basic issues, definitions and terminology are established, an outreach program will be developed that is tailored to the specific needs of several targeted organizations. Program components will include a summary that captures molecular imaging as a whole and specific ways molecular imaging ties into each organization or group. March 2007 Update: The Standard Definitions Task Force, chaired by Dr. Dave Mankoff, was formed and held multiple meetings to develop draft definitions. The MICoE and SNM Boards approved a definition for molecular imaging. Definitions for molecular imaging agents, molecular imaging instrumentation, and molecular imaging quantification and a description of the relevance of molecular imaging to cardiovascular


disease, cancer, and neurology have been approved by the MICoE. These additional definitions and descriptions will be approved by the SNM Board in April 2007. (Please see Attachment G.)

Deliverable: Create a Molecular Imaging Speakers and Experts Bureau that will provide speakers for scientific or educational meetings, chapter or local meetings and serve as a repository of information to serve the molecular imaging community. The goal for the first year is to develop the database of speakers and topics. March 2007 Update: An Education Task Force has been created under the leadership of Dr. Carolyn Anderson, which includes members of the Center of Excellence as well as representatives from the Academic Council, SNM Education Committee, Program Directors, and the YPC. SNM Staff has developed a preliminary list of molecular imaging experts and speakers that will serve as the basis for future work on the Speakers Bureau. The Education Task Force will assist in further developing and refining the list. Other MICoE activities also will provide input into the database. Deliverable: Develop an advocacy database of medical associations, pharmaceutical organizations. (Please refer to B2-1 for further information.) Deliverable: Establish relationships with key medical and patient groups to identify areas of common interest and identify future collaborative educational/outreach activities. (Please refer to B1-2 for further information.) Deliverable: Create relationships with coalitions through membership and participation in groups such as the National Coalition for Cancer Research March 2007Update: SNM has worked with and provided suggestions for topics for a National Coalition for Cancer Research Hill Briefing in June. SNM is also an active member in the Commission on Cancer and the Biomarkers Consortium. Deliverable: Develop an in-house mechanism for technology evaluation and create position statements on how these technologies can become viable. This may involve convening a workshop of representatives in other leading technologies to discuss the complementary features of each. Goals for the workshop will include outlining the critical issues surrounding the technology and identifying experts (which will also feed into the speakers bureau). March 2007 Update: A new Task Force on Leading Technologies and Assessment, chaired by Dr. Sandy McEwan, has held several conference calls. The Task Force, in conjunction with other Task Force chairs, has developed a plan for a series of


retreats/workshops for 2007 and early 2008. Invitations have been sent for the first retreat in June, entitled “Development Strategies for Emerging Molecular Imaging Technologies: The Development of an Action Plan” in June 2007. The purpose of the retreat is to develop an action plan to enable imminently emerging molecular imaging technologies to become clinically useful within the next five years. The second workshop will be a working retreat that will broadly review molecular imaging leading-edge technologies (5-10 year time-frame) and evaluate issues associated with each. Using the results of the first two meetings, a third workshop will evaluate future molecular imaging agents to determine what is needed to validate them for clinical use. Lastly, a Leading Technologies Advancement workshop will bring together the ideas generated in the first three workshops to examine the pathways for gaining acceptance of new molecular imaging technologies and identify key barriers to moving them from the research environment to the bedside. (Please see Attachment H.) Goal D: SNM will be a significant supporter of innovations in translational research. D1: Objective: Define translational research from bench to bedside – research to practice. Deliverable: Develop brochures, case studies, Web site links and other resources for physicians and researchers in basic biological sciences that illustrate the practical significance of molecular imaging. This information will be targeted so that physicians see the practical benefits of molecular imaging and researchers understand how molecular imaging can be used to answer basic biological questions. March 2007 Update: The Communications Task Force will be addressing this deliverable with input from other Task Forces. D3. Develop research program to assist new investigators in the field of molecular imaging. (See also A2) Deliverable: Award and track pilot research grants for young investigators and provide bridge funding for those entering the field. March 2007 Update: A new Grants & Awards Task Force has been created under the leadership of Dr. Mathew Thakur. Several MI Center of Excellence members and others from the molecular imaging community are serving on the group. Several calls have


been held and individual members are working on specific assignments. The Task Force is on schedule to recommend new grants and awards to further the field of molecular imaging at the SNM Board meeting in June. D4. Objective: Identify new funding opportunities Deliverable: Create a database of funding sources highlighting non-imaging sources of funding for the molecular imaging community website. March 2007Update: The SNM Development Director and MICoE Director are taking the lead on developing the database. It should be completed by September 2007. D5. Objective: Develop standardized imaging protocols, outcome measures and the role of biomarkers in clinical trials. Deliverable: Convene a workshop to discuss standardized imaging protocols. Invite SNM members and leaders along with experts in the field including those from other societies that have an interest in this topic. Outcomes of the workshop include identification of the information needed to develop standardized protocols and a plan and timetable for protocol development. March 2007 Update: A Standardized Imaging Protocols Task Force has been formed under the leadership of Dr. Henry VanBrocklin. This Task Force will work with the SNM Clinical Trials group to develop a plan for addressing this deliverable. D7. Objective: Assure the viability of MI through the development of techniques that meet a clinical need and that are reimbursable. Deliverable: Convene a workshop or MI Summit to discuss the next tracers (future “FDG”s). The workshop participants will include experts in the field. March 2007 Update: A Future Tracers Task Force has been formed under the leadership of Dr. Henry VanBrocklin. To avoid duplication and ensure coordination, Dr. VanBrocklin has been working with the Leading Technologies and Assessment Task Force to develop the series of workshops for 2007-2008. A retreat on Future Tracers is the third retreat planned and the Task Force will discuss participants and an agenda in an April conference call. Workshop participants will identify the next “generation” of tracers, why these are selected, how to validate them, and how to get to the stage for reimbursement. The outcome of the workshop will be a plan for new tracer development.


D8. Objective: Position SNM as a central repository for information on research in molecular imaging. (See also A1) Deliverable: Develop a Web site to provide information to the community on molecular imaging research and research tools. March 2007 Update: A new Communications Task Force was formed under the leadership of Dr. Al Sinusas that includes members of the Molecular Imaging Center of Excellence and others from the molecular imaging community. The group has met by conference call and in person to review plans for the Web site and other communications vehicles, such as the new Molecular Imaging Center of Excellence Welcome Packet. SNM has retained the firm Erickson-Barnett to revamp the SNM website. Design work has already begun on the molecular imaging Web site as it is expected to be delivered in June 2007. Deliverable: Publish more non-nuclear and multi-modality molecular imaging research papers and research information in JNM. March 2007 Update: Dr. Heinz Schelbert, Editor in Chief of JNM, has instituted four new initiatives to increase the journal’s non-nuclear molecular imaging content. The Newsline section of JNM has been expanded to include a monthly update column from the MI Center of Excellence and additional briefs on non-radionuclide molecular imaging papers in the Lit Briefs section. JNM will be doing a series of 4-page molecular imaging review articles, one per issue. The MI COE suggested a list of topics/authors for that series in late March so the first of the articles could appear as early as the December 2007 issue. In addition, Dr. Schelbert plans a molecular imaging supplement in 2007, guest edited by Sam Gambhir. SNM pulled together "hot papers" on molecular imaging from 2006 JNM issues and provided this list at the SNM Molecular Imaging Booth at the RSNA meeting and then created a CD containing these papers for the MI COE. This list—and papers—is also available on the MICoE web page. Goal E: SNM will be recognized as the society that positions molecular medicine as an essential tool in providing the highest standards of patient care around the world. E1. Objective: Develop an integrated strategic marketing plan to position SNM as the recognized leader in molecular imaging initiatives.


Deliverable: Rebrand SNM within the first six to nine months of fiscal year 2007 to reflect the organization’s molecular imaging direction.

March 2007 Update: McKinley Marketing has developed a rebranding strategy that has been approved by SNM Leadership. McKinley Marketing has finalized our segmented messages. This strategy includes segmented messages that have been developed to help reinforce SNM’s molecular imaging initiatives. Erickson Barnett has finalized the new SNM logo. SNM staff is working on the remaining components related to the visual identity, which include business cards, stationary suite and other templates. This is expected to be finalized by May 31. Erickson Barnett is also in the final stages of redesigning our Web site, which is scheduled to launch at our annual meeting in June. SNM staff are working on all marketing and educational materials to reflect the new brand. This transition will take place over the next couple of months. McKinley Marketing will be finalizing the SNM Took Kit. The new tool kit will help explain the new brand to staff and leadership and will be presented on April 17. McKinley Marketing and Erickson Barnett are working together to create a brand standards guideline. The guidelines will consist of things such as: logo, templates, Web site, etc. This is schedule to be finalized by June 2007. McKinley Marketing is help us develop internal brand behaviors to help staff maintain good customer service. This will be completed and presented to staff on April 17. Senior staff are working closely together to develop an evaluation criteria program. This will be an ongoing process as new programs are developed. (For all of the above items, please see Attachment I.) Deliverable: Develop a major public relations plan. To influence the introduction and acceptance of molecular imaging technology and diagnostic and therapeutic benefits within the broader medical community as well as the general public, SNM will need to develop and implement a public relations plan.


March 2007 Update: A public relations plan has been developed for SNM’s molecular imaging initiative. (Please see Attachment J.) Some ongoing activities from that plan include: Updating and expanding press lists (add new audiences); Revising the Society’s fact sheets to reflect the MI focus; Developing initial copy for SNM’s online Newsroom; Redefining and revising key messages and continuing to relay them through new

and established channels; and Monitoring news coverage to track successes.

As part of this plan, press releases are developed and used to pitch stories about MICoE and its related activities to reporters from both trades and consumer media. For example, a press release focusing on the increasing pledges to Bench to Bedside Campaign and the hiring of Marybeth Howlett as MI COE Director was distributed the week of March 26th. Another press release highlighting the educational/advocacy activities coming from MI COE has been completed and is being distributed the week of April 1st. It’s anticipated that both will generate positive news coverage for SNM, Bench to Bedside, MI and the Society’s Rebranding activities. Additionally, all Journal of Nuclear Medicine research press releases are being messaged (where appropriate) to emphasize SNM’s mission with molecular imaging. Press clippings are being monitored to observe media pick up of SNM and its molecular imaging-related news. For January 2007 (and with clippings still coming in), one-third of that month’s press hits highlighted “JNM” and “MI”. The other releases highlighted “SNM” and its Web site. This monitoring will allow tracking of MI-related media successes. Goal F. SNM will attract researchers, technologists and laboratory technicians involved in molecular imaging as members. Deliverable: SNM and SNMTS membership committees will develop an MI recruitment plan to increase membership of molecular imagers and affiliated professions. March 2007 Update: Scott Holbrook has been appointed as the new chair of a new Membership Task Force. Members are being recruited. In addition, the SNMTS has established a category of membership that addresses the MI community. Further, it has enacted requisite bylaws changes and it is developing strategies to mount a substantial membership acquisition program directed at the molecular imaging professional.


The MICoE created nine new Task Forces that are implementing many of the Campaign deliverables. Each Task Force, led by a COE Board member, has reached out and engaged a diverse membership from the Center, other SNM committees and councils, and the wider molecular imaging community. All Task Force members who are not currently SNM members are receiving a complementary one-year free trial SNM membership to fully acquaint them with all of the available resources and programs. In addition, the MICoE web site is now open to all registered users as of March 2007. All users who register are eligible for a 90-day free trial membership to the MICoE and all of its resources. Furthermore, as mentioned above, MICoE is reaching out to the molecular imaging community in developing its retreats and workshops.


Attachment A

Invitations for Molecular Imaging “Gateway” at SNM Annual Meeting

Academic Centers

Contacts

Boston University (Optical Spectroscopy for Management of Cancer Treatment)

Irving Bigio, PhD [email protected]

Case Western Reserve University * National Foundation for Cancer Research (NFCR) Center for Molecular Imaging Northeastern Ohio Animal Imaging Resource Center http://www.nfcr.org/Default.aspx?tabid=316 4600 East West Highway Suite 525 Bethesda, MD 20814 Phone: (301) 654-1250 Fax: (301) 654-5824 Email: [email protected]

Director: James Basillion, PhD Jeffrey Duerk, Ph.D. [email protected]

Duke University Molecular Imaging Center * Center for In Vivo Microscopy Center for In Vivo Microscopy Box 3302 Duke University Medical Center Durham, NC 27710 http://www.civm.mc.duke.edu

G. Allan Johnson, Principle Investigator Duke University 919 .684-7754, Room 141 Timothy R. DeGrado, Ph.D. Phone: 919.684.7727 Fax: 919.684.7130

Emory Divison of Nuclear Medicine and Molecular Imaging* 1364 Clifton Rd., NE Atlanta Georgia 30322 Scheduling: 404-778-5364; Fax: 770-712-0945

David Schuster, MD, Director, Nuclear Medicine and Molecular Imaging Clinical Director, Center for Positron Emission Tomography

Mark M. Goodman, Ph.D. Phone: 404.727.9366 Fax: 404.727.4366

Harvard University * Massachusetts General Hospital Building 149, 13th Street Charlestown, MA, 02129 Mailstop: Room 5406 55 Fruit Street Boston, MA 02114-2622 617.726.2000

Director: Ralph Weissleder, MD, PhD Phone: (617) 726-8226 Fax: (617) 726-5708 Email: [email protected]

Johns Hopkins University * Director: Zaver Bhujwalla, PhD

Page 1 of 11 Molecular Imaging Centers List

Academic Centers

Contacts

In Vivo Cellular and Molecular Imaging Center – JHU ICMIC www.icmic.rad.jhmi.edu

Johns Hopkins University School of Medicine Russell H. Morgan Dept. of Radiology & Radiological Sciences Division of MR Research 720 Rutland Avenue 208 Traylor Building Baltimore, MD 21205 Phone: (410) 955-9698 Email: [email protected]

Johns Hopkins University School of Medicine * Molecular Imaging Center and Cancer Functional Imaging Core http://oncweb1.onc.jhmi.edu/cischeduling/index.cfm Broadway Research Building Contact: (410) 503-2598

Martin Pomper, MD, PhD Associate Professor, Departments of Radiology, Pharmacology and Oncology Division of Neuroradiology Johns Hopkins University School of Medicine, 600 N. Wolfe Street/ Phipps B-100 Baltimore, MD 21287-2182 410/955-2789 (office) 410/614-1213 (fax) e-mail:[email protected]

MD Anderson Cancer Center Juri Gelovani Director of Molecular Imaging

Memorial Sloan Kettering Cancer Center* Animal NMR and Radionuclide Imaging (SAIRP) MSKCC Center for Multidisciplinary In Vivo Molecular Imaging in Cancer (ICMIC) Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021 Phone: 212-639-2000 http://www.mskcc.org/mskcc/html/44.cfm

Wadsworth Center Director: Lawrence Sturman, MD, PhD Email: [email protected] Jason A. Koutcher 646-422-4421 [email protected]

MICAD at NIH Molecular Imaging Contrast Agent Database

Ron Blasberg, PI Office Phone: 212.639.7337 E-mail: [email protected] Lab Phone: 212.639.2720 Lab Fax: 212.717.3063 Kenneth Cheng, Ph.D. Kam Leung, PhD Elisabeth Lutanie, PhD e-mail: [email protected]

National Cancer Institute, Center for Cancer Research Chief: Peter L. Choyke


Academic Centers

Contacts

Molecular Imaging Program http://ccr.cancer.gov/labs/lab.asp?labid=175 Building 10, Room 1B40 Bethesda, MD 20892-1002 Phone: (301) 451-4220 Fax: (301) 402-3191

Email: [email protected] Jim Tatum Email: [email protected]

National Institute of Health National Institute of Biomedical Imaging and Bioengineering http://www.nibib.nih.gov/ 6707 Democracy Boulevard Bethesda, MD 20892-5469 Telephone: 301-496-8859 Fax: 301-480-0679 Office of Science Policy and Public Liaison Telephone: 301-451-4772 Fax: 301-480-1613

Karen Kurdziel


Academic Centers

Contacts

Stanford * Molecular Imaging Program In Vivo and Molecular Imaging Center at Stanford http://mips.stanford.edu/public/grants/ccne/ The James H Clark Center 318 Campus Drive East Wing, 1st Floor Stanford, CA 94305-5427 Phone: (650) 725-6175 Fax: (650) 724-4948 The Bio-X Program James H. Clark Center, E150 318 Campus Drive Stanford, California 94305-5427

Sanjiv Sam Gambhir, MD, Director In Vivo and Molecular Imaging Center at Stanford Stanford University School of Medicine James H. Clark Center, East Wing 318 Campus Dr. Dept. of Radiology Stanford, CA 94305-5427 Phone: (650) 725-2309 Fax: (650) 724-4948 Email: [email protected] Christopher Contag, Ph.D. [email protected]

Targasome, Inc.

Technische Universitat Munchen Markus Schwaiger, MD 49-89-4140-2971 fax: 49-89-4140-4841

UCLA’s Johnson Comprehensive Cancer Center Cancer Molecular Imaging http://www.cancer.mednet.ucla.edu/institution/groups-detail?group_id=231432 University of California, Los Angeles 8-684 Factor Building Box 951781 Los Angeles, CA 90095-1781 Tel: (310) 825-5268 Fax: (310) 206-5553 Email: [email protected]

Director: Anna Wu, PhD Phone: (310) 794-5088 Email: [email protected] Associate Director: Wolfgang Weber, MD

University of Arizona* Southwest Small Animal Imaging Resource Southwest Small Animal Imaging Resource The University of Arizona

1515 N. Campbell Avenue Tucson, AZ 85724 [email protected]

Program Director: Robert Gillies Director, Advanced Research Institute in Biomedical Imaging (ARIBI) Professor of Radiology, Biochemistry and Physiology University of Arizona Arizona Cancer Center 1515 N. Campbell Avenue Tucson, AZ 85724 (520) 626-5050 [email protected]


Academic Centers

Contacts

www.biochem.arizona.edu/gillies_lab/

University of California, Berkeley Berkeley Molecular Imaging Center (MIC) http://imaging.berkeley.edu/ Cancer Research Laboratory 447 LSA Berkeley, CA 94720-2751

Contact: Holly Aaron Phone: (510) 642-2901 Fax: (510) 642-5741 Email: [email protected]

University of California, Irvine (Breast Cancer Multi-Dimensional Diffuse Optical Imaging) The Henry Samueli School of Engineering University of California, Irvine 305 Rockwell Engineering CenterOffice/Lab: BLI P201 Irvine, CA 92697-1475

Bruce Tromberg, PhD [email protected]

University of California, Los Angeles * Crump Institute for Molecular Imaging The UCLA Center for In Vivo Imaging in Cancer Biology (ICMIC) http://www.crump.ucla.edu/ 700 Westwood Blvd. Los Angeles, CA 90095-1770 Fax: (310) 206-8975 Email: [email protected]

Director: Michael E. Phelps, MD Crump Institute for Molecular Imaging Department of Molecular and Medical Pharmacology UCLA School of Medicine Box 951735 Los Angeles, CA 90095-1735 Phone: (310) 825-6539 Fax: (310) 825-6267 Email: [email protected] Harvey Herschman, PhD The UCLA Center for In Vivo Imaging in Cancer Biology (ICMIC) [email protected] (310) 825-8735

University of California, San Francisco Center for Pharmaceutical and Molecular Imaging (CPMI) http://www.radiology.ucsf.edu/research/lab_pharma_molecular_imaging.shtml

Director: Robert C. Brasch, MD Phone: (415) 476-2275 Email: [email protected]

University of California-Davis *

Center for Molecular and Genomic Imaging (CMGI) (Department of Biomedical Engineering)

CMGI Director: Simon Cherry, Ph.D. University of California, Davis Center for Molecular and Genomic Imaging


Academic Centers

Contacts

Mouse Cancer Imaging Program

Genome and Biomedical Sciences Building 451 East Health Sciences Drive Davis, CA 95616-5294

http://imaging.bme.ucdavis.edu/

Phone: (530) 754-8033 Fax: (530) 754-5739

451 E. Health Sciences Drive GBSF Building Davis, CA 95616 (530) 754-9419 [email protected]

University of Michigan * In Vivo Cellular and Molecular Imaging Center Michigan Small Animal Imaging Resource Program (SAIRP) Department of Radiology http://www.med.umich.edu/msair/

Principal Investigator: Brian D. Ross, MD, Ph.D. Professor of Radiology and Biological Chemistry University of Michigan 200 Zina Pitcher Place BSRB, Room 2071 Ann Arbor, MI 48109-2200 Phone: (734)-763-2099 Fax: (734)-763-5447 Email: [email protected]

University of Missouri-Columbia* USVA Imaging Center Center for Single Photo-Emitting Cancer Imaging Agents (ICMIC) Biochemistry 117 Schweitzer Hall University of Missouri Columbia, MO 65211 Phone: 573-882-4845 Fax: 573-882-5635 www.va.gov/columbia-mo/bic

Timothy J. Hoffman, Ph.D. Director, VA-Biomolecular Imaging Center 573-814-6000 ext 52593 [email protected] Wynn Volkert, PhD Radiopharmaceutical Sciences Institute 330 Hadley Hall University of Missouri-Columbia Columbia, MO 65211 Phone: (573) 882-2557 Fax: (573) 882-6129 [email protected]

University of Pennsylvania Radiology Department Small Animal Multi-Modality Imaging Center (SAMMIC) University of Pennsylvania Medical Center 3400 Spruce St. Philadelphia, PA 19104

Jerry Glickson, PhD University of Pennsylvania Department of Radiology University of Pennsylvania Medical Center 3400 Spruce St.


Academic Centers

Contacts

http://www.uphs.upenn.edu/radiology/

Main Dept: (215) 662-3000

Philadelphia, PA 19104 Phone: (215) 898-1805 Fax: (215) 573 –2113 Email: [email protected]

University of Pennsylvania (Netrork for Translational Research)

Wafik El-Deiry, MD, PhD [email protected]

University of Washington Bio-Molecular Imaging Center (BMIC) Department of Radiology 815 Mercer Street Box 358050 Seattle, WA 98109 Phone: (206) 543-3061 Fax: (206) 616-9354 Email: [email protected]

Director: Chun Yuan, PhD Department of Radiology 1959 NE Pacific St, Box 357115 Seattle, WA 98195 Email: [email protected]

Vanderbilt University Institute of Imaging Science 1161 21st Ave South MCN AA-1105 Nashville, TN 37232-2310 615-322-7396

VCUHS Molecular Imaging Center www.molecularimaging.vcu.edu 1200 East Marshall Street PO Box 980001 Richmond, VA 23298

Website says: Karen Kurdziel

Washington University in St. Louis School of Medicine* Mallinckrodt Institute of Radiology – Molecular Imaging Center In vivo Cellular and Molecular Imaging Center http://www.mir.wustl.edu/research/internal.asp?NavID=585 510 S. Kingshighway St. Louis, MO 63110

Contact: David Piwnica-Worms, MD, PhD Phone: (314) 362-9356 Email: [email protected] Gregory M. Lanza, M.D., Ph.D. Phone: 314.454.8635 Fax: 314.454.5265 Jason S. Lewis, Ph.D. Phone: 314.362.4696 Fax: 314.362.9940


Academic Centers

Contacts

Washington University Small Animal Imaging Resource Small Animal Cancer Imaging Core* Barnes-Jewish Hospital South, East Building, Suite 2313 One Barnes-Jewish Hospital Plaza St. Louis, MO 63110 http://www.siteman.wustl.edu/internal.aspx?id=900&content=242

Co-Director: Joseph Ackerman 660 S. Euclid Campus Box 8227 St. Louis, MO 63110 Office Phone: 314-747-1212 Fax: 314-362-0526 Email: [email protected]

Yale School of Medicine Center for Cell and Molecular Imaging Yale University Department of Diagnostic Radiology 789 Howard Avenue, TE2 New Haven, CT 06520-8042 http://cellserv.med.yale.edu/imaging/

Jim Frost Director Al Sinusas

Other Societies/Organizations

Contacts AAAS (American Association for the Advancement of Science) 1200 New York Avenue NW Washington, DC 20005

AAAS Chief Exexutive Officer Dr. Alan I. Leshner 202.326.6640 fax: 202.371.9526

AMI (Academy of Molecular Imaging) Box 951735 Los Angeles, CA 90095-1735 Phone: 310.267.2614 Fax: 310.267.2617 [email protected]

Dova Levin Admin Manager 310-794-4328 [email protected] Tim McCarthy President, Exec Director

ACS (American Chemical Society) Washington, DC Headquarters American Chemical Society 1155 Sixteenth Street, NW Washington, DC 20036 202.872.4600 fax: 202.872.4615 [email protected]

Catherine T. Hunt President Madeleine Jacobs Executive Director & CEO


American College of Radiology Imaging Network (ACRIN) www.acrin.org

Network Chair Bruce J. Hillman, MD University of Virginia 434-982-0211

American Society of Gene Therapy

ASCO 1900 Duke Street Suite 200 Alexandria, VA 22314

Alan Lichter [email protected]

ASTRO 8280 Willow Oaks Corporate Drive, Suite 500 Fairfax, VA 22031 Phone: 703-502-1550 Toll Free: 1-800-962-7876 Fax: 703-502-7852

Laura ThevenotChief Executive Officer

SMI (The Society for Molecular Imaging) PO Box 293878 Kerrville, TX 78029-3878 Phone: 1.830.257.0112 Fax: 1.830.257.0119 Physical Address: 874 Harper Road, Suite 101B Kerrville, TX 78028-2985

Executive Director Charles Metzger [email protected] Associate Director Stephen S. Mabry, CAE, CFRE [email protected] Juri Gelovani President Director

ACR (American College of Radiology) Headquarters Office 1891 Preston White Drive Reston, VA 20191 703.648.8900

Jen Fisher Associate Phone: 703.262.9317 Al Van Moore, MD Chair, ACR Board of Chancellors Phone: 703.648.8902


European Association of Nuclear Medicine Holland Strasse 14/Mezzainine Vienna, Austria 1020

Andrea Bauer [email protected]

Korean Society of Molecular Imaging Phone: 110-744-02-2072-3341 Fax: 110-744-02-745-7690

http://www.molecularimaging.or.kr/In Korean

Japanese Society for Molecular Imaging Phone: +81-776-61-8430 Fax: +81-776-61-8170 http://www.molecularimaging.jp/ [email protected] Attn: BIRC, University of Fukui, 23-3, Shimoaizuki, Matsuoka, Eiheiji-cho, Yoshida Japan 910-1193

Yasuhisa Fujibayashi, PhD, D.Med.Sci Director, Professor of Molecular Imaging 81-776-61-8430 [email protected]

RSNA (Radiological Society of North America, Inc.) 820 Jorie Blvd, Oak Brook, IL 60523-2251 || (630) 571-2670 || fax (630) 571-7837

Dave Fellers, CAE Executive Director

Optical Society of America 2010 Massachusetts Ave, NW Washington, DC 20036 202/416-1907 or 800/766-4672 [email protected]

Executive Director Elizabeth A. Rogan 202.416.1944 [email protected] Chief Operating Officer John Heberlein 202.416.1404 [email protected]

European Society of Molecular Imaging BioPark II http://www.bioregio-regensburg.de Josef-Engert-Str. 11 D-9.053 Regensburg, Germany

Joan Oefner, CAE, Executive Director Tel. +49 (0) 941-698-7645 FAX +49 (0) 941-698-7647 (do not dial the (0) if calling from outside Germany) Email: [email protected] Tim Bertrand Tavitian President

Taiwan SMI & Taiwan Veterans General Hospital National Ynag-Ming University Med School

Ren Shyan Liu President of TSMI


Nuclear Medicine 155, Sec 2, Li-Non St Taipei, 11217 Taiwan Ph: 886-2-28757301-299 Email: [email protected] INTERNATIONAL EPR(ESR) SOCIETY Prof. Wolfgang Lubitz Max-Planck-Institut fuer Bioanorganische Chemie Stiftstr. 34-36 D-45470 Muelheim an der Ruhr Tel. +49 208 306 3614 Fax +49 208 306 3955 [email protected] Americas Prof. Balaraman Kalyanaraman Medical College of Wisconsin Dept. of Biophysics 8701 Watertown Plank Road Milwaukee, WI, 53226, USA Tel: 414/456-4035 Fax: 414/456-6512 [email protected]

Prof. Wolfgang Lubitz President Prof. Balaraman Kalyanaraman Vice President


Attachment B

From the SNM Molecular ImagingCenter of Excellence: An OpenInvitation

Often the most significant leap forward that a labo-ratory study can take is when it can be extended tothe in vivo case––a necessary and often sufficient

precondition for success in the clinic. Molecular imaging isconcerned with taking that leap forward, where importantdiscoveries are translated to new diagnostic and therapeu-tic agents to improve patient care. The union of recent ad-vances in hybrid imaging technology with advances inhigh-throughput target discovery and chemical synthesisalong with the generation of increasingly relevant animalmodels of human disease has enabled the current explosionof molecular imaging research that is ripe for clinicaltranslation. Optical- and ultrasound-based techniques weretreated dismissively by the medical community until re-cently, but now clinically useful and commercially availablefluorescent probes are proliferating and ultrasound bubblescan be derivatized for site-selective targeting. There is evena trend to develop multimodality/multifunctional probes formolecular imaging, anticipating the expansion in hybridimaging technology. The ultimate goal of these efforts is toprovide early detection of disease and enable rapid thera-peutic decisions––on individual patients in real time.

As you may know, SNM has recognized the expandingrole of molecular imaging in 21st-century patient care andacknowledged a unique ability to ensure that the medicalcommunity is well prepared to adopt these new technologies.Our ‘‘Bench to Bedside’’ campaign will help implement SNM’snew core purpose: To improve health care by advancingmolecular imaging and therapy.

This past summer, SNM explored basic research,instrumentation, drug development, clinical issues, andeducational needs at its ‘‘Shaping the Future’’ MolecularImaging Summit. Participants from industry, academia,and government published their recommendations inNewsline in December. These recommendations formed

the basis of a 5-year action plan—infused with substantial corporatefinancial support from the cam-paign—that will be a priority forSNM during the coming months andyears.

To bring molecular imaging fromthe bench to the bedside, SNM willwork to raise awareness about mo-lecular imaging and related patientcare benefits, train the current work-force and help educate future generations of scientists andpractitioners, expand funding available for research, fostertranslational research, and enhance collaboration withreferring physicians and patient groups.

Molecular imaging is a multidisciplinary enterprise,and we recognize that a collaborative approach is nec-essary to accomplish these ambitious goals. We welcomeall who share our interest. We have many important tasksahead and would like to invite the molecular imagingcommunity—those with expertise in optical, MR, and ul-trasound imaging, in addition to nuclear modalities—towork with us. We have recently formed new task forcesand are reaching out to the community for membership inthose groups.

We thank Conrad Nagle, MD, editor of Newsline, forexpanding the format to include a monthly update on theactivities of the molecular imaging community. Check thepages of Newsline in the coming year for new develop-ments in molecular imaging and therapy.

Martin Pomper, MD, PhDPresident, SNM Molecular Imaging Center of Excellence

Martin Pomper, MD,PhD

Newsline 39N

NE

WS

LI

NE

M O L E C U L A R I M A G I N G U P D A T E

MICoE: Moving Forward

Rarely do we have an opportunity to match good ideaswith the funding to make them happen. Two thousandand seven will be an exciting year for SNM and the

Molecular Imaging Center of Excellence (MICoE) as webring the personalized medicine of molecular imaging andtherapy into the forefront of patient care. As the newlyappointed staff director of the center, I have seen first hand thetremendous vision of our leaders and the intellectual re-sources of our members linked with the financial support ofthe Bench to Bedside Campaign. SNM’s 53-year history ofmultidisciplinary educational offerings, leading publica-tions, and sophisticated government affairs and publicrelations infrastructure will enable the translation of molec-ular imaging research to clinical practice. The MICoE willfocus these efforts and act as the central repository for in-formation and activities in molecular imaging and therapy.Here is a brief description of some of the goals and initialaccomplishments of the MICoE.

Becoming a Central RepositoryThe MICoE is now open to all

registered users to help bring newsand information on molecular imag-ing to both the wider SNM communityand the molecular imaging commu-nity. New information is continuallybeing added to the existing MICoEWeb site while a new Web site is beingdeveloped. Communications, advo-cacy, and education task forces havebeen formed with representation fromwithin SNM and from the molecularimaging community at large. Thesetask forces are developing campaigns to raise the awarenessof the benefits and possibilities of molecular imaging. Agrants and awards task force is developing support programs

(Continued on page 25N)

Marybeth Howlett,MEMDirector, MolecularImaging Campaign,SNM

M A I N T E N A N C E O F C E R T I F I C A T I O N U P D A T E

New MOC Requirements in Effect

The American Board of Medical Specialties (ABMS)voted unanimously in 2001 to expand on and replacerecertification programs with maintenance of certifi-

cation (MOC) programs, which are more comprehensiveefforts to assess the ongoing competence of physicianspecialists and their ability to provide quality health care in6 general competencies: medical knowledge, patient in-terpersonal and communication skills, professionalism,practice-based learning and improvements, and practice.In the past, the certification and processes requiredsuccessful completion of an educational program, posses-sion of an unrestricted license as evidence of professionalstanding, completion of the certification examination. Withthe new ABMS requirements, however, nuclear medicineprofessionals can no longer simply take an exam torenew a certificate. Instead, ‘‘lifelong learning’’ activitiesmust be documented. The American Board of NuclearMedicine (ABNM) MOC program is designed to document

for each nuclear medicine physi-cian the necessary competencies toprovide quality patient care.

MOC Components andRequirements

ABNM MOC includes 4 maincomponents. To renew certification,a nuclear medicine physician willbe required to present evidence of:

1. Professional standing: evidenceof professional standing is provided by a medical licensethat has no limitations on the practice of medicine andsurgery in that jurisdiction. Each physician must annuallydocument maintenance of unrestricted licenses in alljurisdictions in which he or she practices.


16N THE JOURNAL OF NUCLEAR MEDICINE • Vol. 48 • No. 3 • March 2007

NE

WS

LI

NE

Lynn Barnes, MEdDirector of Education,SNM

M O L E C U L A R I M A G I N G U P D A T E

Cardiovascular Molecular Imaging

At this year’s SNM Mid-Winter Meeting in SanAntonio, TX, the Cardiovascular Council and Mo-lecular Imaging Center of Excellence cosponsored

a program entitled, ‘‘Advances in Cardiovascular MolecularImaging.’’ The program was organized by Mehran M.Sadeghi, MD, from Yale University, and included a seriesof lectures focused on the emerging field of molecularcardiovascular imaging. Novel approaches to target identi-fication and development of new ligands for molecularimaging were reviewed. The panel of experts compareddifferent imaging modalities for detection and evaluationof cardiovascular disease at the molecular and cellular levels.

The first presentation, ‘‘Proteomic and Genomic Ap-proaches for Identifying Imaging Targets,’’ was by PeterP. Liu, MD. He suggested that proteomics could potentiallybe utilized to: (1) yield novel biomarkers reflecting car-diovascular disease; (2) establish earlier detection strategiesfor cardiovascular disease; and (3) monitor responses totherapy. New approaches permit the large-scale identifica-

tion of peptide sequences in biolog-ical samples with mass spectrometry,whereas gel-based techniques pro-vide further refinement on thestatus of posttranslational modifica-tion. The application of this high-throughput protein evaluation with asubset of predefined targets, identi-fied through proteomics, microarrayprofiling, and pathway analysis, isgaining momentum in the preclinical and clinical evaluationof cardiovascular disease. Proteomic analysis has pro-vided important insights into ischemic heart disease, heartfailure, and atherosclerosis. The combination of proteomicbiomarkers with clinical phenotypes and genetic haplo-type information can lead to more precise diagnosis andtherapy for individual patients, facilitating ‘‘personalizedmedicine.’’


M A I N T E N A N C E O F C E R T I F I C A T I O N U P D A T E

ABMS Requires Lifelong Learning

The 2001 decision by the American Board of MedicalSpecialties (ABMS) to replace recertification examswith maintenance of certification (MOC) programs

went into effect this year. MOC programs are more com-prehensive efforts to assess the ongoing competence ofmedical specialists and their ability to provide qualityhealth care in 6 areas: medical knowledge, patient care,interpersonal and communication skills, professionalism,practice-based learning and improvements, and system-based practice.

In the past, the certification renewal processes requiredsuccessful completion of an approved residency program,possession of an unrestricted medical license, and success-ful completion of the recertification examination. However,under the new ABMS requirements, physicians can nolonger simply take an exam and show their license to renewa certificate. Instead, ‘‘lifelong learning’’ activities must bedocumented. The MOC program is designed to documentthe necessary competencies to provide quality patient care.

Participation is mandatory for dip-lomates with time-limited board certi-fication. Although MOC programs arenot mandatory for diplomates withlifetime certification, specialty boardsare strongly encouraging all of theirdiplomates to participate in MOC forthe following reasons:

• Enhanced expertise. Medicalknowledge is enhanced by keeping current with thelatest research and advancements.

• Patient benefit: Patients are assured that they arereceiving high-quality medical care.

• Reimbursement: It is anticipated that third-partypayers will begin requiring all physicians to participatein a MOC program (pay-for-performance initiatives)in order to be eligible for reimbursement.


Albert J. Sinusas, MD

Lynn Barnes, MEd

26N THE JOURNAL OF NUCLEAR MEDICINE • Vol. 48 • No. 4 • April 2007

NE

WS

LI

NE

(Continued from page 26N)

Gregory M. Lanza, MD, PhD, gave the second pre-sentation, ‘‘Synergy of Molecular Imaging and TargetedTherapy in Cardiovascular Disease.’’ He discussed a varietyof new nanotechnological techniques and tools for bothdiagnostic imaging and therapy, including current productsand late-stage preclinical research. He focused on the use ofintegrin-targeted paramagnetic nanoparticles for MR imagingdetection of angiogenesis invery early atherosclerotic disease.This novel MR agent provides quantification of the extent ofdisease and, at the same time, can convey therapeutic doses ofan antiangiogenic drug, fumagillin, which slows plaqueprogression. After the targeted nanoparticle therapy, MRimaging, using the diagnostic version of the targeted para-magnetic nanoparticles, allows the longitudinal monitoring oftherapeutic effects. Because the targeted nanoparticle drugdelivery concentrates the drug at the desired site, the results areachieved with a total drug dose thousands of times lower thanthose in similar studies using conventional drug deliveryschemes. Thus, targeted nanoparticles can improve the safetyprofile of the drug by lowering overall dosage and concen-trating levels in disease sites. These nanotechnology applica-tions appear to hold tremendous promise in medicine;however, the safety, function, and environmental effects ofthese new tools and techniques remain undefined.

The third presentation, ‘‘Novel Applications in VascularMolecular Imaging,’’ was provided by Sadeghi, whoreviewed the potential of novel radiolabeled integrin- andmatrix metalloproteinase-specific molecules for in vivodetection of vascular injury and remodeling. Targetedradiotracer imaging of atherosclerosis or vascular remodel-ing presents a unique problem, in that the target lesion hasa very low mass and may be located deep in the body. Thiswork was facilitated by the application of several novelexperimental models and a hybrid microSPECT/microCTimaging system that allowed co-localization of radiotracer

uptake with in vivo arteriograms. He highlighted the im-portance of developing and applying targeted probes withboth fluorescent and radioactive labels in these preclinicalstudies, as well as the use of fluorescent probes for cellularlocalization within the target tissues or organ.

The final presentation of this session, ‘‘Role of TargetedMolecular Imaging for Prediction of Post Myocardial In-farction (MI) Remodeling,’’ was given by Albert J. Sinusas,MD. He presented preclinical studies demonstrating thepotential of targeted imaging of integrins and matrixmetalloproteinases for the prediction of post-MI remodel-ing. Targeted molecular imaging was used to directly relatecritical regional molecular and cellular processes with theassociated physiological consequences and changes in myo-cardial perfusion and mechanical function in both small andlarge animal models of ischemic injury. These preclinicalexperimental studies employed hybrid SPECT/CT imagingas well as MR imaging.

The future of targeted molecular imaging of the cardio-vascular system rests on the development of targeted bio-logic markers and reporter gene techniques to evaluate genetherapy and of novel imaging instrumentation. Althoughtargeted imaging of the molecular and physiological pro-cesses associated with cardiovascular disease will clearlyplay an important role in future advances, the translation ofthese imaging approaches to patients can be accomplishedonly through close collaboration among multidisciplinaryteams with a wide range of expertise. Novel targeted imagingstrategies complement standard imaging of physiologicalparameters, and such hybrid approaches are likely to play animportant role in both diagnostic and prognostic purposes aswell as for evaluation of therapeutic interventions.

Albert J. Sinusas, MDProfessor of Medicine and Diagnostic Radiology

Yale UniversityNew Haven, CT

(Continued from page 26N)

• Privileges and credentialing: It is expected that mosthospitals will require physicians to participate in anMOC program to maintain privileges.

• Self-governance: Instead of having the governmentdictate what constitutes high-quality medical care, theABMS prefers that specialties define and disseminatetheir own standards through their respective MOCprograms.

• Malpractice premium reductions: Research indi-cates that participation in a MOC program may resultin reduced malpractice insurance premiums.

Self-assessment credit may be obtained by completingmodules included on the SNM Lifelong Learning & SelfAssessment Web site: www.snm.org/llsap.

Lynn Barnes, MEdDirector of Education, SNM

Newsline 27N

NE

WS

LI

NE

[banner]

Advances in Molecular Imaging of the Brain

Henry VanBrocklin, Ph.D. – UCSF

Peter Herscovitch, M.D.- NIH

The Molecular Imaging Center of Excellence and the Brain Imaging Council

cosponsored a symposium entitled “Advances in Molecular Imaging of the Brain” at the 2007

SNM Mid-Winter Meeting in San Antonio, TX. Peter Herscovitch, MD, and Henry

VanBrocklin, PhD, organized the symposium, which featured 4 lectures highlighting the breadth

of molecular imaging (MI) applications and the potential for brain imaging to have significant

effects on patient care. An international group of lecturers covered MI assessment of brain tumor

physiology using probes other than 18F-FDG, the measurement of beta amyloid Ab[NK1] plaque

burden in Alzheimer’s disease (AD), and the use of MI probes to evaluate drug delivery,

development, and therapeutic efficacy.

Karl Herholz, MD, from the Wolfson Molecular Imaging Center (Manchester, UK),

opened the session with an enlightening discussion of brain tumor imaging in his talk “Brain

Tumors: Beyond FDG.” The high uptake of 18F-FDG in normal brain tissue often interferes with

its use as a brain tumor imaging agent. Several other tracers, including amino acids (e.g.,

methionine, fluorotyrosines[NK2], iodomethyltyrosine), cellular proliferation markers (e.g.,

fluorothymidine), intermediary metabolic probes (e.g., choline, acetate), and hypoxia agents

(e.g., 18F-fluoromisonidazole) have been used for clinical assessment of brain tumors. The uptake

and retention of many of these agents have been correlated with tumor grade. These agents have

been used to measure properties associated with chemotherapy delivery and efficacy as well as

for treatment planning for radiotherapy. Several more promising tracers are in the pipeline.

These include receptor-based probes and labeled chemotherapeutics that may find utility in

assessing treatment strategies.

The second lecture, “PET/SPECT in CNS Drug Development,” was given by P. David

Mozley, MD, Senior Director, Imaging, Merck Research Laboratories (West Point, PA). Dr.

Mozley provided an overview of the use of MI in the development of new central nervous

system therapeutics. He discussed the need for multimodality imaging that uses nuclear, MR,

CT, ultrasound, and optical methods and described approaches that employ in vitro models,

Nan Knight

Not sure what Ab means here. Beta amyloid plaque, I would assume. Right?

Nan Knight

Is this suppoed to be plural?

small and large animal imaging, and studies in humans. MI has a role to play in all stages of drug

development. MI studies of the interaction of a proposed new drug with its target tissue can help

test the underlying biological hypothesis about how the drug acts, select the range of drug doses

to use in human studies, and provide early information to terminate development of a drug before

carrying out more costly steps. Using MI in the later phases of drug development can result in

smaller, speedier clinical trials, making them both less expensive and safer.

Christopher Rowe, MD, of the Department of Nuclear Medicine and Centre for PET at

the Austin Hospital (Melbourne, Australia) presented the third lecture, on “Ab[NK3] Imaging with 11C-PIB PET: A Biomarker for Early Detection of Alzheimer’s Disease.” 11C-PIB is a

radiopharmaceutical developed by scientists at the University of Pittsburgh specifically to image

the Ab plaques [NK4]which accumulate in AD. Potential roles for 11C-PIB include accurate

diagnosis of early AD; early intervention when patients are minimally impaired; selection of

patients for clinical trials of antiamyloid therapy; and as a biomarker to monitor the effectiveness

of such therapy. This latter application is an example of the use of a MI biomarker in drug

development, as was reviewed by Dr. Mozely[NK5]. Data were shown demonstrating the

superiority of 11C-PIB over 18F-FDG in the detection of AD and its utility in the differential

diagnosis of dementia. Clinical trials with 11C-PIB are now being carried out in numerous

international sites.

In a talk entitled “Monitoring Gene Therapy in Parkinson’s Disease,” Krystof

Bankiewicz, MD, presented several aspects of using imaging to assess local drug delivery in the

brain. He provided an elegant example of imaging to monitor the expression of a therapeutic

gene. Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons that project

to the striatum. The gene replacement strategy involves the striatal delivery of the genes for

amino acid decarboxylase (AADC) in an adeno-associated virus vector. The expression of

AADC is visualized with 18F-fluoro-m[NK6]-tyrosine or 18F-fluoro-L-DOPA. This gene therapy

has been extensively evaluated in primate models of PD, where it was found that gene expression

was sustained for many years and the PD symptoms were reduced. A phase I study of this

therapy in humans with concomitant 18F-fluoro-m-tyrosine imaging is underway.

The development and application of MI probes will be critical to understanding the

pathophysiology of neuropsychiatric diseases and to developing and monitoring better therapies.

Labeled agonists, antagonists, and substrates for components of neurotransmitter systems have

Nan Knight

Again, should this b be a Greek beta? It’s fine to use the abbreviation, esp. if that was the title of his talk.

Nan Knight

Just let me know what you want me to use here so it’s not incorrect and/or reduncant.

Nan Knight

Is this spelling correct, or the one used previously?

Nan Knight

Should this m be italicized, like the I in fluoro-I-tyrosine?

been applied to assess neuroreceptor density and metabolic processes associated with a variety of

neuropsychiatric diseases. More recently, there has been an increase in the use of MI agents to

monitor drug delivery, dose response, drug metabolism, and drug interactions, all key

components of the drug development paradigm. Although this symposium presented examples

that involved PET or SPECT probes, MR also has an important role in MI applications in the

brain. It is clear that molecular neuroimaging will play a pivotal role in the future of patient

management and care.

4/10/2007 page 1

2007 POSSIBLE TOPICS FOR MI PEER-REVIEW ARTICLES FOR JNM Topic Possible Authors

1.Ultrasound Molecular Imaging Kathy Ferrara, Ph.D – UC Davis George Taylor Jonathan R. Lindner, MD -OHSU

2.Tumor metabolism by MRS Robert Gillies - University of Arizona

3.MRI in Cancer Microenvironment Zaver Bhujwalla – Johns Hopkins

4. Clinical Translation of Molecular Imaging

Rich Wahl - Johns Hopkins Steve Larson – Sloan Kettering

5. Carbon-13 MR Spectroscopy

John Kurhanowicz Sarah Nelson, PhD –UCSF; QB3-

Californiana Institute for Quantitative Biomedical Research

Ralph Hurd, PhD –GE Brian Ross – Huntington Medical Research

Institutes Orest Boyko

6.Impact of MI on Cancer Biology Research

Jan Schnitzer–Sidney Kimmel Cancer Center Lynn Matrisian –Vanderbilt-Ingram Cancer Center

7.Optical Imaging Gary Luker –U. of Michigan

8. Multimodality imaging (combining optical and PET/SPECT)

Sam Achilefu and Barry Edwards –WU

9. Stem cell trafficking/ Stem cell therapy Joseph Wu, MD, PhD – Stanford

10. Clinical prospects for optical/NIR imaging

Bruce Tromberg Eva Sevick-Muraca

11. Bioimaging/PET imaging and MI in clinical trials Colin Miller and Dr. Perrone

12. Cancer Imaging (MR/Nuclear Medicine Imaging) Zaver Bhujwalla, Marty Pomper - Hopkins

4/10/2007 page 2

13. New instrumentation Todd Peterson-Vanderbilt

14. MRI John Gore-Vanderbilt

15. Nuclear Medicine Physics Ben Tsui - Johns Hopkins

4/10/2007 4:03 PM DRAFT page 1

2007 NEWSLINE CONTRIBUTION SCHEDULE Newsline Issue

Conference Call

Responsible/ Topic

Draft article due at SNM

Page proofs done

April Jan 25; 10 am

Al Sinusas Cardiovascular imaging

Feb 22

May Feb 22; 11 am Henry--Peter/

MWM MI Highlights March 22

June March 22; 11 am

Dave Mankoff/ Standard Definitions April 19

July April 26; 11 am Carolyn Anderson:

Cancer Imaging May 24

August May 24; 11 am

Matthew Thakur MI Highlights at Annual Meeting: Focus on Young

Investigators and other awards

June 21

September June 28; 11 am

Kathy Ferara: Ultrasound July 26

October July 26, 11 a.m.

Dan Sullivan/Ann Menkins at NCI—ICMIC programs

August 23

November August 23; 11 am

FDA person (feature Rafel Dwaine Rieves): translational aspects

(hurdles/opportunities)

Sept 20

December Sept 27; 11 am

Andrea Perrone: BioImaging (CRO support)— clinical

trials issues (imaging in trials)

October 25

PRESS RELEASE

Contact: Maryann Verrillo [email protected]

(703) 708-9000, ext. 1211

For Immediate Release Jan. 2, 2007

SNM Examines Molecular Imaging’s Power To Detect, Treat Diseases Four-Day Mid-Winter Educational Symposium To Be Held Feb. 15–18 in San Antonio, Texas; Joint Meeting

With American College of Nuclear Physicians RESTON, Va.—The power of molecular imaging—and its ability to see through layers of skin and tissue to the cell to detect—and treat—heart disease, brain disorders and cancer—will be explored during SNM’s Mid-Winter Educational Symposium Feb. 15–18 at the Hyatt Regency in San Antonio, Texas. “The merging of advances in molecular biology with new technologies, hybrid imaging and existing nuclear medicine techniques helps us understand the molecular basis of disease and provides a way to improve patient care in the future,” said SNM President Martin P. Sandler, who speaks for more than 16,000 physician, technologist and scientist members. SNM, the largest professional society for molecular imaging and nuclear medicine, joins forces with the American College of Nuclear Physicians to provide an exceptional educational program examining advances in cardiovascular and brain molecular imaging, treatment of bone tumors, use of radiotracer imaging with heart disease, treatment of cancer in children, instrumentation, and targeted imaging and therapy. Noted physicians, scientists and technologists will present the latest news about using molecular imaging and nuclear medicine for the diagnosis, management and treatment of diseases to several hundred physicians, radiologists, cardiologists, oncologists, technologists, pharmacists, medical physicists and other health care professionals. SNM’s 2007 Mid-Winter Educational Symposium offers programs that include “Proteomic and Genomic Approaches for Identifying Imaging Targets,” “Imaging Atherosclerotic Plaque Biology,” “Synergy of Molecular Imaging and Targeted Therapy in Cardiovascular Disease,” “Novel Applications in Vascular Molecular Imaging,” “The Biology of Imaging of Neuroblastoma,” “High-Dose I-131 MIBG Therapy in Children,” “Low-Dose I-131 MIBG Therapy in Adults and Children,” “Noninvasive Detection of Cardiovascular Risk and Monitoring Medical Therapy With PET, SPECT and CT,” “Radionuclide Imaging in Assessment Risk Stratification and Management of Coronary Artery Disease,” “Radionuclide Imaging in Patients With Heart Failure and Arrhythmias,” “Interplay Between Radionuclide Imaging and Other Developing Cardiac Image Modalities,” “Panel Discussion: Radiotracer Imaging in the Wide Spectrum of Cardiac Disease,” “Biology and Imaging of Bone Tumors,” “Therapy of Primary Tumors,” “Therapy of Osseous Metastases,” “Brain Tumors: Beyond FDG,” “PET/SPECT in CNS Drug Development,” “Cell Tracking and its Future Implications for Neuroimaging,” “Monitoring Gene Therapy in Parkinson’s Disease,” “Developing a Brain Imaging Practice,” “PET and SPECT Imaging for Dementia,” “Epilepsy,” “Cerebrovascular Disease,” “Protocols for PET/CT,” “Update on PET/CT in Radiotherapy Treatment Planning,” “Interesting and Intriguing PET/CT Cases,” “Emerging Solid-State Detector Technologies,” “Nuclear Mammography,” “Cardiac SPECT” and “SPECT/CT.” Topics for technologists include “Updates on Wide Beam Reconstruction,” “Basic Arrhythmia Review,” “Introduction to CT,” “Cardiac CTA,” “Pitfalls and Artifacts in PET and PET/CT,” “Updates in Radiation Safety,” “Molecular Imaging Update” and “Technical Advances in Nuclear Medicine.” SNM and SNMTS members who are organizers, moderators and presenters for the society’s educational program include Danny Basso, Augusta, Ga.; Cynthia Brodnax, Southside, Ala.; Jacqueline Brunetti, Morristown, N.J.; Richard J. Campeau, New Orleans, La.; Tuhin K. Chaudhuri, San Antonio, Texas; Peter Conti, Los Angeles, Calif.; Chaitanya Divgi, Philadelphia, Pa.; David Eve, Louisville, Ken.’ James Fletcher, Indianapolis, Ind.; Karl Herholz, Manchester, England; Peter Herscovitch, Bethesda, Md.; Diwaker Jain, Philadelphia, Pa.; Marie F. Kijewski, Boston, Mass.; Sheila Knepfle, the Woodlands, Texas; Gregory M. Lanza, St. Louis, Mo.; Janet Lary, Seattle, Wash.; David Lewis, Seattle, Wash.; Peter Liu, Toronto, Ontario; April Mann, South Hadley, Mass.; Satoshi Minoshima, Seattle, Wash.; P. David Mozley, Philadelphia, Pa.; Michael K. O’Connor, Rochester, Minn.; Margaurite Parisi, Seattle, Wash.; James A. Patton, Nashville, Tenn.; Ernst Postema, Edmonton, Alberta, Canada; Mehran N. Sadeghi, West Haven, Conn.; Ronald G. Schwartz, Rochester, N.Y.; Paul Shreve, Ada, Mich.; Barry

PRESS RELEASE


(703) 708-9000, ext. 1211

Shulkin, Memphis, Tenn.; Mark I. Travin, Pleasantville, N.Y.; Henry VanBrocklin, San Francisco, Calif.; Douglas Wagenaar, Northridge, Calif.; Alan Waxman, Los Angeles, Calif.; and Greg Wiseman, Rochester, Minn. These sessions were developed with participation from members of SNM’s Brain Imaging, Cardiovascular, Computer and Instrumentation, Nuclear Oncology and Pediatric councils as well as the Molecular Imaging and PET centers of excellence, SNM’s Technologist Section and ACNP. ACNP, which is holding its 33rd annual meeting in conjunction with SNM’s symposium, will offer programs such as “Exploring Ethical Violations of Physicians: A Consumer’s Perspective,” “Malpractice Issues Related to Imaging Specialists,” “ICANL Update: Who Requires Accreditation and What Are the Challenges?” “Building and Growing Your Medical Imaging Practice,” “Cardiac MRI Techniques,” “Ischemic Heart Disease: Application of MRI,” “Principles of Cardiac CT,” “Cardiac CT and Review of Clinical Cases,” “PET/CT Introductions” and “Review of Clinical Cases.” Sessions organized in collaboration with SNM’s Academic Council include “Physicians Training and Qualifications in the Era of Hybrid Functional/Anatomical Imaging,” “Changes in Resident Education: The RRC Perspective” and “Striving for Perfection.” SNM members who are ACNP session organizers, moderators and presenters include Hazem H. Chehabi, Newport Beach, Calif.; Simin Dadparvar, Gladwyne, Pa.; Dominique Delbeke, Fairview, Tenn.; Leonie Gordon, Charleston, S.C.; Randall Hawkins, San Francisco, Calif.; and Tom Miller and Henry Royal, both St. Louis, Mo. Press registration is complimentary to credentialed media. For press registration only, contact Maryann Verrillo by phone at (703) 652-6773 or via e-mail at [email protected]. For additional information about the program, housing and how to register, please visit SNM’s Web site at http://www.snm.org/mwm.

### About SNM—Advancing Molecular Imaging and Therapy SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced—and continue to explore—biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

PRESS RELEASE


(703) 708-9000, ext. 1211

For Immediate Release Feb. 6, 2007

Improved Imaging for Identifying Breast Cancer in Overweight Women

SPECT/CT “Superiority” Aids in Finding “Hot Nodes,” Produces Fewer False-Positive Readings, Says Research in February Issue of the Journal of Nuclear Medicine

RESTON, Va.—Increasing the ability to identify sentinel nodes—the very first lymph nodes that trap cancer cells draining away from a breast lesion site—has a major impact in the treatment and outcome of breast cancer patients, possibly eliminating the need for unnecessary and painful surgery. Researchers found that using SPECT/CT imaging aids in sentinel node identification—especially for overweight or obese women, according to a report in the February issue of the Journal of Nuclear Medicine. Lymphoscintigraphy (a commonly performed nuclear medicine procedure that makes the lymphatic system visible to specialized cameras)—used with single photon emission computed tomography (SPECT)/computed tomography (CT) imaging—boosted sentinel node identification not only for the general population but also for those who were overweight. “The addition of SPECT/CT with lymphoscintigraphy enhanced sentinel node identification in overweight patients with breast cancer,” noted Hedva Lerman, vice chair of the nuclear medicine department at Tel-Aviv Sourasky Medical Center in Israel. Failure to identify sentinel nodes is more frequent in overweight or obese patients, and improved techniques are needed to guide surgeons to their location, said the co-author of “Improved Sentinel Node Identification by SPECT/CT in Overweight Patients With Breast Cancer.” She explained, “While the identification of the sentinel node is an important part of surgical management approaches in breast cancer, obesity is a significant factor in why it fails and inevitably leads to occasional—and unnecessary—full axillary lymph node dissection (a more complex surgery that removes all lymph nodes in the armpit region).” Breast cancer is the second leading cause of cancer death in this country, with women having a 1 in 8 chance of developing it during their lives. When breast cancer is suspected, women may undergo sentinel node biopsy, a minimally invasive surgical procedure used to determine whether breast cancer has spread to lymph glands under the arm, said Lerman. The biopsy requires the removal of only a few first draining lymph nodes for close review, and the lack of cancer cells in these nodes could eliminate the need for removing additional lymph nodes. Identifying the sentinel node before this surgery is key; by removing and examining it, a doctor can determine if breast cancer has spread. “Accurate staging of newly diagnosed patients with breast cancer is of major importance for optimizing breast cancer patients’ treatment,” said Lerman. Knowing whether the cancer has spread helps determine the stage and approach to treatment, she noted. “Performing lymphoscintigraphy by using SPECT/CT allows detection of sentinel nodes preoperatively in more patients, thus reducing the rate of failure to identify these nodes, especially in overweight patients,” said Lerman. She added, “It also provides a more precise anatomical localization of the nodes prior to surgery, thus facilitating the surgical procedure.” In this study, Israeli researchers calculated their subjects’ body mass indexes and evaluated 220 women with invasive breast cancer by identifying sentinel nodes in three ways: using an intraoperative blue dye technique, lymphoscintigraphy (pre-operative two-dimensional imaging) and SPECT/CT lymphoscintigraphy. Researchers found that SPECT/CT lymphoscintigraphy also discovered sentinel nodes that were not identified with the intraoperative blue dye technique in a significant number of patients. “As the number of integrated hybrid SPECT/CT systems evolves, our results hopefully will encourage the use of lymphoscintigraphic SPECT/CT in other centers,” said Lerman. “Data will continue to be collected in identifying sentinel nodes in ‘problematic’ subgroups of patients with breast cancer and in those with other solid tumors where nodal staging is indicated,” she said. “Improved Sentinel Node Identification by SPECT/CT in Overweight Patients With Breast Cancer” appears in the February issue of the Journal of Nuclear Medicine, which is published by SNM, the leading international molecular imaging and nuclear medicine association. Additional co-authors include Gennady Lievshitz, the nuclear medicine department at Tel-Aviv Sourasky Medical Center; Osnat Zak, GE Healthcare in Haifa, Israel; Ur Metser and Einat Even-Sapir, both with the nuclear medicine department at Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine at Tel-Aviv University; and Shlomo Schneebaum, the Sackler Faculty of Medicine at

PRESS RELEASE


(703) 708-9000, ext. 1211

Tel-Aviv University and the Department of Radio-Isotope Guided Surgery Unit of Surgery A, Tel-Aviv Sourasky Medical Center. Media representatives: To obtain a copy of this article, please contact Maryann Verrillo by phone at (703) 652-6773 or send an e-mail to [email protected]. Current and past issues of the Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org. Print copies can be obtained by contacting the SNM Service Center, 1850 Samuel Morse Drive, Reston, VA 20190-5316; phone (800) 513-6853; e-mail [email protected]; fax (703) 708-9015. A subscription to the journal is an SNM member benefit.

# # # About SNM—Advancing Molecular Imaging and Therapy SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced—and continue to explore—biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

PRESS RELEASE


(703) 708-9000, ext. 1211

For Immediate Release March 6, 2007

Breast Cancer Treatment Heats Up

Attaching Nanoscale Bioprobes to Cancer Cells—and Heating Them—Kills Malignant Cells, According to Pre-Clinical, Developmental Research in the March Journal of Nuclear Medicine

RESTON, Va.—In the March Journal of Nuclear Medicine, researchers demonstrate that miniscule bioprobes could be produced and used with molecularly targeted therapeutic heat to kill malignant breast cancer cells—without damaging nearby healthy tissue. While many researchers have studied using heat in treating cancer, “the inability to deposit effective doses of heat in a tumor without applying similar heat to nearby normal tissue has prevented widespread clinical use,” said Sally J. DeNardo, professor of internal medicine and radiology with the School of Medicine at the University of California Davis in Sacramento. “Our animal study, which combined the future-oriented sciences of nanotechnology and molecular imaging, shows that a method for delivering thermal ablation—removing or destroying cancer cells by using heat—is feasible,” added the co-director of the university’s radiodiagnosis and therapy section. “This exciting study—combining radiolabeled antibodies with nanoparticles or bioprobes—provides a new approach to direct thermal ablation specifically to tumor cells,” she noted. DeNardo stressed that this heat treatment is in the preclinical, developmental stage, having been used only in lab mice; additional tests will need to be performed with cancer patients. Such studies are important, explained DeNardo, indicating that breast cancer is the most common cancer among women (besides skin cancer). Statistics show that a woman has a 1 in 8 chance of developing breast cancer during her life. This year, about 200,000 women in the United States will be diagnosed with invasive breast cancer, and nearly 40,000 will die from the disease. Scientists from UC Davis and Triton BioSystems in Boston, Mass., injected trillions of magnetic iron-containing bioprobes into the bloodstream of a lab mouse bearing a human cancer tumor. The magnetic iron nanoprobes—more than 10,000 of which can fit on the end of a straight pin—are concealed in polymers and sugars, making them nearly invisible to the body’s immune system. Antibodies (joined with a radioactive substance) on these probes latched onto receptors that are on the surface of tumor cells. The heating of the probes can be activated and controlled by the use of a magnetic field from outside the body. By applying an alternating magnetic field to the tumor region, the magnetic spheres changed polarity thousands of times per second and created heat. This heat weakened—and destroyed—cancer cells. The bioprobes cooled off as soon as the alternating magnetic field was turned off and then passed out of the body. This process is described in detail in the JNM article, “Thermal Dosimetry Predictive for Efficacy of 111In-ChL6 Nanoparticle AMF–Induced Thermoablative Therapy for Human Breast Cancer in Mice.” “Using heat to kill cancer cells isn’t a new concept. The biggest problems with using heat are how to apply it to the tumor cell alone, how to determine its effectiveness and how to predict the amount needed,” said DeNardo. “By using heat—along with nanoparticles and a radiolabeled antibody—our quantitative imaging directed—and made safer—the application and development of therapy for cancer,” she added. “This technique could join other cancer therapies, especially for cancers that are hard to treat now, such as breast cancer and metastatic melanoma,” indicated DeNardo. “Thermal Dosimetry Predictive for Efficacy of 111In-ChL6 Nanoparticle AMF–Induced Thermoablative Therapy for Human Breast Cancer in Mice” appears in the March issue of the Journal of Nuclear Medicine, which is published by SNM, the leading international molecular imaging and nuclear medicine society. Co-authors include Gerald L. DeNardo, Arutselvan Natarajan, Laird A. Miers and Grete N. Adamson, all with the School of Medicine, UC Davis, Sacramento; Allan R. Foreman and Robert Ivkov, both with Triton BioSystems Inc., Chelmsford, Mass.; and Cordula Gruettner, Micromod Partikeltechnologie, GmbH, Rostock-Warnemuende, Germany. Media representatives: To obtain a copy of this article, please contact Maryann Verrillo by phone at (703) 652-6773 or send an e-mail to [email protected]. Current and past issues of the Journal of Nuclear Medicine can be

PRESS RELEASE


(703) 708-9000, ext. 1211

found online at http://jnm.snmjournals.org. Print copies can be obtained by contacting the SNM Service Center, 1850 Samuel Morse Drive, Reston, VA 20190-5316; phone (800) 513-6853; e-mail [email protected]; fax (703) 708-9015. A subscription to the journal is an SNM member benefit.

# # # About SNM—Advancing Molecular Imaging and Therapy SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced—and continue to explore—biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

PRESS RELEASE


(703) 708-9000, ext. 1211


SNM: Advances in Personalized Medicine on Agenda for 54th Annual

Meeting Research Presented in Molecular Imaging and Therapy, Nuclear Medicine at June 2–6 Conference in

Washington, D.C., May Revolutionize Patient Care for Cancer, Heart Disease, Brain Disorders RESTON, Va.—The potential of molecular imaging and therapy and the power of nuclear medicine—and their impact on patient care—will be explored as more than 4,000 doctors, technologists, scientists and pharmacists from around the world attend SNM’s 54th Annual Meeting June 2–6 in Washington, D.C. SNM—an international, multidisciplinary society of more than 16,000 molecular imaging and nuclear medicine professionals in 78 countries—annually showcases research that promises to revolutionize health care. “SNM has embarked on a mission to improve health care by advancing molecular imaging and therapy, and our program features an increased presence of related research,” said SNM President Martin P. Sandler. “Molecular imaging—the use of state-of-the-art imaging technologies (such as PET, SPECT, MRI and others) to “photograph” biological targets or pathways in the body—and its therapy value will be at the forefront of ‘personalized medicine,’ eventually providing patient-specific information that allows tailored treatment of disease,” he added. “Nearly 2,000 scientific and technologist studies will be presented during this meeting, offering a look at molecular imaging and nuclear medicine research leading to improvements in the diagnosis and treatment of life-threatening cancer, heart disease and brain disorders,” said Scientific Program Committee Chair Frederic H. Fahey. “A new feature this year is the InfoSNM program, which will allow attendees to participate in interactive computer presentations and educational offerings on the novel applications of computers and information science in molecular imaging and nuclear medicine,” explained Fahey. Also new will be the Molecular Imaging Gateway, an area devoted specifically to this exciting field sponsored by the society’s Molecular Imaging Center of Excellence. “As molecular imaging becomes a significant force in clinical practice, SNM Technologist Section members will assume an expanded role in medical care, and this meeting brings us a look at that future,” said SNMTS President D. Scott Holbrook. “Through research presented here, we can see the evolution of molecular imaging and nuclear medicine and how their advances will impact nuclear medicine technologists in the coming years,” he added. Two invited plenary addresses will be given at the meeting. John C. Gore of Vanderbilt University will present the Henry N. Wagner Jr. lecture on June 3, and James H. Thrall will present the Benedict Cassan Lecture on June 4. SNM and SNMTS will present more than 100 continuing education courses focusing on brain amyloid imaging, functional brain imaging in epilepsy and dementia, imaging instrumentation, infection imaging, lymphoma and thyroid cancer, cardiac molecular imaging, bone scanning, general nuclear medicine, reimbursement and coding and critical elements of care in radiopharmacy. More than 180 representatives from the industry’s top product and service providers are participating in SNM’s exhibit hall. Representatives from the Food and Drug Administration will address the role of the investigational new drug (IND) in clinical research; the will provide a Radioactive Drug Research Committee update on June 5 and present updates on PET regulations on June 7. Additionally, representatives from the Nuclear Regulatory Commission will address “Running an NRC-Compliant Radiation Safety Program” on June 5. SNM members will take to Capitol Hill on June 5 to visit hometown representatives and talk about public policy issues. On June 2, 12 categorical seminars, developed by members of SNM’s various councils and centers of excellence, will be presented. These seminars will cover new directions in molecular imaging of the brain and heart, qualitative SPECT for molecular imaging, emerging clinical applications of SPECT/CT, radiopeptide imaging and therapy, molecular imaging and cancer therapy, pediatric radiotherapy, hot topics in PET/CT, multimodality molecular imaging, an assessment of nuclear cardiology, a PET/CT update in oncology and cardiology, and current issues and advances in nuclear medicine. To register for the meeting, visit the SNM Web site at http://www.snm.org/am. Press registration is complimentary to credentialed media. For press registration only, contact Maryann Verrillo, by phone at (703) 652-6773 or via e-mail at [email protected]. Reporters may also register online at www.snm.org/am. SNM will hold a press conference on Monday, June 4, featuring an overview of the latest research and discoveries in the world

PRESS RELEASE


(703) 708-9000, ext. 1211

of molecular imaging and nuclear medicine. New applications in oncology, neurology and cardiology will be discussed. Also at this press conference, Henry N. Wagner Jr., will announce his 2007 Image of the Year.

# # # About SNM—Advancing Molecular Imaging and Therapy SNM is holding its 54th Annual Meeting June 2–6 at the Washington, D.C., Convention Center. Session topics for the 2007 meeting include brain amyloid imaging, hybrid imaging, molecular imaging in clinical drug development and evaluation, functional brain imaging in epilepsy and dementia, imaging instrumentation, infection imaging, lymphoma and thyroid cancer, cardiac molecular imaging, general nuclear medicine, critical elements of care in radiopharmacy and more. SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced—and continue to explore—biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

PRESS RELEASE


(703) 708-9000, ext. 1211


SNM’s “Bench to Bedside” Campaign Gains Added Support Recent “Bench to Bedside” Pledges From Corporate Leaders Push Total to $3.3 Million; Society Announces

New Director for Its Molecular Imaging Center of Excellence RESTON, Va.—SNM, the world’s largest society for medical professionals in the molecular imaging and nuclear medicine profession, has received nearly $3.3 million in corporate donations for its “Bench to Bedside” campaign. Recent pledges from IBA Molecular, MDS Nordion and Cardinal Health, totaling more than $1 million, have been added to previous commitments from industry donors including GE Healthcare, Bristol-Myers Squibb Medical Imaging, Siemens Medical Solutions USA, Philips and FluoroPharma. “The ‘Bench to Bedside’ campaign is a five-year, concentrated effort to raise $5 million to power SNM’s important initiative: uniting the imaging community in the effort to translate new molecular imaging research into health care innovations that can be used in patient care,” said SNM President Martin P. Sandler. “Molecular imaging—‘seeing’ biological targets or pathways in the body to understand how individual molecules are working—is at the forefront of ‘personalized medicine,’ which eventually will allow us to tailor the treatment of a disease to each individual patient. Molecular imaging is advancing the understanding, diagnosis, treatment and follow-up on disease to improve the lives of people worldwide,” he added. “We are pleased that innovative corporate leaders believe in SNM and support our mission. The campaign’s importance is underlined by the fact that pledges are well ahead of our intended goal,” said Sandler. “Bench to Bedside: A Molecular Imaging Campaign” is being carried out in partnership with SNM’s Education and Research Foundation. The campaign was jump-started last summer with $1 million from lead donor GE Healthcare. Through collaboration with members of SNM’s Molecular Imaging Center of Excellence, the society has drafted a separate, five-year action plan to move molecular imaging research from bench to bedside. “Bench to Bedside” funds will be used to support translational research; facilitate clinical research and clinical trials; support outreach activities to referring physicians, patient groups, regulators and funders; increase advocacy for molecular imaging; and train the current imaging workforce and educate future generations of practitioners on the applications of molecular imaging. “To underscore the importance of this campaign and the society’s mission to improve health care by advancing molecular imaging and therapy, SNM has named Marybeth Howlett as the director of our Molecular Imaging Center of Excellence,” said Virginia Pappas, chief executive officer. Howlett, the founding executive director of the Public Health Policy Advisory Board—an independent, nonpartisan organization in Washington, D.C., created by former Health and Human Services Secretary Louis W. Sullivan—will implement the center’s strategic initiatives, explained Pappas. As the center’s director, Howlett—who launched and ran PHPAB for three years and has an educational background in public policy and environmental science—will help Molecular Imaging Center of Excellence leadership create a Web site devoted to molecular imaging; establish collaborative relationships within the medical community; develop new grants and awards and educational curricula to support the field; initiate action plans to enable emerging molecular imaging technologies to become clinically useful; and initiate dialogues with regulatory, funding and legislative officials to explore areas of mutual interest. Prior to her work at PHPAB, Howlett held positions of senior science manager for the Chlorine Chemistry Council in Arlington, Va., and project manager for American Management Systems in Fairfax, Va. A graduate of Yale College and the Yale School of Forestry and Environmental Studies, she also worked for the U.S. Environmental Protection Agency. Corporate and individual donors will find information about the “Bench to Bedside: A Molecular Imaging Campaign” and how to donate on SNM’s Web site at http://www.snm.org/micampaign. Those interested in learning more may also contact Kathleen Bates, SNM director of development, by phone at (703) 326-1194 or via e-mail at [email protected], or Megan Schagrin, SNM associate director of industry and international relations, by phone at (703) 326-1184 or via e-mail at [email protected]. Additional information about the Molecular Imaging Center of Excellence can be found on SNM’s Web site: http://www.snm.org.

# # #

PRESS RELEASE


(703) 708-9000, ext. 1211

About SNM—Advancing Molecular Imaging and Therapy SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced—and continue to explore—biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

PRESS RELEASE


(703) 708-9000, ext. 1211

For Immediate Release April 3, 2007

Heart Failure: Intervention Possibilities From Imaging Programmed Cell

Loss Researchers in April Journal of Nuclear Medicine Suggest Annexin A5 Imaging Offers Opportunity to

‘Minimize’ Damage to Heart Muscle RESTON, Va.—Using a nuclear medicine technique and molecular imaging to “see” programmed cell loss—the body’s normal way of getting rid of unneeded or abnormal cells—may help in early identification of those individuals who are at risk of developing heart failure, say researchers in the April Journal of Nuclear Medicine. “Our study indicates that it is feasible to noninvasively identify cell loss—or apoptosis—in heart failure patients using annexin A5 imaging,” explained Leo Hofstra, director of cardiovascular imaging at the University Hospital of Maastricht in the Netherlands. “Such a strategy may offer a new possibility for studying interventions to minimize damage to the heart muscle,” he added. “This research is significant since cell loss is potentially reversible and earlier intervention could delay the development of cardiomyopathy or heart muscle disease,” noted Hofstra. He indicated that additional research is needed since the study was performed on a small group of heart patients. “Heart failure is a major health care problem,” said Hofstra, “and researchers are looking at novel ways to improve patient care.” With heart failure, a person’s heart no longer pumps sufficient blood to the body’s organs. Nearly 5 million Americans are living with heart failure—a long-term condition that tends to gradually worsen—and 550,000 new cases are diagnosed each year. Researchers attached a radioactive substance to annexin A5, a protein that binds to dying cells, said Hofstra. They then used nuclear imaging that produces three-dimensional computer-reconstructed images to reveal information about both structure and function to measure the amount of annexin A5 absorbed. Annexin A5 bound to the damaged heart muscle. “We discovered that higher uptake was uptake with a worse outcome. Cell death is one of the biological events that worsens left ventricular events,” said Hofstra. “Our results indicate that heart muscle cell death is an active and ongoing process in heart failure, and that annexin imaging could possibly guide treatment for heart patients and be used to determine whether a treatment was working,” said Hofstra, co-author of “Noninvasive Detection of Programmed Cell Loss with 99mTc-Labeled Annexin A5 in Heart Failure.” He anticipates that this research would spur development of new drugs for heart disease. “Noninvasive Detection of Programmed Cell Loss with 99mTc-Labeled Annexin A5 in Heart Failure” appears in the April issue of the Journal of Nuclear Medicine, which is published by SNM, the world’s largest molecular imaging and nuclear medicine society. Other co-authors are Bas L.J.H. Kietselaer and Harry J.G.M. Crijns, both with the Department of Cardiology, University Hospital of Maastricht; Chris P.M. Reutelingsperger, Department of Biochemistry, University of Maastricht; Hendrikus H. Boersma, Department of Clinical Pharmacy and Department of Nuclear Medicine, University Hospital of Maastricht; Guido A.K. Heidendal, Department of Nuclear Medicine, University Hospital of Maastricht; Ing Han Liem, Department of Nuclear Medicine, Maxima Medical Center, Veldhoven—all in the Netherlands; and Jagat Narula, Division of Cardiology, University of California, Irvine College of Medicine. Media representatives: To obtain a copy of this article, please contact Maryann Verrillo by phone at (703) 652-6773 or send an e-mail to [email protected]. Current and past issues of the Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org. Print copies can be obtained by contacting the SNM Service Center, 1850 Samuel Morse Drive, Reston, VA 20190-5316; phone (800) 513-6853; e-mail [email protected]; fax (703) 708-9015. A subscription to the journal is an SNM member benefit.

# # # About SNM—Advancing Molecular Imaging and Therapy SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose,

PRESS RELEASE


(703) 708-9000, ext. 1211

manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced—and continue to explore—biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

file://///SNMDC1/SNM%20Shares/SHARE/LED/BOD/Meetings/Spring%2...pring/AGENDA%20TOPICS/MI%20Center/Email_Blast_MI_AttachB7.htm

From: Marisa [[email protected]]Sent: Thursday, March 29, 2007 3:59 PMTo: Howlett MarybethSubject: Message from the Society of Nuclear Medicine (Preview)

Trouble viewing this e-mail? Click here to view the web version.Is this e-mail going to your junk/bulk folder? Add [email protected] to your address book to ensure that you receive all

future e-mails in your inbox.

SNM Home Page

MICoE Page

The Journal of Nuclear Medicine

The Journal of Nuclear

Medicine Technology

March 2007

Molecular Imaging References Are Now Online Use the link above to read selected research papers on various molecular imaging topics published in recent weeks through PubMed. Live links to PubMed are included for each reference.

MI in the News Molecular Imaging Agent Promising For Alzheimer's Diagnosis Holographic images show responses to anti-cancer drug.

New Molecular Imaging Compound Pinpoints Cancer Spread in Mice Researchers have created a new imaging compound in mice that selectively binds to certain cancer cells and glows, or fluoresces, only when processed by these cells.

A Closer Look Inside Our Lungs - Penn Researchers Develop Two

file://///SNMDC1/SNM%20Shares/SHARE/LED/BOD/Meeti...%20TOPICS/MI%20Center/Email_Blast_MI_AttachB7.htm (1 of 2)4/10/2007 5:28:29 AM

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=index.phpaction%3Dviewsenthtmlid%3D1924ids%3D5542ef94de1f2c0494b71ccf4f4442e67380a108viewers_email%3Dmhowlett%40snm.org&id=1924&[email protected]&dest=http%3A%2F%2Fmailcenter.newmediagateway.com%2Fsnm%2Fmain%2Findex.php%3Faction%3Dviewsenthtml%26id%3D1924%26ids%3D5542ef94de1f2c0494b71ccf4f4442e67380a108%26viewers_email%3Dmhowlett%40snm.org

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=mi&id=1924&[email protected]&dest=http%3A%2F%2Fwww.snm.org%2Fmi

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=About+MI+Center+of+Excellence&id=1924&[email protected]&dest=http%3A%2F%2Finteractive.snm.org%2Findex.cfm%3FPageID%3D4551%26RPID%3D2324

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=index.cfmLogin%3DTruePageID%3D10RPID%3D1795CFID%3D12267170CFTOKEN%3D85640987&id=1924&[email protected]&dest=http%3A%2F%2Finteractive.snm.org%2Findex.cfm%3FLogin%3DTrue%26PageID%3D10%26RPID%3D1795%26CFID%3D12267170%26CFTOKEN%3D85640987

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=About+MI+Center+of+Excellence&id=1924&[email protected]&dest=http%3A%2F%2Finteractive.snm.org%2Findex.cfm%3FPageID%3D4551%26RPID%3D2324

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=index.cfmPageID%3D1402&id=1924&[email protected]&dest=http%3A%2F%2Finteractive.snm.org%2Findex.cfm%3FPageID%3D1402




http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=March_MIReferences.doc&id=1924&[email protected]&dest=http%3A%2F%2Fmailcenter.newmediagateway.com%2Fsnm%2Ffiles%2Fflash_docs%2F1d%2F51%2F3c%2F81%2F0%2FMarch_MIReferences.doc

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=March_MIReferences.doc&id=1924&[email protected]&dest=http%3A%2F%2Fmailcenter.newmediagateway.com%2Fsnm%2Ffiles%2Fflash_docs%2F1d%2F51%2F3c%2F81%2F0%2FMarch_MIReferences.doc

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=89&id=1924&[email protected]&dest=http%3A%2F%2Fwww.healthimaging.com%2Fcontent%2Fview%2F6211%2F89%2F

http://mailcenter.newmediagateway.com/snm/main/index.php?action=t&tag=index.cfmPageID%3D6022RPID%3D3897&id=1924&[email protected]&dest=http%3A%2F%2Finteractive.snm.org%2Findex.cfm%3FPageID%3D6022%26RPID%3D3897



file://///SNMDC1/SNM%20Shares/SHARE/LED/BOD/Meetings/Spring%2...pring/AGENDA%20TOPICS/MI%20Center/Email_Blast_MI_AttachB7.htm

Novel Imaging TechniquesResearchers at the University of Pennsylvania School of Medicine (Philadelphia) are harnessing two new, non-invasive techniques to look more closely inside the working lungs—leading to early detection of diseases, like emphysema, before it becomes evident in other modes of imaging.

Researchers Wake Up Viruses Inside Tumors to Image and Then Destroy CancersResearchers have found a way to activate Epstein-Barr viruses inside tumors as a way to identify patients whose infection can then be manipulated to destroy their tumors. They say this strategy could offer a novel way of treating many cancers associated with Epstein-Barr, including at least four different types of lymphoma and nasopharyngeal and gastric cancers.

Stable, Non-toxic Form of Gold Nanoparticles Developed; May Be Useful in Molecular Imaging and TherapyNew research at the University of Missouri-Columbia has found that a plant extract can be used to create a new type of gold nanoparticle that is stable and nontoxic and can be administered orally or injected.

This e-mail was requested by: [email protected]

Change subscription preferences:

Change

Unsubscribe by mail: SNM1850 Samuel Morse Dr.Reston, VA 20190

Forward to a Friend: Forward

file://///SNMDC1/SNM%20Shares/SHARE/LED/BOD/Meeti...%20TOPICS/MI%20Center/Email_Blast_MI_AttachB7.htm (2 of 2)4/10/2007 5:28:29 AM






http://mailcenter.newmediagateway.com/snm/main/index.php?action=unsubscribe&[email protected]&id=1924

http://mailcenter.newmediagateway.com/snm/main/index.php?p=email.forward_to_friend&id=1924&[email protected]&dt=1

Attachment C

4/10/2007 page 1

Molecular Imaging Center of Excellence Strategic Plan Task Force Membership

Key Task Forces

Chair Task Force Members

Commun-ications Task Force

Al Sinusas, MD (Yale) [email protected] 203/785-4915 SNM Staff: Marybeth Howlett, Sue Abreu Rebecca Maxey

Todd Peterson, PhD (MI BOD, Vanderbilt) Sandy McEwan, MD (U. of Alberta) Scott Holbrook BS, CNMT, PET, RT(N), FSNMTS SNMTS President (Precision Nuclear, CPS) Conrad Nagle, MD (William Beaumont Hospital) Heinz Schelbert, MD, PhD (U of C, Los Angeles) Alan Packard,BS, PhD (Harvard Med School) Peter Herscovitch, MD (NIH) Robert Levene, MD (Yale) Orest Boyko, MD, PhD (Temple)

Editorial Board

SNM Staff: Marybeth Howlett Rebecca Maxey Ann Coleman

Marty Pomper, MD, PhD (Johns Hopkins) Carolyn Anderson, PhD (Washington U.) Henry VanBrocklin, PhD (U. California, SF) Todd Peterson, PhD (Vanderbilt) Orest Boyko Peter Herscovitch

Advocacy Task Force

Robert Atcher, PhD (Los Alamos Nat’l Lab) [email protected] 505/667-0585 SNM Staff: Marybeth Howlett, Sue Abreu Hugh Cannon

Robert Atcher, PhD (Los Alamos) Peter Conti, MD, PhD (U. Southern CA) Joe Wu, MD, PhD (Stanford) Mathew Thakur, PhD (Thomas Jefferson) Chaitanya Divgi, MD (U. Penn) Lily Wu, MD, PhD (UCLA) Alan Packard, BS, PhD (Harvard) Terry Beven, MD Gary Dillehay, MD (Northwestern) Bob Henkin, MD (UNM, Ltd) Howard Halpern, MD, PhD (U. Chicago) David Gilmore, MS,CNMT, (Mass. Coll of ) Gary Luker, MD (U. Michigan) Katherine Ferrara, PhD (U. California-Davis) Jonathan R. Lindner, MD (OSU) Bennett Greenspan U. Missouri, Columbia) Mark Soffing (IBA Molecular)

Education Task Force

Carolyn Anderson, PhD (Washington U.) [email protected] 314/362-8427 SNM Staff: Marybeth Howlett, Sue

Carolyn Anderson, PhD (Washington U) Robert Atcher, PhD (Los Alamos Nat’l Lab) Michael Stabin, PhD (Vanderbilt) Ed Holmes, MD (Inland Imaging PS) Joe Wu, MD, PhD (Stanford) Ben Franc, MD, MS (YPC, U. California, SF) Heather Jacene, MD (YPC, Johns Hopkins) Alan Maurer, MD (Temple) Darlene Metter, MD, PhD (U. Texas)

4/10/2007 page 2

Key Task Forces


Abreu Lynn Barnes

Bennett Greenspan, MD, MS (U. Missouri, Columbia) Mark Madsen, PhD (U. Iowa) George Zubal, PhD (Yale) Jeff Norenberg Julie L. Sutcliffe, Ph.D. (UCDavis)

Grants & Awards Task Force

Mathew Thakur, PhD (Thomas Jefferson) [email protected] 215/503-7874 SNM Staff: Marybeth Howlett Kathy Bates Renee Bergen

Marty Pomper, MD, PhD (Johns Hopkins) Craig Levin, PhD (Stanford) Amol Takalkar, MD (YPC, Louisiana State) Peter Kirchner, MD (ERF, Nat’l Institute of Biomedical Imaging and Bioengineering) Hani Abdel-Nabi, MD, PhD (Buffalo) Lily Wu, MD, PhD (UCLA) Mike Welch, PhD (Mallinckrodt Inst. Of Rad.)

Standard Definitions Task Force

David Mankoff [email protected] 206/288-2173 SNM Staff: Marybeth Howlett, Sue Abreu

Mathew Thakur, PhD (Thomas Jefferson) Michael Stabin, PhD (Vanderbilt) Al Sinusas, MD (Yale) Craig Levin, PhD (Stanford) Jerry Glickson, PhD (U. Penn) Bennett Chin, MD (Duke) Bill Eckelman, PhD (Molecular Tracer, LLC) Barry Shulkin, MD (St. Jude’s Children’s Research Hospital) Ron Van Heertum, MD (Columbia) Benjamin Tsui, PhD (JHU) Chet Mathis, PhD (U. Pitt) Sue Abreu, MD (Consulting)

Leading Technologies/Assess’t

Sandy McEwan, MD (U. Alberta) [email protected] 780/432-8524 SNM Staff: Marybeth Howlett, Sue Abreu

Henry VanBrocklin, PhD (U. California, SF) Dave Mankoff, MD (U. Washington) Chaitanya Divgi, MD (U. Penn) Benjamin Tsui, PhD (JHU) Arden Kwan, MD (Kaiser) Dan Sullivan (NCI) George Mills, MD (FDA)

Standardized Imaging Protocols Workshop

Henry VanBrocklin, PhD (U. California, SF) [email protected] 415/353-4569 SNM Staff: Marybeth Howlett, Sue

John Gore, PhD (Vanderbilt) Michael Zalutsky, PhD (Duke) George Sgouros, PhD (JHU) Michael Stabin, PhD (Vanderbilt) George Mills, MD (FDA) Scott Holbrook, BS, CNMT, FSNMTS (Precision Nuclear, CPS) Benjamin Tsui, PhD (JHU) Michael Haka, PhD (Buffalo) Rutao Yao, PhD (Buffalo) David Mankoff, MD (U. Washington) Orest Boyko, MD, PhD (Temple)

4/10/2007 page 3

Key Task Forces


Abreu

Tracers & Future “FDG”s

Henry VanBrocklin, PhD (U. California, SF) SNM Staff: Marybeth Howlett

John Gore, PhD (Vanderbilt) Michael Zalutsky, PhD (Duke) George Sgouros, PhD (JHU) Dave Mankoff, MD (U. Washington) Sandy McEwan, MD (U. Alberta) Chaitanya Divgi, MD (U. Penn) Ken McKusick, MD Barry Siegel, MD (Washington U/Mallinckrodt Inst. Of Rad.) Ken Krohn, PhD (U. Washington)

Liaison/Reporting for Clinical Trials

N/A David Mankoff, MD (U. Washington)

Members-hip

Invited: SNM Staff: Marybeth Howlett Joanna Spahr

Scott Holbrook

Overall Staff Support

Marybeth Howlett [email protected] 703/652-6798 703/655-7132 (cell) Sue Abreu, MD, Marisa Vivalda

Attachment D

SNM Advancing Molecular Imaging and Therapy

Presentation to: NameTitle

Company

By: NameSNM Leadership Title

Month Day, Year

Overview

• About SNM

• Nuclear medicine today

• Today’s challenges and opportunities

• Changing landscape of imaging and therapy

• Future issues and vision

• What is Bench to Bedside?

SNM

• Founded in 1954

• The largest international scientific organization dedicated to molecular imaging and therapy

• A multi-disciplinary organization– over 16,000 physicians, scientists, pharmacists, and

technologists

– industry and other partners interested in the diagnostic, therapeutic, and investigational uses of molecular imaging and therapy agents, instrumentation and techniques

councilscouncilschapterschapters centers of excellencecenters of excellence

Progression of Nuclear Medicine

2D small region scan–thyroid

2D whole-body scan–bone

3D dynamic scan–heart

3D whole-body fusion scan

History of Nuclear Medicine

Discovery 1896 Tracers and

therapeutics 1922–today

Instrumentation development 1947–today

Clinical application 1972–today

Nuclear Medicine Procedures

• 19.7 million nuclear medicine procedures in the United States (2005)

• 7,205 hospital and non-hospital sites

• Hospital volume unchanged, 2002 – 2005

• Non-hospital volume increased by 22 percent, 2002 – 2005

Source: IMV

Source: IMV

Proc

edur

es in

mill

ions

Total U.S. Nuclear Medicine Procedures

0

2

4

6

8

10

12

14

16

18

20

1977 1998 1999 2000 2001 2002 2005

U.S. Nuclear Medicine Procedure VolumeHospital vs. Non-Hospital

Source: IMV

0

2

4

6

8

10

12

14

16

1996 1997 1999 2001 2002 2005

HospitalsNon-Hospitals

Proc

edur

es in

mill

ions

U.S. PET Procedure Volume

Bio-Tech Systems Radiopharmaceutical Report 2004

0

0.5

1

1.5

2

2.5

3

3.5

2003 2004 2010

Proc

edur

es in

mill

ions

U.S. PET Imaging Sites

0200400600800

10001200140016001800

2001 2002 2003 2005

Source: IMV

• PET/CT is improving diagnostic accuracy and optimizing patient care

• Data from concurrent studies are essential for timely diagnosis and management decisions

PET

PET/CT

PET/CT Hybrid Technology

0

20

40

60

80

100

2001 2002 2003 2004 2005

PET/CTPET

Source: IMV

Percent of Dedicated PET vs. PET/CTScanners in the U.S.

Current Challenges in Current Challenges in Nuclear MedicineNuclear Medicine

Clinical TrialsClinical Trials

ResearchResearchFundingFunding

EconomicsEconomics RegulatoryRegulatory

EducationEducation

• Elimination or stagnation of Federal funding– Diminished resources for radiotracer and instrumentation

research

– Limited funding for development of imaging biomarkers and new drugs

– Limited availability of isotopes for research

• Competition among too many professional societies for corporate support

Funding Challenges

• Ensuring practitioners keep abreast of emerging technologies and cutting-edge research

• Communicating new Maintenance of Certification requirements

• Reaching out to and educating other specialists and patients

• Ensuring academic curricula incorporate new technologies

• Ensuring adequate supply of new practitioners and researchers

Education Challenges

• Cost of bringing new and orphan drugs to market, particularly new imaging probes

• Increasing recognition of the importance of imaging biomarkers in drug development

• Evolving FDA guidelines for radiopharmaceuticals, biologics and other agents

Regulatory Challenges

• Requirement for uniform imaging protocols in clinical trials–NIH and FDA initiatives

• Increased NRC regulatory burden for use of radioisotopes and accelerators

Regulatory Challenges (cont’d)

• Reimbursement – Avoiding cuts/restoring

funding

– Adding new procedures

• “Pay for Performance”– How will nuclear imagers

become stakeholders?

– How will imagers be judged?

• Intellectual Property

Economic Challenges

• Need to prove clinical utility of imaging and therapy agents – Framework

– Funding of clinical trials

– More clinical trials for new agents

– More use of nuclear medicine in existing trials

• Develop data to support regulatory change to facilitate imaging biomarker proof-of-principle studies

Clinical Trial Challenges

• Aggressively working to restore federal funding

• Collaborating with other specialty societies to reduce fragmentation

• Pursuing patient advocacy and education

What SNM Is Doing Today

• Introducing new physician education programs

– LLSAP self-assessment programs, including CT and PET/CT cases

– Programs to help physicians meet MOC requirements

– Curriculum for nuclear medicine training, including CT and molecular imaging (3-year residency)

What SNM Is Doing Today (cont’d)


• Increasing referring physician outreach

• Creating a central repository of information for:

– Medical community

– Patients and the public

• Publishing cutting edge research articles and abstracts in journals and at meetings

• Promoting novel research through pilot grants

• Attracting talented students through fellowships

• Managing a clinical trials program

• Enhancing patient care and quality of services through:– Practice guidelines

– Laboratory accreditation guidelines

• Collaborating with other societies on Pay for Performance and practice standards


The Evolution of Diagnostic Imaging

PAST PRESENT FUTURE

AnatomicAnatomic

Plain films, CT, Plain films, CT, MRI, USMRI, US

FunctionalFunctional

Angiography, Angiography, Doppler US, NM, Doppler US, NM,

MRI, PETMRI, PET

HybridHybrid

PET/CT, PET/CT, SPECT/CT, PET/MRSPECT/CT, PET/MR

MolecularMolecular

NM, PET, SPECT, NM, PET, SPECT, MRS, optical, MRS, optical,

PET/MRIPET/MRIcontrastcontrast--enhanced enhanced

MRI/US/CTMRI/US/CT

Existing and Emerging Modalities–Vision of Future Patient Care

PET/CTMR Spectroscopy

SPECT/CTContrast-enhanced US/Doppler

Bio-active MR contrast agents

Bioluminescence

PET/MRI

Existing and Emerging Modalities–Vision of Future Patient Care (cont’d)

• Study in vivo molecular biology and guide individualized patient care

• Facilitate the understanding of the molecular basis of disease

• Enhance drug development through the use of molecular imaging in clinical trials

Goals of Molecular Imaging

• Assess the biological nature of disease early and throughout its evolution

• Facilitate drug discovery and development

• Provide biological information for developing and assessing innovative therapies

• Predict, monitor, and measure treatment response

• Support clinical trials through imaging biomarkers

Molecular Imaging: Research

• Improve diagnostic effectiveness

• Predict treatment response

• Improve patient outcomes

• Individualize treatment plans

• Direct most appropriate therapies

• Enhance resource utilization

Molecular Imaging: Research (cont’d)

• In vivo biological characterization

• Pharmacokinetics measurements

• Imaging biomarkers in clinical trials

• Determination of treatment effect

• Drug response

• Improve drug development successes

• Novel diagnostic molecular imaging agents

Molecular Imaging: Drug Development

• Streamlining drug discovery

• Enhancing patient care– Finding the best drug

against the right target to treat the right patient at the right time

FDGFDG FESFES

“Targeted Imaging” Drive TowardPersonalized Medicine

• In order to bring molecular imaging from Bench to Bedside we must address these issues:

– translational

– clinical

– drug development

Bench to Bedside

• Increase success rate for new pharmaceutical targets

• Define and promote molecular imaging in drug development

• Introduce novel diagnostic molecular imaging agents

• Facilitate the use of molecular therapies such as Radioimmunotherapy

Molecular Imaging and Therapy Issues

• Few new tracers

• No methodologies to validate and standardize quantitation

• No standardized protocols for cooperative clinical trials

• Lack of integration with other imaging methodologies

• Absence of health technology assessment


• Need for regulatory change to reduce requirements for proof of principle studies

• Need to define correlative outcomes required for imaging biomarkers

• Decreased funding for research on molecular probe development and instrumentation improvements


• Ensuring imaging practitioner of the future is well prepared to adopt new technologies

• Meeting multidisciplinary educational needs

• Raising awareness of applications and benefits of molecular imaging

• Molecular imaging is not a medical specialty


• Basic scientists conducting multi-modality research

• Clinicians practicing molecular imaging and therapy; conducting supporting clinic

• Health policy infrastructure addressing regulatory, funding, and outreach activities

• Educational offerings and knowledge base that cross the interdisciplinary boundaries

Who will provide the leadership and guidance forthe field of molecular imaging and therapy going forward? SNM

SNM’s New Mission

Position SNM as the leader for molecular imaging in drug development and therapy

• Refocusing/rebranding SNM

• MI Center of Excellence

• Capital campaign

Core Purpose: To improve health care by advancing molecular imaging and therapy

Vision: SNM will be the leader in advancing and unifying molecular imaging and therapy

SNM Rebranding—2006 and Beyond

Campaign Overview• To support the translation of molecular imaging

research into clinical practice

• To foster the use of molecular imaging in drug discovery and development

• To engage industry and the molecular imagingcommunity

• To raise $5,000,000 over 5 years

Value of the Campaign• Recognizes expanding role of molecular imaging in patient

care

• Builds on SNM’s unique role in medical community

• Highlights importance of molecular imaging in drug discovery and development

• Ensures imaging practitioners are well prepared to adopt and use this technology

• Ensures medical community is well informed and partnerships are formed outside imaging field

Goals of the Molecular Imaging Campaign• Provide indispensable resources for education,

knowledge exchange, training and networking

• Advocate for molecular imaging and therapy

• Educate and promote collaboration with referring physicians and patient groups

• Support innovations in translational research

• Position molecular medicine as an essential tool in providing the highest standards of patient care around the world

Provide indispensable resources for education, knowledge exchange, training and networking

• Be a central repository for molecular imaging

• Create and award grants and fellowships

• Develop fellowship and residency curriculum

• Conduct workshops to attract and meet diversified needs of molecular imaging practitioners

• Implement continuing educational programs and web-based training

Provide indispensable resources for education, knowledge exchange, training and networking

• Perform clinical trials in nuclear medicine and molecular imaging

• Implement communications plan to raise awareness that SNM is the indispensable resource for molecular imaging

Advocate for molecular imaging and therapy

• Proactively lobby for reimbursement and research funding

• Strengthen relationships with federal agencies and Congress

• Educate community on benefits of molecular imaging and emerging technologies

Educate and promote collaboration with referring physicians and patient groups

• Create outreach program for referring physicians, patient groups, federal agencies, regulators and the general public

Support innovations in translational research

• Define translational research from bench to bedside – research to practice

• Provide institutional grants for training workshops on translating basic research into clinical application

• Develop research programs to assist new investigators in the field of molecular imaging

• Identify new funding opportunities

Support innovations in translational research (cont’d)

• Develop standardized imaging protocols and outcome measures

• Define the role of biomarkers in clinical trials

• Investigate the implications of molecular imaging in diagnosis and the prediction and monitoring of treatment response

• Develop technology assessment mechanism

Support innovations in translational research (cont’d)

• Assure the viability of MI through the development of techniques that meet a clinical need and that are reimbursable

• Partner with basic science organizations, academia, and industry to promote translational research

• Position SNM as a central repository for molecular imaging research

• Identify and validate new tracers

SNM will be recognized as the society that positions molecular medicine as an essential tool in providing the highest standards of patient care around the world

• Develop major media marketing plan to influence the introduction and acceptance of molecular imaging technology and benefits

• Develop an integrated strategic marketing plan to position SNM as the recognized leader

• Increase membership by molecular imaging professionals outside of nuclear medicine

Strategic Plan Implementation• Molecular Imaging Center of Excellence has

the lead

• Developed 8 Task Forces to implement objectives/strategies for each goal

• Task Forces include Center members and other leaders in the field

Communications - First Year Strategies• Develop new community Web site and listserv

• Develop case studies and brochures that illustrate practical benefits

• Expand JNM and Newsline coverage

• Create“Road Show” and other new communications vehicles

• Design media campaign

Advocacy- First Year Strategies• Congressional outreach campaign during

annual meeting

– Strengthen relationships

– Raise awareness of molecular imaging

• Meet with representatives from 5 clinical, 5 research, 5 patient and pharmaceutical groups to discuss areas of collaboration

• Identify new funding sources

Education – First Year Strategies• Develop curriculum outline for fellowships and

residents

• Initiate clinical and research grants and fellowships

• Create a speakers’ bureau

• Institute more workshops, symposia and Web-based training on molecular imaging, especially during SNM annual meeting

Science/Research – First Year Strategies• Support translational clinical studies and small

innovative trials

• Convene meetings and/or retreats to discuss key issues

– New tracer development

– Technology assessment and advancement

– Translational research education

– Standardized imaging protocols

MI Center of Excellence Leadership

• Martin Pomper, MD., PhD. - President

• Henry Van Brocklin, PhD – Vice-President

• Carolyn Anderson, PhD – Secretary/Treasurer

Staff• Marybeth Howlett, MEM

• Sue Abreu, MD

• Marisa Vivalda

Task Force Chairs• Communications – Al Sinusas, MD

• Education – Carolyn Anderson, Ph.D

• Advocacy – Robert Atcher, Ph.D

• Grants & Awards – Mathew Thakur, Ph.D

Task Force Chairs (cont’d)• Standard Definitions – David Mankoff, MD

• Leading Technologies – Sandy McEwan, MD, PhD

• Future Tracers Workshop – Henry VanBrocklin, PhD

• Membership – Scott Holbrook, MS CNMT NCT

Editorial Board• New monthly Newsline section

• New literature searches

• New quarterly newsletter

• New monthly email blasts

• New MI Center Welcome Packet

How to Support the Campaign• Corporate donations and pledges

• Individual gifts and pledges

• Collaboration in task forces, summits

• Feedback and ideas

• Involvement through MI COE, Web site, list serve

Financial Support

• Corporate pledges over five years or less –Campaign Staff Kathy Bates and/or Megan Schagrin

• Individual gifts and pledges – Education and Research Foundation Staff Kathy Bates

• Donor recognition began in 2006

• Co-chairs of the campaign:

Hadi Moufarrej, GE Healthcare

Peter S. Conti, M.D., Ph.D.; SNM Past President

Michael D. Devous, Sr., Ph.D.; ERF Past President

• SNM Campaign staff:

Virginia Pappas; CEO

Kathy Bates; Director Development

Megan Schagrin; Assoc. Director, Industry Relations

Marybeth Howlett; Director, MI Center of Excellence

Campaign Leadership and Staff

Industry Donor Categories

• Corporate Circle: $500,000 or more

• Corporate Visionary: $250,000 - $499,999

• Corporate Partner: $100,000 - $249,999

• Corporate Friend: $50,000 - $99,999

• Corporate Contributor: <$50,000

• Corporate Circle: $500,000 or more

• GE Healthcare

• Bristol-Myers Squib Medical Imaging

• IBA Molecular

• Siemens Medical Solutions USA

• Corporate Visionary: $250,000 - $499,999

• Philips

• MDS Nordion

• Cardinal Health

• Corporate Partner: $100,000 - $249,999

• Corporate Friend: $50,000 - $99,999

• Corporate Contributor: <$50,000

• FlouraPharma

Pledges

Attachment E

Overview of Capitol Hill Day and Associated Events for the 2007 Annual Meeting

The 2007 SNM Annual Meeting in Washington, D.C. presents a historic opportunity to launch SNM as the preeminent advocacy organization in Washington for molecular medicine, including imaging and therapy. A number of items have been planned to ensure that SNM capitalizes on this great opportunity.

Capitol Hill Day SNM will be offering the opportunity for those coming to the Annual Meeting to participate in a Capitol Hill Day (CHD). CHD will provide participants with valuable insight into the intersection of public policy, legislative advocacy, and SNM’s overall goals, particularly the positioning of SNM as a leader on the molecular imaging issue. Registrants have the opportunity to indicate they would like to participate in CHD when the register. SNM has set-up a form to then give those participants background and confirm their participation. The timeslot for CHD visits is 11am -3:00pm (see timetable below). This includes preparation/briefing (SNM is applying for CE credit for the training), bus transportation to and from Capitol Hill, packets, and visits. If SNM receives the CE designation the presentation will be done by Bob Waters (Drinker, Biddle and Reath - DBR), Dr. Atcher, Dr. Conti, and David Gillmor. In order to assure as smooth a process as possible we will attempt to assign team leaders to the majority of first meetings of the day so that folks who are new to the process have leadership, someone to ask questions of, someone to direct the meeting, and organize the delegation. We will identify team leaders as soon as possible, on a rolling basis. We envision having two conference calls with team leaders closer to the annual meeting. The first will focus on logistics and what to expect and the second will focus on background about this issues selected for CHD. In addition, as feasible, we will email information ahead of time to team leaders and participants. Every participant will be scheduled for a Senate meeting and a House meeting. DBR will handle all scheduling. To maximize CHD, DBR will work with SNM to target participants to ensure that there are meetings with all key Members of Congress. Timeline:

• 11:00-noon: Training at convention center • 12:00-12:30pm: Buses to Senate • 12:30 – 12:45pm: Find Senate office • 12:45- 1:15pm: One Senate Meeting • 1:15 - 1:45pm: Participants walk to House side and find office • 1:45 – 2:30pm: One House side office visits • 2:30 - 3:00pm: Buses return to convention center

Capitol Hill Day Set-Up The training will take place in one of the convention center ballrooms. There will be tables outside the room for people to register and receive their packets. Inside the room, tables will be set up with signs for each state so that people from the same states can sit together and coordinate. Capitol Hill Day Briefing As indicated about, DBR will conduct a training session for participants. This session will include SNM members. The session will cover logistics, what to expect at the meetings, tips for a good meeting, issue background, and the “asks” and messaging points. Capitol Hill Day – Buses Following the briefing, participants will board buses to the Senate side of the Capitol. The Senate meetings will be the first meetings scheduled. After their second meetings, participants will board buses to return to the convention center from the House side of the Capitol, which will be with House offices. Capitol Hill Day – Materials DBR, with input and technical assistance from SNM, will produce a participant packet for every CHD participant, as well as packets that participants will “leave behind” with the offices they visit. Participant packets have all background materials, maps of Capitol Hill, office information, elected official biography, talking points and ask sheets. Leave behind packets are what is left behind with the staff and will include relevant issue briefs, talking points, etc. To the extent possible packets will be customized to reflect the Members of Congress with whom participants will be meeting, i.e. if a Member of Congress serves on a particular committee of interest then talking points and asks will be specific to that jurisdiction. Capitol Hill Day – Pins Every participant should have a pin identifying them as being on the Hill as part of SNM and molecular imaging week.

Congressional Reception We will plan a congressional reception for Tuesday, June 5th, 5pm-7pm in the Capitol complex – preferably in the Capitol. At this small reception, SNM will honor our congressional champions. The reception will be by invitation and will include SNM leadership and SNM members from the states/district of those being honored.

- 2 -

Outreach to Administration Officials SNM and DBR will capitalize on having key SNM members in Washington, D.C. during the annual meeting. This provides a great opportunity to pursue meetings with high-level Administration officials. These meeting will likely include appropriate corporate people. The following is a list of with whom we have requested a meeting (and invited to speak at the annual meeting).

• NIH Director Zerhouni • FDA Commissioner von Eschenbach • Nuclear Regulatory Commission Chairman Dale Klein • HHS Secretary Leavitt • DOE Secretary Bodman • NCI Director Niederhuber • NIBIB Director Pettigrew

We have also extended an invitation to these Administration officials to speak at the annual conference.

Molecular Imaging Week Designation SNM and DBR will work to have Members of Congress enter statements into the official Congressional Record declaring the week of the Annual Meeting as Molecular Imaging Week DC01/ 523327.1

- 3 -

Molecular Imaging Campaign Washington, D.C. Annual Meeting Activities

Overview Outlined below are descriptions of the key cost components of the plan designed to take advantage of this year’s annual meeting in Washington and use this occasion as an opportunity to help identify the SNM as the nation’s leading voice on public policy matters associated with molecular imaging. SNM will probably not meet in Washington, D.C. again for many years. Coincidently this year’s meeting is at the same time the Society is launching a major initiative to be identified with molecular imaging. The activities described below are part of a comprehensive effort we will mount in conjunction with the annual meeting to reinforce this rebranding effort with key policymakers in the executive and legislative branches. Key Cost Elements of the Plan 1. Molecular Imaging Week. We will work with our friends on Capitol Hill and within the executive branch to identify the week of the annual meeting as Molecular Imaging Week. This recognition will take the form statements in the Congressional record in both the House and the Senate and letters from key officials in the executive branch. 2. Molecular Imaging Buttons. We are recommending that all attendees at the annual meeting be issued buttons recognizing molecular imaging week and the SNM. A sufficient supply of extra buttons will be ordered to ensure all attendees on Capitol Hill and executive branch meetings display these buttons. 3. Transport Buses. We anticipate moving approximately 200 -250 people from the convention center to Capitol Hill and back during a three hour period during. This will require rental of up to four buses for four hours each. This is a potential sponsorship opportunity. 4. Box Lunches. We will have a very narrow window to train and move people to Capitol Hill over the lunch hour. We anticipate the best way to accomplish this objective is to issue a box lunch to each attendee. Possible sponsorship opportunity is also tied to this activity. 5. Materials. These are the handouts for Members of Congress and their staff. It represents the hard costs of the folders and inserts that will be left behind in each Congressional office. 6. Prescheduled Hill Visits and SNM Team Leader Training. This is a critical component of the program. If the Hill meetings are not prescheduled with care the experience and the impact will be seriously compromised. We will group participants by state delegation and schedule the Capitol Hill meetings with the key offices prior to the annual meeting. In addition, we will conduct a training program to ensure that all of the key groups will have someone who has be trained to lead the group.

7. Staffing Capitol Hill Operation. We will provide at least four staff associated with the Capitol Hill Day outreach. Two staffers will cover the registration and call in desk. They will be responsible for providing material and modifying schedules as necessary. They will also serve as the intake staff for the post Hill reports. Two additional staff will be assigned to attend the most critical meetings on Capitol Hill with key delegations. 8. Priority Meeting Scheduling. Our plan is to set up 5-6 key meetings in Washington with senior government officials to discuss the molecular imaging campaign. Targets for this project include Cabinet Secretaries at HHS and DOE, White House Staff, Senior Members of Congress with jurisdiction over SNM issues. These meetings would be limited to a small set of senior SNM leadership and some of our corporate leaders. 9. Materials Preparation – Key Meetings. This line item represents the time associated with preparing the talking points and handouts for each of the Priority Meetings as well as the generic material for Capitol Hill day visits. The Priority Meeting material will need to be customized and there will be some exchange with each of the target offices regarding the content and focus of the discussion prior to the actual meeting. 10. Congressional Reception. This figure represents a rough estimate of the hard costs associated with a small Congressional lunch or reception in the Capitol with senior SNM leadership and corporate leaders. We have assumed that SNM will provide photography or film capabilities. The objective will be to provide awards to key Congressional champions. This will be captured on film and projected to the SNM audience at some point during the annual meeting. If will also tie in a tour of the Capitol for the participants. Sponsorship may be an opportunity depending on Senate and House Rules. 11. Advertising. It is typical for major associations doing sizable Hill visits to purchase advertising in either Roll Call or The Hill. Our ads would highlight molecular imaging week and complement the other aspects of this campaign. These are the two newspapers that are delivered daily to every Congressional staffer. The prices listed are based on two ½ page advertisements.

Working Draft page 1

Strawman Themes for Advocacy/ Annual Meeting Overall Statement:

We are on the brink of revolutionary change in medicine. Molecular imaging is the catalyst for this change.

We enable personalized medicine—through imaging we can find the best drug for that patient and their disease at the right time.

Patient diagnosis and therapy can be personalized and tailored to the disease and the person.

For example, the current use of biologics for therapy sometimes fails. This could be prevented through the appropriate use of molecular imaging. Molecular imaging could be used to guide the delivery of therapy so that it is successful.

Targeted imaging and targeted therapy (as Tykerb therapy is now being discussed in the news)

Personalized imaging and customized care Revolutionizing the practice of medicine.

What is Molecular Imaging?

Molecular imaging is the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems.

The techniques used include radiotracer imaging/nuclear medicine, MRI, MRS, optical imaging, ultrasound and others.

Molecular imaging offers unique insights that allow a more personalized approach to evaluation and management of heart disease.

Molecular imaging plays a pivotal role in guiding the management of cancer: - Diagnosing - Staging—extent and location - Assessing therapeutic targets - Monitoring Therapy - Evaluating Prognosis Molecular imaging is playing an increasingly significant role in conditions

such as: - Tumors - Dementias (Alzheimer’s and others) - Movement disorders - Seizure disorders - Psychiatric disorders

Why is Molecular Imaging Important? Critical to Quality Health Care Personalized medicine

Working Draft page 2

Enhance patient care Prevention- detect disease earlier Individualize and predict treatment Improve diagnosis Facilitate drug discovery and development Finding the best drug against the right target to treat the right patient at the right

time Made possible through advances in genetics, biochemistry, nanotechnology.

Closing Statements Targeted therapy and treatment for specific individuals will be possible, provided

that there is sufficient funding for research Tie-in to current news story (e.g., Tykerb therapy) if possible SNM is the Lead Professional Organization for Molecular Imaging We will provide an image to illustrate our point

The “Ask” We want:

Appropriate reimbursement for molecular imaging agents/services - specifically, expensive drugs and imaging services need a different

pathway for reimbursement than regular drugs - molecular imaging may be more expensive initially, but it will save money

in the long run (e.g., it can help predict whether therapies will be effective) More funding for molecular imaging training programs to meet national demand

- physician scientists - radiochemists - radiopharmacists - health physicians

CARE Bill Research funding restored to DOE Research funding expanded for molecular imaging at NIH/NCI A stable, domestic supply of clinical and research radioisotopes necessary for

imaging - upgrade Muir facility - build a national accelerator

Regulatory relief - more efficient approval of new molecular imaging agents - define appropriate level of regulations relative to traditional drugs

Increased understanding within regulatory agencies regarding molecular imaging (e.g. FDA, NRC).

Attachment F

Patients

PageKey

SectionHomePage

StandardContent

Page

MICenterHomePage

Contact

SubPages

SubPages

PressReleases

PressReleases

News &Events

IndustryNews

MI Prac-titioners

PrivacyPolicy

LegalNotices

Site Map

FooterLinks

PrimaryOptions

SecondaryOptions

News-letter

News-letters

ReferringPhys-icians

SNM MI CenterHigh-Level Site MapMonday, April 02, 2007C:\Documents and Settings\Erickson\Desktop\SNM MI Center Site Map20070402.vsd - 4/2/2007, 5:58:58 PM

Refer-ence

LibraryLinks

MIResource

Center

GlossaryResearch& Studies

Speakers& Experts

SpeakerBios

LimitedAccess

ClinicalTrials

Industry

NewsItems

SubPages

SubPages

Event &Workshop

Details

EventCalendar

PAGES INCLUDEWhat is MI?

OverviewLink to Glossary

How does it work?MIMRIMRSContrast enhanced US

How can it improve my care?

When is MI used? (includes usage by disease /condition)

Safety Information

Reimbursement Information

Research & Clinical Trials (links to MI Res Ctr)

Patient Resources & LiteratureGeneral Patient BrochuresUses of MI by OncologistsStudiesScansPET ImagingPublications

* Less detailed info for patients, more detailed info foradvocates

INCLUDESBoard of DirectorsTask ForcesStrategic Plan (high level outline)

SubPages

PAGES INCLUDEHow MI Improves Patient Care

Practical Uses for MI

Case Studies (links to MI Res Ctr)

Research / Studies (links to MI Res Ctr)

Clinical Trials (links to MI Res Ctr)

Publications (links to MI Res Ctr)

Reimbursement Information

Literature & BrochuresPractical Uses of MIFor Patients

About theMI Center

SubPages

Advo-cates

PAGES INCLUDEFunding opportunities

Sponsorship opportunities

MI & drug development

Research / Studies (linksto MI Res Ctr)

Clinical Trials (links to MIRes Ctr)

SubPages

Govern-mentAffairs

INCLUDESPoliciesLettersLegislation of Interest

CaseStudies

TO INCLUDEPublications, Literature andBrochures - organized by topic

PAGES INCLUDEMI Overview

Modalities & UsesPractical UsesRecent Advances in MIThe Future of MI

ResearchBasic ResearchTranslational ResearchDesigning MI ResearchFunding Opportunities

Clinical TrialsCurrent TrialsFindingsDesigning Trials

Publications

Training & EducationContinuing Education CalendarWorkshopsOnline CoursesCase StudiesGrants, Awards & FellowshipsResources for Developing CurriculaCareers in MI

Upcoming Events (links to Events page)

Policy & Practice GuidelinesHealth Care PolicyPractice GuidelinesAccredidation

MI ForumsAccess to forumsJoin forums

Note - studies, trials, publications, education,training and events all link to MI Res Ctr andare sortable by modality & type as appropriate

Join theMI Center

SubPages

INCLUDESMembership pricingSign up formJoin SNM (link to SNM.org)

Patients

PageKey

SectionHomePage

StandardContent

Page

MICenterHomePage

Contact

SubPages

SubPages

PressReleases

PressReleases

News &Events

IndustryNews

MI Prac-titioners

PrivacyPolicy

LegalNotices

Site Map

FooterLinks

PrimaryOptions

SecondaryOptions

News-letter

News-letters

ReferringPhys-icians

SNM MI CenterHigh-Level Site MapMonday, April 02, 2007C:\Documents and Settings\Erickson\Desktop\SNM MI Center Site Map20070402.vsd - 4/2/2007, 5:58:58 PM

Refer-ence

LibraryLinks

MIResource

Center

GlossaryResearch& Studies

Speakers& Experts

SpeakerBios

LimitedAccess

ClinicalTrials

Industry

NewsItems

SubPages

SubPages

Event &Workshop

Details

EventCalendar

SubPages

About theMI Center

SubPages

Advo-cates

SubPages

Govern-mentAffairs

CaseStudies

Join theMI Center

SubPages

Notes:

1

Copyright © 2007 SNM. All Rights Reserved.

Advertising/Sponsorhip Opportunities | Help/Policies | Site Map

SNM logo

Quick Reference for:PhysiciansTechnologistsScientistsResidents & FellowsTechnologist StudentsPress & MediaSNM Websites A-Z

My SNM (Login) | SNM Store | Membership Directory | Contact Us

News & Events | Education | Publications | Practice Management | Resource Center | Gov’t Relations | About SNM | Career Center | Membership

> Search | Advanced Search

AD

Event Name Appears HereMar 10, 2007Pellentesque habitant morbi tristique senectus et netus et malesuada fames

June 2 - 6, 2007 Washington D.C.

Visit Site

2 0 0 7 A N N U A L M E E T I N G

O N L I N E C O U R S E S

Lpsum Maencans Felis Sit Amet

J O U R N A L S

THE NEW SNM

Pellentesque habitant morbi

tristique senectus et netus et

malesuada fames ac turpis

egestas. Nec pharetra eros eros

et purus donec ac quam morbi

luctus mi ut ligula.

A Message from our President

Join SNM Today

E D U C A T I O N P U B L I C A T I O N S R E S O U R C E S M E M B E R S H I P

Pellentesque habitant morbi tristique

senectus et netus et malesuada fames

ac turpis egestas. Nec pharetra eros

eros et purus donec.

About the SNM Learning Center

> Online Courses> Continuing Education> Symposia> Certification & Licensure

Go to SNM Learning Center

L L S A P

KEEP UP-TO-DATETHE LATEST NEWS >See All

T A K E A C T I O N

Ac turpis egestas nec pharetra eros eroset purus donec acQuam morbi luctus.

A N N O U N C E M E N T S

Pellentesque habitant morbi tristique senectus et netus et malesuada fames

H E A D L I N E S

Feb 22, 2007Pellentesque habitant morbi tristique senectus et netus et malesuada fames(Source appears here)

Feb 20, 2007Ac turpis egestas nec pharetra eros eroset purus donec ac (Source appears here)



E D U C A T I O N> Visit SNM Learning Center

Pellentesque seach for CE credit,tristique senectus et netus et malesuada.

S N M C E N T E R S O F E X C E L L E N C E

Pellentesque habitant morbi tristique senectus et netuset malesuada fames.

QuickTime™ and aTIFF (Uncompressed) decompressor

are needed to see this picture.

UPCOMING EVENTS >See All

CURRENT TEACHING FILE

Nec pharetra eros eros etpurus donec ac quammorbi luctus mi ut ligula.

SNMHome

PageKey

SectionHomePage

StandardContent

Page

Govern-ment

Relations

Publi-cations

SubPages

ExternalSite

Scientists Press /Media

Technolo-gists

Physi-cians

AudiencePages

SubPages

EducationNews &Events

SubPages

AboutSNM

SubPages

Member-ship

SubPages

ContactUs

SubPages

My SNM

SubPages

ResourceCenter

SubPages

CareerCenter

SubPages

Site Map

SecondaryOptions

PrimaryOptions

MolecularImaging

Site

2007AnnualMeeting

2007 Mid-WinterSym-

posium

Bench toBedside

SNMLearningCenter

PatientSite

TertiaryOptions

PracticeManage-

ment

SubPages

ClinicalTrialsSite

Technolo-gist

Students

Residents& Fellows

SNMStore

SubPages

INCLUDESPatient focused content to includemuch of what is currently in thesection "About Nuclear Medicine"Patient brochuresPatient educationTravel advisoryReference to Nuclear Medicine Week

Advertis-ing /

Spon-sorships

SubPages

NOTEWill eventually fold into MISite

JNMJournal

JNMTJournal

ExternalSites

RequiresLog In

SNM Site MapWednesday, February 28,2007Page 1 of 7

Z:\P-T\SNM\SNM Web\100-Analy sis\Site Map\SNMsite Map 20070228.vsd - 2/28/2007, 1:23:16 PM

Help /Policies

SubPages

Grants,Awards &Scholar-

ships

SubPages

News &Events

AnnualMeeting

IndustryNews

Articles

Mid-WinterSym-

posium

Reimbur-sementRoadShow

NuclearMedicine

Week

Calendarof Events

Submit anEvent

OnlineRegistra-

tion

Gov'tRelations

News

Articles

MembersIn TheNews

ArticlesSubmit a

NewsItem

SNMPress

Releases

Archives

INCLUDESSubmission formGuidelines (as a sidebar)

INCLUDESSubmission formGuidelines (as a sidebar)

SNMNews-letters

Leader-ship

UpdateArchives

Publica-tions

TheJournal ofNuclear

Medicine

Publishing Guide-

lines

Journal ofNuclearMedicine

Technology

Subscribe Subscribe

Info forBook

Authors

Education

CONTENTOverview of all the SNM education offerings to includegeneral info on:

EducationOnline coursesWorkshopsSymposiaLLSAP

Continuing EducationPhysicians - AMA PRATechnologists - VOICEPharmacists - ACPEPhysicists - CAMPEP

Links to appropriate sections of the SNM Learning Center(including Certification and Licensure)

Promos for new and/or timely courses



RequestReprints

INCLUDESFeatured books, publications,etc. with links to bookstore

Sidebar with link to Advertising/Sponsorship Opportunities

AuthorQuestion-

naire

EventPages

PrimaryOptions

UptakeArchives

Govern-ment

Relations

ResourceCenter

PracticeManage-

ment

Procedure Guide-

lines

CodingCorner

PracticeAccredi-

tation

QualityAssurance

(Phan-toms)

ForPrivate

Practices

ForHospitals For PET Q&A

CodingPages

CodingPages

CodingPages

EACH "For..." PAGE INCLUDESIntroductionLinks to related itemsList of educational mat'ls pages

NOTEWe are removing a level from thecurrent site structure by moving theeducation pages up one level andlinking to them directly from the"For..." pages

AboutSNMGov't

Relations

Find YourLegislator

Gov'tRe-

sources

ContactYour

Legislator

CurrentLegis-lation

Gov'tRelations

News

Articles Tips

StateHealth Pol-icy LiaisonNetwork

SHPL'sby State



DocumentLibrary

Sub-Pages

AdvancedSearch

IndustryGlossaryLinks

Q&APages

PrimaryOptions

POTENTIAL CATEGORIES INCLUDEEvent archives

Scientific abstracts

SNM surveys and research

SNMTS information and resources

For your patients

For referring physicians

Practice management (to include adversereaction table and radiologic incidents asdocuments)

TakeAction

AboutSNM

SNMOverview

Planningfor theFuture

SNMGovern-

ance

SNMTechnolo-

gistSection

AnnualReports

SNMHistory

INCLUDESSNM overview / mission

Descriptions of and links to:Technologist SectionMI Center of Excellence

DownloadsStrategic plan (PDF)Bylaws (PDF)Policies & Procedures (PDF)

INCLUDESOverview of SNM's visionfor the future of theindustry

Description of and links tokey initiatives:

MI CenterPET CenterEtc.

INCLUDESDownloads of recentannual reports

Board ofDirectors

House ofDelegates

Leader-ship Councils

PETCenter of

Excel-lence

Com-mittees Chapters National

CouncilExecutive

BoardCom-

mittees

INCLUDESBrief history

Links to History Cornerarchive articles (PDFs)

INCLUDESName, photo, title,location for eachboard member

INCLUDESName, photo, title,for senior SNMleadership

Sidebar forLeadership Update

INCLUDESName, title for eachmember

Com-mitteePages

CouncilPages

CouncilSub-

Pages

Com-mitteeSub-

Pages

Com-mitteePages

Com-mitteeSub-

Pages

INCLUDESSNMTS overview / mission

DownloadsStrategic plan (PDF)Bylaws (PDF)Code of Ethics (PDF)Practicioner Competencies (PDF)Scope of Practice (PDF)

Blurb about PDEF

ChapterPages

ChapterUpdateForms

ChapterAdminManual



PrimaryOptions

SNMInter-

national

ClinicalTrials

PDEFCenters

ofExcelence

MI Centerof Excel-

lence

INCLUDESLinks to Clinical Trials Site

Grants,Awards &Scholar-

ships

Awards Fellow-ships

ResearchGrants Awards Research

GrantsScholar-

ships

Honorary/Distinc-

tionAwards

For Phys-icians &

Scientists

For Tech-nologists

INCLUDESOverview of programs

Link to ERF site



PrimaryOptions

CareerCenter

Job Bank

Positions

CareerInforma-

tion

Physi-cians

Technol-ogists

Pharm-acists Physicists

Certifica-tion &

Licensure

Post Jobsor Resi-dency

Openings

INCLUDESClassified advertisingpolicies and procedures

Resi-dency

Openings

Physi-cians

Technol-ogists

Pharm-acists Physicists

Member-ship

MemberBenefits

FAQs Become aMember

Cate-gories &

Dues

OnlineAppli-

cations

RenewYour

Member-ship

RenewCurrent

NewMemberGuide

INCLUDESLinks to most important pages fora new member

NOTEThis page should be structuredlike the audience pages forphysicians, technologists, etc. Itshould have the same look andfeel as the rest of the site



Member-ship

Overview

INCLUDESSidebar with link to SNM MailingList page/Member Directory

PrimaryOptions

Reacti-vate

Lapsed

ContactUs

PrivacyPolicy

My SNM Site Map

LegalNotices

SNMStore

Item /Checkout

Pages

Adver-tising /

Sponsor-ships

INCLUDESList of memberships (committees,communitites, etc.)

Administrative functions (renewalstatus, password change, updateaddress, subscriptions, etc.)

Links to pages that are onlyaccessible upon login


Z:\P-T\SNM\SNM Web\100-Analysis\ Site Map\SNMsite Map 2007 0228.vsd - 2/28/2007, 1:23:16 PM

ChangePassword

Subscrip-tion

Manager

SavedPages

UpdateMember

Info

SNMEvents

OnlineAdver-tising

PrintAdver-tising

IndustryPartner-

shipProgram

SNMMailing

List

Help /Policies

AdobePDF

Trouble-shooting

SecurePages &Encryp-

tion

Use ofCookies

LoginHelp

TertiaryOptions

Secon-dary

Options

MemberDirectory

Attachment G

Definitions Task Force• David A. Mankoff, MD (chair)

• Bennett Chin, MD

• William Eckelman, PhD

• Jerry Glickson, PhD

• Craig Levin, PhD

• Chet Mathis, PhD

• Barry Shulkin, MD

• Albert Sinusas, MD

• Michael Stabin, PhD

• Mathew Thakur, PhD

• Benjamin Tsui, PhD

• Ronald Van Heertum, MD

Molecular ImagingMolecular imaging is the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems.

– Molecular imaging typically includes two- or three-dimensional imaging as well as quantification over time.

– The techniques used include radiotracer imaging/nuclear medicine, MRI, MRS, optical imaging, ultrasound and others.

Molecular Imaging Agents

Molecular imaging agents are probes used to visualize, characterize, and measure biological processes in living systems.

- Both endogenous molecules and exogenous probes can be molecular imaging agents.

Molecular Imaging InstrumentationMolecular imaging instrumentation is tools that

enable visualization and quantification in space and over time of signals from molecular imaging agents.

Molecular Imaging Quantification

Molecular imaging quantification is the determination of regional concentrations of molecular imaging agents and biological parameters.

- Molecular imaging quantification provides measurements of processes at molecular and cellular levels. - This quantification is a key element of molecular imaging data and image analysis, especially for inter- and intra-subject comparisons.

Molecular Imaging (MI) in Patient CareMolecular imaging reveals the clinical biology of the disease process.

MI personalizes patient care by characterizing specific disease processes in different individuals.

MI is useful in drug discovery and development, for example, for studying pharmacokinetics and pharmacodynamics.

MI in Cardiovascular DiseaseMolecular imaging offers unique insights that allow a more personalized approach to evaluation and management of entities such as:

- Ischemic injury- Heart failure and left ventricular remodeling- Thrombosis, atherosclerosis, and vulnerable plaque- Angiogenesis- Transplant rejection- Arryhthmic substrates

MI in CancerBy accurately characterizing tumor properties or biological processes, molecular imaging plays a pivotal role in guiding patient management:

- Diagnosing- Staging—extent and location- Assessing therapeutic targets- Monitoring Therapy - Evaluating Prognosis

MI in NeurologyMolecular imaging is a tool for assessment, risk stratification, evaluation and follow-up for patient management and drug discovery. Molecular imaging is playing an increasingly significant role in conditions such as:

- Tumors- Dementias (Alzheimer’s and others)- Movement disorders- Seizure disorders- Psychiatric disorders

Attachment H

Molecular Imaging Center Workshops for 2007

The Leading Technologies Workshop Task Force, tentatively renamed the Emerging Technologies Task Force is coordinating with the Future Tracers Workshop task force and the Standardized Protocols Workshop task force to develop a sequence of activities that will address deliverables from the MICoE strategic plan including:

Convene Future Tracer Workshop: Purpose is to discuss the next tracers (future “FDG”s). The workshop participants will include experts in the field as well as industry participants. Questions to address are:

– How to identify new imaging agents? – How will they be validated? – How will we get to the stage of reimbursement?

Develop In-House Technology Assessment Mechanism: A workshop will be convened inviting representatives of other leading technologies to discuss how various technologies would complement each other. Specific outcomes include:

• Outlining the critical issues surrounding this issue • Identifying experts in certain areas and input into the speakers bureau • Creating position statements on how specific technologies can become

viable • Establishing “best approaches” as critical tools or benchmarks to

evaluating molecular therapies. •

(***Note: these may be updated as other relevant items from the various versions of the strategic plan and deliverables documents are reviewed)

To address the items outlined in these deliverables as well as related issues that have been identified, a phased series of actions has been developed. Each phase will have a defined purpose and expected output relevant to these goals. The results of each phase will be presented in a form appropriate for publication in SNM so that we can show we are leading the molecular imaging community. Phase I (Workshop 1): working title: “Bringing Molecular Imaging from Bench to Bedside” Target Date: May or June 2007 [may be a weekend or weekday; possibly early May or third weekend in June; considerations are SNM annual meeting, May events (Mother’s Day, graduations)] Overview/Goals: This first phase will be a retreat/workshop that will focus on what can be done in the short term to realize molecular imaging benefits in the clinical environment. This workshop will identify and discuss any technologies that can be taken to the bedside over the short term (within 5 years), such as proliferation markers, hypoxia markers, receptor (e.g. estrogen) markers, and PET-MR instrumentation. Other molecular imaging technologies may also be identified.

Discussion Paper page 1

An underlying goal of the project is to show other organizations, industries, and government agencies that SNM is leading in all aspects of molecular imaging. Another goal is to build bridges to/between the FDA, clinical trials groups, and others so that we can better develop the clinical data that will move technologies to clinical use. Participants: selected members of the Leading Technologies and Future Tracers Task Forces; a representative from the Clinical Trials Group; an oncologist (perhaps with early drug development expertise), cardiologist, neurologist, and other specialists; biomarker expert, MR expert, HTA expert (health technology assessment), and technology transfer expert (perhaps legal expertise). Audience: the molecular imaging community, but also NIH, FDA, pharmaceuticals industry, HTA community, cooperative research groups (such as ACRIN, RTOG). Output: A position paper that includes identification of specific technologies that can move quickly to clinical usefulness and the reasons for their selection for focused action. Current Action Item: Sandy will prepare a draft agenda for this and send it to Henry, Sue, and Marybeth. It will then serve as the focal point of a joint conference call between the Leading Technologies and Future Tracers Task Forces. Phase II (Workshop 2): Emerging Technologies Assessment Retreat. Target Date: July Overview/Goals: This retreat will look 5-10 years into the future to broadly review emerging molecular imaging technologies, assess the clinical potential for them, and evaluate issues associated with each that affect getting them from bench to beside. Additionally, the retreat will look at what disease states could most likely benefit from molecular imaging technologies to recommend specific molecular imaging technologies that should be developed (e.g. probes for specific targets). This is more of a visioning exercise than Phase I. This may become a recurring retreat (perhaps every 2-5 years). The goals of the retreat would be to develop a list of technologies that will be needed over the next 5 -10 years to benefit clinicians. For example, for the technology of hybrid MR-PET imaging, some issues would be: 1) what hybrid probes might be useful and what target populations need new molecular imaging agents. The topic of F18-F19 probes was given as an example. This could include imaging agents, instrumentation, software, and delivery techniques/protocols. Participants. A facilitator may be needed to assist with having the group do innovative thinking and yet focus enough to deliver the desired product. Additionally, expertise will be needed in: molecular biology (different areas such as oncology, neurology, cardiovascular, etc.), tracers, biomarker, physics, bioengineering, nanotechnology, technology transfer and others. Audience: Similar to Phase I. Output: A position paper that identifies new technologies that should be developed as well as newly emerging molecular imaging technologies that should be further developed. This information will feed into Phases III and IV as well as helping guide academia and industries into coordinated action. This will help guide the entire molecular imaging community so that there is a unification of efforts (and SNM is the leader of this movement).


Phase III (previously Workshop 3): Future Tracers Working Groups (previously known as Future Tracers Workshop). Target Date: summer/fall 2007 and ongoing Overview/Goals: These small working groups will each be tasked with one of the technologies identified in Phases I and II (an imaging agent, a device/software, or a technique/process). The working groups will further evaluate the specific molecular imaging technology to determine what is needed to move them from bench to bedside including validation for clinical applicability. The goal is getting approved for reimbursement. This may include identifying obstacles to this development and proposed methods for overcoming such obstacles. An oversight committee may be developed and may evolve to being a standing Committee or Task Force within the SNM to manage and monitor these working groups. Participants: To be determined based upon the specific technology identified. Audience: The molecular imaging community, industry, government agencies. Output: Each working group will produce determine what specific actions are needed to move the technology to the bedside (including reimbursement) and what resources are needed to accomplish these actions. This will include a periodic reassessment of the technology’s potential for clinical utility as the technology matures. Phase IV (previously Workshop 4): Emerging Technologies Advancement Workshop. Target Date: Early 2008 Overview/Goals: This workshop will examine the general issue of what are the pathways for gaining acceptance of new molecular imaging technologies and what are the barriers to moving technologies from the research environment to the bedside. The technologies identified in Phases I and II along with the issues identified in Phase III will provide a foundation for discussion, but the workshop will extend to include as many different types of molecular imaging technology and pathway issues as possible. This may include diagnostic agents, therapeutic agents, instrumentation, software (acquisition/processing), and/or techniques for utilization of the former. It is possible that separate subgroups or separate workshops will evolve to deal with the different types of technologies. Participants: This will include researchers, industry representatives (production/marketing/etc.), clinicians, regulators, reimbursement specialists, and others. It will need to involve NIST, AAPM, NCI, etc. Audience: Similar to the participants….those who have an impact on overcoming the obstacles on the pathway from bench to bedside. Output: Reference documents (possible JNM publication) that outline the routes of molecular imaging technology development from bench to bedside with notes of the potential obstacles at the steps along the routes with recommendations to overcoming those obstacles so that the time it takes to move along the pathway from bench to bedside is minimized. Phase V: Education on Translational Issues—to be developed. (This workshop may not be needed because the work may be undertaken by the Education Task Force.) The focus would be on education issues relating to translational research.


Addendum (Do we want to include this topic?with its associated deliverables added above): Workshop on Standardized Imaging Protocols: There is already a specific project in this area being done through the Clinical Trials Group regarding the FDG Quantification Study. It was determined that it is premature to have any further meeting now to avoid duplication of effort. We will need to coordinate with the Brain Imaging and Oncology Councils and the Clinical Trials Group. The general thinking regarding this topic is that this is to address problems with the validity of data presented in studies toward obtaining reimbursement (e.g. is quantitation standardized for all facilities from which the data is pooled) as well as the issue of various research studies using different methods such that pooling of data cannot be done. These issues affect our ability to prove clinical utility and get approval for reimbursement. This is NOT the development of routine clinical guidelines as is already being done within SNM.


4/10/2007 2:12 PM DRAFT page 1

DRAFT AGENDA

Molecular Imaging Center of Excellence’s Retreat on Development Strategies for Emerging Molecular Imaging Technologies:

Action Planning June 2007

Reston, Virginia Purpose: To lead the movement of molecular imaging technology from bench to bedside through the development of an action plan that will help imminently emerging technologies. Outcome: An Action Plan for Bringing Specific Technologies into Clinical Practice

Draft Agenda – Day 1

Item Time Discussion Leader

Introductions and Purpose Purpose of the Retreat Outcomes of the Retreat Introductions

8:00-8:15 S. McEwan

Session I: Imminently Emerging Technologies Review list of technologies and determine whether these are the correct topics. Add/change if necessary. Topics were selected because we already have consideration of how to use them clinically; all have been used in humans; and all could be important in drug development.

o Proliferation markers o Hypoxia markers o Vascular markers (DCE-MRI,

H2015PET) o Instrumentation and utilization o Other?

8:15-9:15 S. McEwan

Session II: Current Challenges to moving technology to the bedside:

What is required to: Assure tracer availability (30 minutes)

o Scale up for production o Automated synthesis o Shipping o Availability/cost

Address regulatory issues (45 minutes)

9:15-10:30

S. McEwan

Break 10:30-10:45

4/10/2007 2:12 PM DRAFT page 2

Session II (cont’d) What is required to: Incorporate into clinical trials (30 minutes) Translate into clinical practice (30 minutes) Prove clinical efficacy (HTA) (30 minutes)

10:45-12:15 S. McEwan

Break & Continue w/Working Lunch 12:15-12:30 Break Session III. Break Out Organization Check composition of each group Instructions:

o Develop a business plan for each technology to bring it to bedside

o Address the challenges o Include an action plan

12:30-3:30 S. McEwan Group Leaders

5. Reconvene for status reports by break-out groups.

3:30-4:30 S. McEwan

Group Dinner

Day 2 – Agenda

Item Time Discussion Leader

Optional Breakout Group Meeting(s)

8:00-9:00 Group Leaders

Session IV: Presentation and Discussion of Each Plan (15 minutes presentation/15 minutes discussion for each)

o Proliferation markers o Hypoxia markers o Vascular markers (DCE-MRI) o PET Instrumentation o Other?

9:00-11:00 S. McEwan

Break 11:00-11:15

Session V: Action Plan Consolidation/ Working Lunch What can SNM do?

11:15-1:30 S. McEwan

Adjourn 1:30

Proposed Guest List for “Development Strategies for Emerging Molecular Imaging Technologies: Action Planning” an SNM-Sponsored Retreat

June 2007

1. James K. Cavanaugh Director of Global Marketing Nuclear Medicine PET Philips Medical Systems 595 Miner Road Cleveland, OH 44143 Phone: 440.483.3568 Cell: 216.533.5093 [email protected]

2. Laurence Clarke, PhD

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892 Phone: 301.435.9190 e-mail: [email protected]

3. Barbara Y. Croft, PhD

National Institute of Health Biomedical Imaging/DCTD/NCI 6130 Executive Blvd. Rm. 6064 Rockville, MD 20892-7412 Phone: 301.496.9531 e-mail: [email protected]

4. Ed Jackson Professor and Deputy Chair The University of Texas M.D. Anderson Cancer Center Dept. of Imaging Physics 1515 Holcombe Blvd. Unit 56 Houston, TX 77030 Phone: 713.745.0559 Fax: 713.745.0581 e-mail: [email protected]

5. Joel S. Karp, PhD University Hospital of Pennsylvania Radiology Department, P.I.G. 401 Blockley Hall 423 Guardian Drive Philadelphia, PA 19104 Phone: 215.662.3073 e-mail: [email protected]

6. Paul E Kinahan, PhD Associate Professor, Radiology Director, PET/CT Physics, Adjunct Associate Professor, Bioeng and Electrical Eng. University of Washington Old Fisheries Center, Room 200 Box 357987 Seattle, WA 98195 Phone: +1.206.543.0236 Fax: +1.206.543.8356 [email protected] http://faculty.washington.edu/kinahan/

7. Andreas Laupacis, MD, MSc, FRCTC Chief Executive Officer University of Toronto Institute for Clinical Evaluative Sciences 2075 Bayview Avenue Toronto, ON M5G M4N Canada Phone: 416.480.4297 e-mail: [email protected]

8. George Mills, MD, MBA Vice President, Medical Imaging Consulting Perceptive Informatics/ PAREXEL 630 Still Creek Lane Gaithersburg, MD 20878 Phone: 202.468.1986 e-mail: [email protected]

9. Adrian D. Nunn, PhD Bracco Research USA Inc. 305 College Road East Princeton, NJ 08540 Phone: 609.514.2418 e-mail: [email protected]

10. Ron Nutt, PhD Washington University President and Chief Executive Officer (Past)CTI Molecular Imaging, Inc 810 Innovation Dr. Knoxville, TN 37932 Phone: 865.218.2000 Fax: 865.218.3003 e-mail: [email protected]

11. Rafel Dwaine Rieves, MD DFDA Division Director FDA/Center for Drug Evaluation and Research/Office of Oncology Drug Products Division of Medical Imaging and Hematology Products Bldg. WO22, Room 2354 Mail Stop HFD-160 Silver Spring, MD 20993 Phone: 301.796.1990 Fax: 301.796.9849 e-mail: [email protected]

12. Debasish Roy Chowdhury, MD Vice-President, Global Clinical GSK Development, Oncology Medicines Development Center and VP, Oncology Therapeutic Area, North America 555 8th Avenue Suite 1703 New York, NY 10018

13. Harendra D. Rupani, MD Novartis 1 South Ridgedale Avenue Bldg. 436 Room 1211 East Hanover, NJ 07936 Phone: 862.778.1346 e-mail: [email protected]

14. Dan Skovronsky, M.D. Ph.D Avid Pharmaceuticals President, CEO 3624 Market Street, 5th Floor Philadelphia, PA 19104 Phone 215.966.6208 e-mail: [email protected]

15. Mark Soffing, MBA, RPh, BCNP Iba Molecular, North America 239 East Fourth Street Brooklyn, NY 11218

Phone: 917.519.7138 e-mail: [email protected]

16. Dan Sullivan, M.D. National Cancer Institute/CIP 6130 Executive Boulevard, EPN/6070 Rockville, MD 20852 Work Phone: (301) 496-9531 Fax: (301) 480-5785 e-mail: [email protected]

17. Phil Vernon, PhD. Global PET/CT Research Manager GE Healthcare 700 Nancy Drive Aurora, OH 44202 Phone: 330.204.3299 Cell: 330.204.3299 Fax: 330.995.4665

e-mail: [email protected] 18. JeanLuc Vanderheyden, PhD

GE Healthcare 3000 Grandview Blvd. W-427 Waukesha, WI 53188 e-mail: [email protected]

Task Force/MI Center Members:

1. Robert W. Atcher, PhD, MBA Molecular Imaging Center 2006-2007 SNM Vice President-Elect Los Alamos National Lab. Biosciences Division Mail Stop G758 Los Alamos, NM 87545 Phone: 505.667.0585 e-mail: [email protected] or [email protected]

2. Peter S. Conti, MD, PhD Molecular Imaging Center 2005-2006 Immediate Past President University Southern California 1510 San Pablo Street Suite 350 Los Angeles, CA 90033 Phone: 323.442.5940 Fax: 323.442.5778 e-mail: [email protected]

3. Chaitanya Divgi, MD

Chief, Nuclear Medicine & Clinical Molecular Imaging Hospital of the University of Pennsylvania 3400 Spruce Street, Donner 116 Philadelphia, PA 19104 Phone: 215.615.3687 Fax: 215.349.5843 e-mail: [email protected]

4. Peter Herscovitch, MD Brain Imaging Council Chief, PET Imaging Section NIH Clinical Center 10 Center Drive MSC1180, Room IC401 Bethesda, MD 20892-1180 Phone: 301.451.4248 Fax: 301.402.3521 e-mail: [email protected]

5. David A. Mankoff, MD University of WA Medical Center Box 356113 NN203-Nuc. Med. 1959 NE Pacific Street Seattle, WA 98195 Phone: 206.288.2173 e-mail: [email protected]

6. Sandy McEwan, MB, FRCP(C)

2006-2007 SNM President-Elect Cross Cancer Institute Nuclear Medicine Department 11560 University Avenue Edmonton, AB T6G 1Z2 Canada Phone: 780.432.8524 e-mail: [email protected]

7. Albert J. Sinusas, MD Cardiovascular Council Professor of Medicine and Diagnostic Radiology Yale University 333 Cedar Street, 3FMP P.O. Box 208017 New Haven, CT 06520 Phone: 203.785.4915 Fax: 203.727.1026 e-mail: [email protected]

8. Henry F. Van Brocklin, PhD Vice President Prof of Radiology/Director of Radiopharmaceutical Research University of California San Francisco Dept of Radiology, UCSF 185 Berry Street, Suite 350 San Francisco, CA 94107 Phone: 415.353.4569 Fax: 415.353.9421 e-mail: [email protected]

9. Benjamin M. Tsui, PhD Johns Hopkins University Johns Hopkins Outpatient Center 4263 601 N. Caroline St. Baltimore, MD 21287 Phone: 443.287.4025 e-mail: [email protected]

10. George Zubal, PhD Instrumentation Council Molecular NeuroImaging LLC

60 Temple Street Suite 8 A New Haven, CT 06510 Phone: 203.401.4355 e-mail: [email protected]

Attachment I

SNM Messaging Platform

Prepared for:

Joanna Spahr Director of Marketing

Prepared by:

McKinley Marketing, Inc. 2233 Wisconsin Ave, NW, Suite 525

Washington, DC 20007 Phone: 202-333-6250

www.mckinleymarketing.com

Jay Younger Vice President

[email protected]

Samar Khleif Senior Consultant

[email protected]

March 2007

McKinley Marketing Inc. Draft: SNM Messaging Platform

Messaging platform Objective: Accurately and convincingly tell SNM’s “story” in order to communicate the promise of SNM’s vision for an evolving field.

Approach: By presenting the story in its entirety, rather than in the form of isolated positioning statements, SNM can efficiently address all areas of marketing without having to constantly reformulate statements that may or may not be effective given a particular marketing vehicle. Once in place, this platform will serve as a holistic picture of SNM’s messaging to key constituents and can be leveraged to communicate the new brand identity by guiding internal decisions as well as an array of marketing efforts. For example, the story can be easily adjusted to address content for press releases, presentations, web content, internal communications, etc. as needed by SNM. The story addresses the following questions: (It is important to note that McKinley has accounted for any variations that may be applicable to distinct audiences) 1. What are we doing? (SNM’s objectives relative to MI) 2. Why are we doing it? 3. What is the benefit to you? 4. What “success stories” can SNM communicate to key constituents? SNM should continue to communicate successes in the field as they become evident to ensure that key audiences are well aware of the strides SNM is making in an evolving field on their behalf.

McKinley Marketing Inc. 2 Draft: SNM Messaging Platform

Audience “What are we doing?” (SNM’s objectives)

“Why are we doing it?” “What is the benefit to you?”

Members Physicians Scientists Technologists Corporate

1. Clearly communicate

SNM’s continued support of NM in addition to the inclusion / refocusing of MI

2. Address diversified needs of molecular imaging practitioners and non-imaging specialists

3. Educate core members about the evolution of the field as well as principles and concepts of molecular imaging

4. Promote cutting edge initiatives/successes that SNM has already started and continue to do so as new initiatives are developed in the future.

5. Recruit and retain members from a broad cross-section of related backgrounds to increase the multidisciplinary nature of membership

Diagnosing and treating disease is increasingly requiring a multidisciplinary approach. The world of nuclear medicine is facing a similar an evolutionary shift in focus - from function at the organ / tissue level to changes at the molecular level. Increasingly, nuclear medicine is being coupled with other medical modalities to improve diagnostic accuracy and optimize patient care. The importance of nuclear medicine in this evolution is undeniable, as molecular imaging breakthroughs stem directly from nuclear medicine tools and techniques. Given the evolutionary shift of the field, however, maintaining a sole focus on nuclear medicine without incorporating other imaging modalities would limit our understanding of how diseases will be diagnosed and treated in the future. SNM members have the collective expertise to advance the science, technology and application of both nuclear medicine and the expanding field of molecular imaging for the benefit of patients. As a result, we will continue to push the Society to the cutting edge of disease diagnosis and treatment by expanding our programming and focusing on the imaging specialties that are so closely related to nuclear medicine. In looking ahead to the future, SNM membership will be essential as we provide a unique knowledge base and continue to ensure that our members are at the forefront of their profession as well as on the cutting edge of patient care.

Overall: The greatest benefit SNM can provide to members is to keep them abreast of the developments and evolution in the field. The society will continue to deliver peerless education to expand your knowledge base and ensure that our meetings provide rich collaboration opportunities across disciplines. Technologists – SNM will help members anticipate changes in the field that impact their overall competitiveness. SNM will be a window to innovation, and our focus on molecular imaging will allow technologists to enhance their levels of practice and acquire new skills needed to stay current with technically complex SPECT, PET and CT imaging as the field moves towards a multi-modality focus. Physicians – SNM will help translate multi-modality breakthroughs from the lab into practical tools physicians can use to improve diagnostic accuracy. This will expand treatment options for patients with once debilitating and incurable diseases and improve accuracy in disease diagnosis/treatment, which will ultimately lead to lower costs in providing patient care. Scientists – SNM will foster a multi-disciplinary community focused on bringing the “bench to the bedside.” Imaging-focused education provided through our Centers of Excellence, coupled with our unique publishing capabilities across different disciplines ensures that our science is well positioned in an evolving field. Corporate – Members have the unique benefit of working with the one organization that has the collective expertise and corporate support to advance the science, technology and application of molecular imaging.


Audience “What are we doing?” (SNM’s objectives)

“Why are we doing it?” “What is the benefit to you?”

Medical Community (Outside SNM membership)

1. Promoting MI diagnostic

and therapeutic initiatives to patient advocacy groups to increase awareness in the broader medical community.

2. Outreach to physicians and

medical professionals in a variety of specialty areas in order to expand the role and visibility of molecular imaging in research and patient care.

Diagnosing and treating disease is becoming increasingly multi-modal, with teams of physicians collaborating on treatment options and outcomes. Clearly, patient care is in a period of evolution. The world of nuclear medicine is facing a similar evolution whereby the focus on diagnosing and treating disease at the organ / tissue level is being replaced with a focus on changes at the physiological / molecular level. Increasingly, nuclear medicine is being coupled with other medical modalities such as molecular imaging technology to improve diagnostic accuracy and optimize patient care. SNM is in a unique position to further the evolution of patient care by bringing our community of physicians, scientists, technologists and industry to the table to discuss the translation and application of new technologies. SNM provides the latest information and hands on tools to ensure that our members stay current with developments in the field and have the collective expertise and support to advance the science, technology and application of nuclear medicine and molecular imaging for the benefit of patients. SNM’s collaboration with other organizations in the medical community such as (insert relevant groups here), as well as broad industry support, will ensure that the physicians providing patient care are well informed about the direct benefits that nuclear medicine and molecular imaging can bring to enhance diagnostic accuracy and improve patient care. SNM membership and support will play a critical role in the medical community as we provide a unique knowledge base and continue to ensure that our constituents are at the forefront of their careers as well as on the cutting edge of patient care.

A multi-modality focus on imaging to diagnose and treat disease will provide doctors and medical practitioners with the most scientific, cutting edge approach to improving patient care. SNM is committed to collaboration, and to ensuring that new technology is embraced at the practical level. In short, SNM knows that the medical community can best diagnose and treat disease by working together and sharing knowledge to optimize treatment outcomes. SNM’s instrumental role in translating multi-modality breakthroughs from the lab into tools physicians can use in improving their diagnostic accuracy will allow for the optimized treatment of patients with once debilitating and incurable diseases. Furthermore, improved accuracy in disease diagnosis/treatment will inevitably lead to lower costs in patient care. SNM’s “Bench to Bedside” capital campaign ensures that the association has the support of key industry participants who are committed to ensuring that the evolution to molecular imaging is supported through training, awareness and outreach. Ultimately, in order for MI techniques to improve patient care, physicians must have documented proof that outcomes are improved by the use of new technologies. SNM is working to build the appropriate infrastructure and relationships to further define and disseminate this evidence.


Success Stories #1: Expanding Education to Meet the Needs of an Evolving Field Issues SNM recognizes how examining the development and management of diseases at the cellular level will impact future patient care diagnosis, predicting treatment response and monitoring individualized treatment plans. As the rate of discovery and introduction of novel molecular imaging technologies escalates, as the field continues to evolve and as members are expected to be “experts” in areas of existing and emerging technology that impact patient care, the need for effective education across a broad spectrum of research, clinical practice and basic science becomes increasingly important, ultimately ensuring members’ continued relevance in a changing field. Actions SNM is working on a variety of cutting edge initiatives, including: MI Industry Summit: SNM hosted a collaborative summit with industry partners on ‘‘Molecular Imaging: Shaping the Future,’’ July 27–30, 2006. The purpose of the summit was to bring together molecular imaging academic and practice innovators with industry leaders to discuss, explore and expand on molecular imaging issues with the end goal of providing recommendations and future direction. Results MI Industry Summit: This summit featured educational sessions focused on developments in the field of molecular imaging, including: Drug discovery – Focused on the application of molecular imaging methodologies to the

identification of promising drug agents. Clinical issues – Addressed the challenges confronting the transition of molecular imaging

from research to the clinical area as well as the development of emerging molecular imaging technologies and their clinical applications.

Research issues – Focused on research underway within molecular imaging as well as trends / challenges likely to be encountered in the near future.

Instrumentation and animal models - Addressed issues and challenges relevant to the pivotal position of animal models in the growing research focus on molecular imaging in a range of applications.

Standardization in education – Focused on the need for continued standardized areas of practice and education within molecular imaging.

A number of consistent conclusions emerged, including the need for: Standardization: The need for shared standards in all aspects of research and practice in

molecular imaging was emphasized as central to progress in creating the sound scientific base that will support novel discoveries, fast bench-to-bedside translation and the generation of solid data for cross-boundary cooperative studies and regulatory approval.

McKinley Marketing Inc. 5

Education: An emerging scientific field demands new professionals and innovative approaches to attracting the best and the brightest. There is a critical need to attract and train physicians and scientists for what promises to be a multidisciplinary endeavor that will draw on fields as diverse as biochemistry, organic chemistry, genetics, bioengineering, optics, medical imaging, medical physics, radiation oncology and many others. The central challenge here is that scientists with this multidisciplinary approach are urgently needed. As a result, establishing new molecular imaging curricula in medical schools, graduate medical training, scientific PhD programs and continuing scientific and medical education takes on central importance.

Draft: SNM Messaging Platform

Cooperative change management: The field of molecular imaging constitutes an exciting yet ever-moving target. Summit participants agreed that the most difficult challenge for planning any aspect of the field is to devise strategies today that are likely to remain relevant and effective tomorrow. The only way that rapid advances in science and technology can be managed effectively for the optimal benefit of health and disease is through open discussion, cooperative work and iterative strategic efforts carried out jointly by representatives of the molecular imaging community.

It is important to note that changes to SNM’s strategic plan have been implemented as a result of the findings uncovered in the MI Industry Summit.


# 2: “Bench to Bedside” Capital Campaign Issues SNM’s “Bench to Bedside” capital campaign is a critical milestone in translating cutting edge science into tools and resources that clinicians can use to improve patient care. The goal of the campaign is to actively address the paradigm shift in the diagnosis and treatment of disease and expand opportunities for molecular imaging to play a critical role in enhancing patient care. SNM realizes the need for an objective, scientifically based organization to marshal financial, legislative and medical support for molecular imaging in an effort to improve patient care. Actions SNM has secured financial commitments in excess of $3.06 million (as of 1/31/07) from key corporate supporters and leaders in molecular imaging dedicated to bringing MI to the forefront of patient care. This active engagement by a range of supporters from the molecular imaging community includes corporations, SNM members and other individuals / entities dedicated to the improvement of patient care. Commitments have been received from the following corporations: GE Healthcare Bristol-Myers Squibb Medical Imaging IBA Molecular Siemens Medical USA MDS Nordion Philips Flourpharma

Results: The “Bench to Bedside” capital campaign will fund: Outreach activities to referring physician and patient groups Translational clinical studies Small innovative trials Research grants and fellowships to advance new medical developments Expanded advocacy efforts

Through the campaign, SNM will also create a broader interface with industry to promote the use of molecular imaging in therapeutic drug development, use of novel molecular therapeutics (such as RIT) and development of new diagnostics. We also expect to achieve the following in the first year: Communications Develop new community website and listserv Develop case studies and brochures that illustrate practical benefits Expand JNM and Newsline coverage Create “Road Show” and other new communications vehicles Design media campaign

Advocacy Outreach to Congressional and Industry stakeholders to raise awareness of molecular

imaging and strengthen relationships Identify new funding sources

Education Initiate clinical research grants and fellowships Develop curriculum outline for fellowships and residents Create a speakers’ bureau


Institute additional workshops, symposia and web-based training on molecular imaging, especially during the SNM Annual Meeting.

Science / Research Support translational clinical studies and small innovative trials Convene meetings and / or workshops to discuss key issues such as new tracer

development, technology assessment and advancement, translational research education, standardization imaging protocols, etc.


#3: Expanding Outreach to Raise Awareness of New Developments Issues Molecular imaging is already benefiting clinical care, but if its myriad of potential benefits are to be realized in practice, the community must work together to define, demonstrate and promote the value of molecular imaging for improvement in health care and lead the transition to personalized medicine. Molecular imaging is evolving rapidly, and will need substantial investment from its constituent communities to see that an infrastructure is put in place and nurtured. SNM is in a position to partner with other organizations to initiate this process and to work to provide the continuous updates and innovation that must accompany accelerated change and growth. Furthermore, SNM understands the critical need to inform / educate the legislative community on ways to enhance patient advocacy efforts. That said, there is a need to keep a watchful eye on developments with federal and state government activities, especially as they relate to funding basic science research and developing guidance documents for investigational new drugs as well as manufacturing practices for drug discovery and development. Actions SNM is reaching out to a number of associations, patient advocacy groups, industry and government in an effort to expand outreach efforts emphasizing the broad implications of molecular imaging on advancing patient care. Results Outreach: SNM is currently reaching out to the following organizations: American Society of Clinical Oncology American Society of Therapeutic Radiology Oncology American Society of Nuclear Cardiology Radiological Society of North America American College of Radiology Commission on Cancer Biomarkers Consortium National Coalition on Cancer Research Pharmaceutical companies (such as Merck, GlaxoSmithKline, Novartis, etc.)

Advocacy: Furthermore, although SNM already has a history on working closely with government entities on legislative / regulatory issues, the Society is continuously looking to strengthen relationships with Federal Agencies and Congress by engaging in the following regulatory and legislative efforts relative to patient advocacy: Congressional outreach campaign to take place at the Annual Meeting (June 2007) Increasing dialogue with regulators Introducing programs to address new physician regulatory requirements; MOC and practice

standards with related promotional and educational programs Aggressive efforts to restore and increase Federal funding for MI; includes education of

regulators / legislators as well as patient advocacy Industry collaboration: Additionally, SNM collaboratively launched an FDG Survey with industry stakeholders.


SNM Rebranding Launch Plan Prepared by: SNM Marketing I. Executive Summary Over the past year SNM has worked towards the identification of a new brand that will reflect the Society’s updated organizational focus. As the field of nuclear medicine shifts towards molecular imaging, Society leadership saw the need to take a proactive role to remain at the cutting edge of the field, and relevant to our members. A new brand image will help SNM transition into the new “space” of molecular imaging. By working with various consultants, we have identified the attributes of the new SNM brand as well as a graphical representation of the brand (ie logo). As we prepare to launch the brand we need to keep in mind that what we are launching is not just a new “look” for SNM, but rather a refreshed focus on how we serve our members. Messaging should focus on topics that will resonate with our members, such as what this means to them and how they can benefit. Additionally the launch of the new brand will incorporate the release of our new web site. II. Messaging McKinley Marketing has created a messaging platform to be used in the communication of the brand to varied audiences such as members and the outside medical community. While the messaging will be useful to tell the whole story, we also need to break it into sound bites to be used to capture the audiences’ attention leading up to the launch at Annual Meeting. The concept we had devised for the pre-launch campaign is “Shaping The Future”. This concept addresses four of the five brand attributes, and positions SNM as vital, credible, influential and evolving. The concept also addresses the primary message conceived by McKinley—that SNM will provide a unique knowledge base as our membership moves forward into the future. In that way we are shaping the future of the field, and the future of those involved in the field, i.e. our members. III. External Launch Campaign Strategies & Deliverables Our goal during the launch campaign is to capture our audiences’ attention and let them know that SNM is going through a change. We will explain how the changes will affect them as we move forward, and how they will benefit from the changes. It is our hope that by reaching out to our membership before the Annual Meeting, we will create excitement and they will be “ready” for the change. Our strategy is divided into 3 parts. The first part addresses the pre-launch activities that occur before Annual Meeting. The second part will address what will happen onsite at the Annual Meeting. A third part of the campaign will also be implemented to address ongoing communications with our members after the initial launch. This ongoing communication will be essential to ensuring our members are “in the loop” and don’t feel left out by the change.

Part I: Pre-launch While we are working with a limited budget, we will produce severable deliverables leading up to the Annual Meeting. These pieces will help create excitement and expectation leading to the meeting. We will detail the message for each piece below. Postcard 1: April Message: First glimpse at new SNM logo, shaping the future message, unveiling during AM07 Audience: all SNM members Budget: $3500 (possibly less if 2 color) To print: April 6 Mail date: April 18 Postcard 2: May Message: Unveiling of web site at/during AM07 Audience: all SNM members Budget: $3500 (possibly less if 2 color) To print: April 30 Mail date: May 14 JNM Cover Wrap (June issue) Message: web site unveiling at AM, shaping the future Audience: all JNM subscribers (members and institutions) Budget: approx. $800 apply tip-on $1500 postage JNM/JNMT Advertisements (May/June) Message: to echo postcards, design should be eye catching (limited text, lots of color) Audience: JNM & JNMT readers Budget: N/A Letter from CEO May: focus on rebranding June: Sandler farewell issue, look to past and future Email blasts #1 Pre-launch (April) Message: come to plenary to hear about new SNM Send date: April 25 #2, #3 Pre-launch (May) Message: new website to be launched at AM (design template to look like new SNM web site), why new web site, features of site (potentially replace Quickread for one-two weeks) Audience: all SNM members, audiences Send date: May 21 Ammo Box Mailing Message: launch of new brand and website Budget: $200 postage

Mail date: June 4 Press Releases Message: SNM to launch new identity, web site and new organizational focus (message will be included in most pre-meeting press releases) Audience: Medical Imaging pubs, reporters Letter to AM07 participants Message: add message to letter sent by Meetings encouraging them to come to plenary session Audience: AM07 pre-reg attendees Part II: Onsite During the Annual Meeting we will use the new brand extensively while we have the attention of over 6,000 onsite attendees. SNM Booth Message: new SNM colors, logo, futuristic molecular concept Audience: all AM attendees Budget: included in AM budget Polo shirts for staff at Plenary Session Message: SNM logo/colors Audience: all attendees of plenary session Budget: 50 @ $15 = $750 Giveaways for Plenary Session Message: SNM logo/colors Audience: all attendees of plenary session Budget: 1000 pieces @ $1 = $1,000 Video/Slide Presentation Message: Launch new logo, organizational focus Audience: Plenary session attendees (later posted to SNM web site for members and visitors, may also be used in email blast) Budget: $5,000 Email blasts #1 Launch of web site Message: check out new SNM web site, key features (use design template that echoes SNM site) Send date: June 2 #2 Launch of new brand Message: SNM unveils new organizational focus at AM Send date: June 11 InfoSNM Computer Session Audience: Session attendees (June 4)

Message: The session will provide a virtual tour of the new SNM Web site, focusing on educational resources and information. In addition, SNM’s new Online Courses, Lifelong Learning and Self-Assessment Program and Interactive PET/CT and Diagnostic CT cases will be demonstrated. Program Book Ad Message: same as June JNM ad Audience: AM attendees Microsite to explain new SNM Website Audience: all SNM members MI Week buttons Buttons to be handed out to those who attend Capital Hill Day, and will be designed to incorporate new colors Audience: Capital Hill Day attendees Total Budget: $16,250 IV. Internal Rebranding Launch In addition to educating our members and the community, the staff will also need to understand the new brand. McKinley Marketing will hold two staff sessions. The first to train the entire staff and the second a more intimate setting for those that have day-to-day contact with our members. The following elements will be covered in the April 17, 2007 staff session. SNM Took Kit The tool kit will serve as a top-level plan to communicate with key constituencies, including staff, volunteers and members. McKinley will train the staff to understand the new brand and how to use it. Brand Behaviors Good customer service skills are essential in carrying out the new brand. Staff will be trained to demonstrate the brand attributes we want our members to associate with SNM. Brand Standards Guideline A set of guidelines will be developed to help govern the use of the new brand identity. The guide will consist of templates for usage while supporting creativity with the framework of the brand model. V. Ongoing Plan for Rebranding After the Annual Meeting is over we will continue to work to disseminate the messages to our membership as well as the medical community. This will include a redesign of most of our existing marketing materials, on an as-needed basis. Also, we will utilize the approved messaging whenever possible in our new marketing materials. Deliverables include:

Stationary Suite Design and Printing Redesign of all stationary products to include letterhead, envelopes (various sizes), business cards, etc. New Media Gateway Work with NMG to incorporate new logo and color palette into existing templates. Old templates still in use will have to be redesigned to incorporate new logo. House Advertisements House ads will be revamped to include new logo. If the ad utilized blue color scheme it will have to be redesigned to incorporate new color palette. Email Blasts Launch of new products to reflect new brand (post-meeting) Message: new logo products now available Ongoing email communication about new web site features as necessary Membership brochure New membership brochure will be created to echo new SNM value proposition and brand attributes. Power Point Presentation New template will be created that incorporates new logo and color palette Publication templates Publications, both print and electronic, will be revamped to include new logo.

SNM Public Relations Plan 2005–08 Molecular Imaging Public Relations Components 2007–08, 2008–09

Overview The following plan details the proposed public and media relations activities of the in-house public relations team and outside PR consultants for SNM and molecular imaging PR campaigns, beginning with last fiscal year. The SNM media relations campaign is designed to raise awareness of the society, its members, its mission, and molecular imaging and nuclear medicine. The molecular imaging campaign seeks to raise awareness of the emerging science and to demonstrate SNM’s position in the medical field in relation to molecular imaging science. The PR plan builds on itself each year by adding additional PR and media relations activities. The molecular imaging PR plan is described separately. The activities are similar to those of the SNM PR campaign; however, the molecular imaging campaign requires its own messages, media lists, media pitching, media tracking, etc. SNM staff continues the work of the society’s three-year plan—integrating molecular imaging messages—while supervising Bendure Communications consultants who are responsible for the bulk of work related to the molecular imaging rebranding/campaign.

SNM Public Relations Plan Year 1 (March 2005–06)

Media Activities: Accomplishments Researched/wrote monthly press releases for JNM articles and quarterly JNMT articles Researched/wrote press releases for products, services, awards, etc. Researched/wrote JNM/JNMT columns with officers Researched/wrote articles for trade publications (i.e., Advance, RT Image) Fielded media queries Developed, refine media lists Began Web site pressroom work Tracked media coverage of SNM and JNM/JNMT Media trained SNM and SNMTS leaders (at 2005 Annual Meeting; no budget for activity)

Message Development: Accomplishments Developed content including media folder, fact sheets, SNM mission and goals, structure and profile of

leaders, FAQs and stats, materials for public and government relations distribution Determined key messages with leadership in 2004 Determined key audiences with leadership in 2004 Completed metatag development (as budget allowed)

External Communications: Accomplishments Explored developing a Web site pressroom Received PR Committee support for press queries

Meeting Coordination and Development: Accomplishments Attended SNM Mid-Winter Educational Symposium Attended SNM Annual Meeting; coordinated pressroom and press conference

Additional Support: Accomplishments Monitored other organizations’ Web sites as time allowed Began research of existing materials as time allowed

SNM Public Relations Plan Year 2 (2006–07) Media relations and PR activities continued and new activities were added for year 2. New focus included developing a pressroom for the Web site, using media stories to promote SNM and JNM/JNMT, and tracking media and reporting successes to the leadership.

Media Activities: Accomplishments Researched/wrote monthly press releases for JNM and quarterly JNMT articles Researched/wrote press releases for products, services, awards, etc. Researched/wrote JNM/JNMT columns with officers Researched/wrote articles for trade publications (i.e., Advance, RT Image) Handled media queries Refined media lists Tracked media coverage of SNM and JNM/JNMT; created and distributed reports Began actively pitching stories; promoted SNM experts to select media outlets Developed story lines, media packages on molecular/nuclear imaging experts (to be offered as op-ed or

bylined article) Kept current with hot topics and angles SNM can pursue to position its members as experts to be

interviewed/quoted

Planned Send media kits to reporters (no budget) Media train SNM and SNMTS leaders and those placed at important meetings (no budget) Notify reporters when pressroom is operational (under development)

Message Development: Accomplishments Updated SNM media materials including: media folder, fact sheets, SNM mission and goals, structure and

profile of leaders, FAQs and stats, an image library, materials for public/government relations distribution Refined key messages with Public Relations Committee Refined key audiences with Public Relations Committee

Planned Continue metatag development (completed in 2005–06; needs to be revised with molecular imaging

activities, no budget)

External Communications: Accomplishments Began work on identifying and placing possibly recovering patients at important meetings and as sources

for articles Began direct outreach: contacted reporters Developed story lines with staff and leadership

Planned Worked with SNM’s IS staff to explore offering a more consumer-friendly Web site (under development)

Meeting Coordination and Development: Accomplishments Attended SNM Mid-Winter Educational Symposium Attended SNM Annual Meeting; coordinated pressroom and press conference

Planned Survey Annual Meeting reporters Determine a branding event to generate press interest at SNM Annual Meeting

Additional Support: Accomplishments Continued monitoring and analysis of other organizations’ Web sites as time permits and report Completed addition of “Member News” section of Web site Continued research of existing materials as time allowed

SNM Public Relations Plan Year 3 (2007–08) Media relations and PR activities will continue and build for year 3 with a new focus on external communications activities including articles, op-eds, etc., as well as media training opportunities for members (if budget allows). Future activities include identifying and holding a media event to draw more focused coverage; developing closer relationships with key media representatives; actively pitching stories; and professional media training for spokespersons.

Media Activities Research/write monthly press releases for JNM and quarterly JNMT articles Research/write press releases for products, services, awards, etc. Research/write JNM/JNMT columns with officers Research/write articles for trade publications (i.e., Advance, RT Image) Field media queries Refine media lists, begin pitching JNM stories to national consumer media Notify reporters that pressroom is operational; update as needed Track media coverage of SNM and JNM/JNMT and create and distribute reports Continue to actively pitch stories; promote SNM experts to select media outlets Continue to develop story lines and media packages on molecular/nuclear imaging experts (can be offered

as op-ed or bylined article) Send media kits to reporters (if budget allows) Media train SNM and SNMTS leaders (if budget allows) Keep current with hot topics and angles SNM can pursue to position its members as experts to be

interviewed/quoted

Message Development Update SNM media materials including: media folder, fact sheets, SNM mission and goals, structure and

profile of leaders, FAQs and stats, an image library, materials for public and government relations distribution

Continue refining key messages (with molecular imaging emphasis) Continue refining key audiences Continue metatag development (completed in 2005–06; needs to be revised with molecular imaging


External Communications Work on identifying and placing possibly recovering patients at important meetings and as sources for

articles Continue direct outreach: contact reporters Continue to develop story lines with staff, leadership

Meeting Coordination and Development Attend SNM Mid-Winter Educational Symposium Attend SNM Annual Meeting, coordinate pressroom and press conference Hold Annual Meeting survey of reporters Hold a branding event to generate press interest Research radio/television outlets; identify SNM members active in those areas; promote SNM members as

indispensable experts

Additional Support Continue monitoring and analysis of other organizations’ Web sites as time permits and report Continue “Member News” on Web site For councils, chapters: provide resources, such as media training, develop practice manual (if budget

allows)

Molecular Imaging Campaign Public Relation Plan Year 1 (2007–08) The goal of the molecular imaging PR campaign is to develop basic messaging and content for SNM’s molecular imaging initiative and to begin to lay the groundwork among the trade and consumer press to position SNM as the leader and innovator in the field of molecular imaging. SNM staff continues the work of the society’s three-year plan—integrating molecular imaging messages—while supervising Bendure Communications consultants who are responsible for the bulk of work related to the molecular imaging rebranding/campaign. As part of the molecular imaging/rebranding PR efforts, emphasis (press releases, story lines, pitches, etc.) will be placed on promoting SNM’s efforts to guide and enhance health policy and regulatory affairs (HPRA), utilizing messages and advance information provided by HPRA staff. Additionally, the PR consultants will promote initiatives developed by HPRA staff and consultants for the Annual Meeting, including activities such as Capitol Hill visits, awards to key government representatives, special sessions, etc.

Media Activities Promote/support the molecular imaging campaign and related molecular imaging advances in tandem with

the society’s rebranding efforts Promote/support SNM’s efforts to guide and enhance health policy and regulatory affairs (i.e., press

releases, story lines, pitches, etc.) Pitch molecular imaging news angle of JNM/JNMT and SNM articles and stories to the media Pitch advocacy initiatives developed by health policy and regulatory affairs staff for the Annual Meeting Look for op-ed and bylined article opportunities Relay molecular imaging messages through new and established channels Execute extensive trade and consumer media outreach activities for SNM Annual Meeting Expand and update press lists to include wider medical audience and national consumer media Assist with the development of the pressroom Track media coverage of molecular imaging/SNM/JNM/JNMT-related stories; manage clippings Communicate SNM rebranding to trade and consumer media Include molecular imaging messaging in any media training of SNM spokespersons (no budget)

Message Development Develop molecular imaging messaging Promote SNM’s advocacy messages Define molecular imaging target audiences Develop molecular imaging content including Web site content, FAQs, fact sheets, backgrounders, etc. Strengthen emphasis on disseminating news about non-radionuclide research through press releases and by

seeking new article placement opportunities (bylined articles, op-eds) Develop new stories and tailor existing ones to a consumer audience Hold focused brainstorming session with leaders to research/develop suggested key messages, new

channels, new audiences Continue metatag development (completed in 2005–06; needs to be revised with molecular imaging


External Communications Identify patients to be available at important meetings or to serve as resources for news stories Develop initial copy for the Web site Initiate outreach activities concentrating on researching and establishing relationships with related medical

associations and patient advocacy groups

Meeting Coordination and Development Provide molecular imaging materials for SNM exhibits Attend SNM Mid-Winter Educational Symposium and pitch molecular imaging angles to media Attend SNM Annual Meeting, pitch molecular imaging news angles to media

Molecular Imaging Campaign Public Relation Plan Year 2 (2008–09) Media relations and PR activities will continue and build for year 2. The new focus will be on rolling out SNM’s new molecular imaging deliverables with impact and continuing to strengthen SNM as the leader and innovator in the field of molecular imaging. Future activities include identifying and holding a media event to draw more focused coverage; developing closer relationships with key media representatives; actively pitching stories; and providing professional media training for spokespersons. Several molecular imaging activities were removed from the year 1 budget of the molecular imaging campaign PR plan. These items are listed below and suggested for inclusion in year 2.

Media Activities Roll out the rebranding with impact: Plan for the launch, development of materials, mailings, direct media

contact to arrange major features, assistance in implementing the launch at the Annual Meeting in Washington, D.C.; arrangement of media interviews; advice on member communications and mementos; assistance with special events; ongoing media contact and outreach (approximately six months). Provide effective materials that explain the society’s new reach, mission and approach, policy positions, plans for the future and membership. Prompt distribution of those materials to key audiences. Immediately reach all key stakeholders through the media and other communications channels; media attention that reflects the new organization’s leadership, updated mission and priority messages; broader awareness of mission, services and influence on health care issues that translates into expanded membership and sale of products.

An immediate round of interviews of the society’s leadership with key media to provide insights to the transformation process, the rationale behind it, and the value to new and future members. A major outreach mini-campaign tied to the former Nuclear Medicine Week toward the end of 2007, which will afford SNM an excellent opportunity to reach its external audiences.

Media tour for SNM president/Virginia: Take to four cities (i.e., NYC, Chicago, LA, DC) and get them as much media as possible in each market.

Expand and update press lists; researching and developing press lists for new audiences, as resources allow. Prospective members: Purchase individual member lists from other associations.

B roll shoot: crew, editing time, duping (in DC area) Pitch molecular imaging news angle of JNM/JNMT and SNM articles and stories to the media. Look for op-ed and bylined article opportunities Relay molecular imaging messages through new and established channels Execute extensive trade and consumer media outreach activities for SNM Annual Meeting Expand and update press lists to include wider medical audience and national consumer media Refine pressroom content Track media coverage of molecular imaging/SNM/JNM/JNMT-related stories; manage clippings Communicate SNM rebranding to trade and consumer media Media train officers

Message Development Refine molecular imaging messaging Refine molecular imaging target audiences Refine molecular imaging content including; Web site content, FAQs, fact sheets, backgrounders, etc. Continue to strengthen emphasis on disseminating news about non-radionuclide research through press

releases and by seeking new article placement opportunities (op-eds, bylined articles)

External Communications Identify patients to be available at important meetings or to serve as resources for news stories will begin Update copy for the Web site Continue outreach activities concentrating on researching and establishing relationships with related

medical associations and patient advocacy groups

Meeting Coordination and Development Attend SNM Mid-Winter Educational Symposium and pitch molecular imaging angles to media Attend SNM Annual Meeting, pitch molecular imaging news angles to media

Additional Resources Communications audit provides a complete analysis of an organization's communications—internal and/or

external—designed to take a picture of communication needs, policies, practices and capabilities and to uncover necessary data to allow top management to make informed, economical decisions about future objectives of the organization's communication. It also provides valuable data for developing or restructuring communications functions, guidelines and budgets, as well as recommendations for action tailored to an organization's particular situation as uncovered by an analysis of the collected data.

VOCUS: professional edition (e-mail distribution, media contacts, list service, archive/manage clips) NAPS/public service announcements (for radio spot, PSA) Possible ads to mark the rebranding in the key trade press.

SNM Molecular Imaging 2007

Campaign Budget—Updated with Projections 4/1/07

The following initiatives have been identified for resource allocation for the upcoming 2007 fiscal year: I. Develop MI Web site. A major focus of the campaign will be to develop resources for the molecular imaging community. Establishment of a sophisticated Internet vehicle to convey MI efforts is critical to the success of the campaign. The site will address a wide variety of molecular imaging modalities and include information, education and training and resources for the networked MI communities. As per Strategic Plan Initiative A1 (2): $30,000 II. Develop a speaker’s bureau of noteworthy experts in the field of molecular imaging to deliver educational programs to the SNM grassroots chapters. This will require administrative support, scheduling assistance and coverage of travel expenses. As per Strategic Initiative A1 (5): --n/c III. Creation of a task force of MI experts and MICoE directors to develop consensus on terms, definitions, and conditions regarding MI initiatives. This will provide the foundation of the SNM MI outreach, advocacy and industry relations efforts. To achieve this, SNM will convene a task force and a series of facilitated workshops and material (i.e., the white paper from the July 2006 MI Summit). It will be necessary to provide resources for meeting space, meals, travel and other incidentals to achieve this objective. As per Strategic Plan Initiative A1 (6): --n/c IV. A major strategy of the SNM MI plan is to elevate MI technologies within the academic and research communities. A key element of this strategy is the creation of an awards program that promotes MI-related scientific abstracts, grants and fellowships. It will be necessary to convene a task force composed of MI experts, scientists, industry representatives and academicians to create a comprehensive awards program that promotes scientific endeavors. This task force will require funding for meetings, travel, and printing, postage, etc. As per Strategic Plan Initiative A2: --n/c

Confidential SNM MI 2007 Budget Projections - Page 1 4/10/2007

V. Support of the blossoming technology of MI will require a considerable commitment from the academic community to develop curricula, standards and educational platforms. To support this, it will be necessary to create a curricula task force comprised of educators, program directors, and other representatives to begin discussions regarding a curriculum in molecular imaging. Costs associated with this endeavor will include travel, meeting space, printing, consulting, printing, etc. As per Strategic Plan Initiative A3: $10,000 VI. Current recognition of MI outcomes is reasonably low within the medical community, the regulatory community, the legislative community, the funding community, the scientific community and the general public. The distinct diagnostic and therapeutic advantages of MI will need to be communicated to differentiated audiences. To achieve this, it will be necessary to create a comprehensive database (including data collection, merge/purge, dupe checks, data processing time, etc.) of various audiences for SNM’s outreach, funding and advocacy strategies. As per Strategic Plan Initiative BI (1): --n/c VII. It will be necessary to recruit and staff new SNM positions (staff and/or consultants) that are dedicated to achieving the deliverables contained within the SNM MI Strategic Plan. Definitions, standards, information and techniques will need to be developed and disseminated to various audiences to support the therapeutic applications of MI. This will require the engagement of a highly skilled individuals with expertise within the regulatory, corporate and science disciplines. In addition, campaign deliverables will require staff with project management experience with a high degree of media relations, with specific emphasis upon message development, media strategies to influence divergent constituencies, and exposure to print campaigns. Included within this budget allocation are direct labor expenses, fringe benefits, and other ancillary employment expenses. As per Strategic Plan Initiative (or in a support capacity) A1 (4), A1 (6), B1, B2, C1, D3, E2: $205,000 VIII. Integrating the SNM MI platform within external organizations is a critical component to the campaign. Groups of organizations within the medical association community, the research community and pharmaceutical community will be vital aspect to developing momentum to adopt molecular imaging objectives. Current plans call for planned interaction with five organizations from each of these three communities in an effort to build collaboration for common MI initiatives. Achievement of this campaign deliverable will require funding for travel, support, meetings space, food and beverage and other incidental expenses. As per Strategic Plan Initiative B1 (2) --n/c


IX. A key element of the campaign is to raise awareness within the research community of the critical need to invest in MI research efforts. This will require that SNM develop a comprehensive portfolio of potential partners within the foundation community. This information would include organizations, funding cycles, key foundation leaders, and efforts to determine if there are any existing relationships between current SNM leaders and the foundation community. This will require an investment of approximately 30% of the time of a current associate within the SNM Development department to collect this information, initiate foundation meetings, brief SNM staff/leaders about foundation meetings. As per Strategic Initiative Plan Initiative D4. $5,000 X. Development of standardized imaging protocols, outcome measure and the role of biomarkers in clinical trials is a major goal. A series of workshops is being planned for establishing a plan to bring emerging technologies into clinical practice. Resources are required for travel, meeting, food, and ancillary costs. As per Strategic Initiative Plan Imperative D5. $50,000 XI. Inasmuch as a primary focus of SNM will shift to reflect the MI initiatives, the organization’s brand must be revised to reflect this shift in emphasis. To that end, SNM has compiled exhaustive market research to develop a rebranding strategy. Within the next 6–9 months, SNM will rebrand itself to include logo treatment, color palette, internal communications templates, development of internal marketing tool kits, redesign the SNM core Web site (separate from item 1), redesign all promotional literature, SNM publications, redesign the SNM Mid Winter Meeting and Annual Meeting marketing material, etc. SNM is pursuing the most cost-effective strategies to accomplish rebranding, however it will be necessary to secure consulting advice on rebranding oversight and for Web design. As per Strategic Initiative Imperative E1: $70,000 XII. Foundational public relations materials must be created and changes to reflect the shift in the organization’s brand, and new initiatives must be developed so as to be ready to move forward in the next fiscal year. Key messages will be redefined, audiences will be redefined, press lists will be expanded, materials will be written and updated for print and for the Web site; resources and new relationships (outreach) will be identified and developed so as to be in place for the next stage of the campaign. A communications audit will be conducted, spokespersons will be further educated, and article placement opportunities will be generated and used. Consultants will be utilized for resources (such as press lists), writing and expertise. As per Strategic Initiative Imperative E2: $59,000 XIII. A publication is planned containing the issues and recommendations from the molecular imaging summit held in July. This publication will summarize and discuss the


current and future state and possibilities of the science and the profession. The publication will be written, published, and disseminated with the journal in print and on CD. As per Strategic Initiative Imperative C1: $14,000 Total Expenses $443,000 XIV. A key element of the campaign is to raise awareness about the Campaign and SNM within the molecular imaging community. SNM began this process by creating communications vehicles for the Molecular Imaging Center of Excellence that can be used as a foundation for additional community-wide activities in subsequent years. (Welcome Packet with CD of MI References; Quarterly Newsletter, Email Blasts)

$8,500 XV. The 2007 SNM Annual Meeting location in Washington, DC coincides with SNM’s launching of the rebranding and molecular imaging initiatives. This provides an ideal and unique opportunity to cultivate relationships with key Congressional and Federal agency policymakers. A comprehensive program has been developed. $50,000 XVI. The 2007 SNM Annual Meeting will feature a new element, a Molecular Imaging Gateway. This new feature will provide complimentary space for academic and government molecular imaging centers to highlight SNM’s broadened mission and to inform and educate SNM members and meeting participants about molecular imaging. $7,000 XVII. MI Campaign Advisory Board Update Meetings $7,000 XVIII. Staff Travel/Conference Calls (for all Task Forces combined) $6,000 REVISED Total Expenses $521,500


Molecular Imaging: Shaping the Future

The Ritz-Carlton, Key Biscayne, Florida July 27-30, 2006

Final Agenda

Thursday, July 27: 7:00-8:00pm Welcome Reception

Room: Salon 1 Friday, July 28: 7:30-8:00am Continental Breakfast 8:00-8:30am Introduction and Welcome Martin Sandler, MD Mathew Thakur, PhD 8:30-9:30am Keynote Presentation Steven Gutman, MD - FDA

Invivo Biomarkers in Dx; FDA Regulations & Industry/Academia Partnership

9:30-10:45am SESSION ONE

Drug Discovery Presentations (15 minutes each) • Trends in innovation in drug discovery (Steven Bodovitz, MD) • Light Activated Gene Therapy, New Selective Therapies for

Disease (Richard Pestell, MD, PhD) • Rational Design for Peptide drugs (Eric Agdeppa, PhD) • Therapeutic applications of antibodies

(Chaitanya Divgi, MD, PhD) • Recent Advances in Biomarkers for diagnosis and treatment

(Juri Gelovani MD, PhD)

10:45-11:00am Questions & Answers 11:00-11:15am Break

11:15-12:30pm SESSION TWOClinical Issues (15 minutes each) • Molecular Imaging in Clinical Area (Steve Larson, MD) • F-18-FDG Imaging: Molecular or Functional? (Steve Larson, MD) • Molecular Imaging: Molecular Imaging: A tool for developing

CNS Drugs (David Mozley, MD) • What is the role of Molecular Imaging in Management of

Cardiac disorders? (Albert Sinusas, MD) • From clinical trials to prescriptions (Adrian Nunn, MD)

12:30-12:45pm Questions & Answers 12:45-1:30pm Lunch

Room: Salon 3 and 4 1:30-7:30pm Free Time 7:30pm Dinner

Room: Salon 3 and 4 Saturday, July 29: 7:30-8:00am Continental Breakfast Room: Ponce De Leon Room 8:00-8:30am Overview 8:30-9:45am SESSION THREE

Basic Research (15 minutes each) • Oncogene Cell differentiation/Cell transduction

(David Geho, MD, PhD) • Recent Trends in Radionuclide based Molecular Imaging

(Mike Welch, PhD) • Role of MR in Molecular Imaging (John Gore, PhD) • Optical Imaging: Progress and Perspectives

(Lihong Wang, PhD) • Radiologic Approaches to Molecular Imaging

(Calum Avison, PhD)

9:45-10:00am Questions & Answers 10:00-10:15am Break

10:15-10:45am SESSION FOURInstrumentation/Animal Model (15 minutes each) • Animal Model for human diseases: Is there a future without

them? (Cheryl Marks, PhD) • Animal Imaging Equipment: Recent Advances

(Paul Acton, PhD)

10:45-11:00am Questions & Answers

11:00-11:30pm SESSION FIVEStandardization/Education (15 minutes each) • PET Standardization, NIH Findings

(Lalitha Shankar, MD, PhD) • Education and Training Activities at NIBIB (William Heetderks, MD, PHD)

11:30 -11:45am Questions & Answers 11:45-12:30pm Lunch Room: Salon 3 and 4 12:30-6:00pm Free Time 6:00-6:15pm Assignment of Breakouts & Instruction Room: Ponce De Leon 6:15-7:30pm Breakout Sessions Drug Discovery - Room: Cabot Clinical Issues - Room: Plaza 1 Basic Research - Room: Matheson Instrumentation/Animal Model - Room: Munroe Standardization/Education - Room: Osborn 7:30pm Dinner Room: Salon 3 and 4

Sunday, July 30: 7:30-8:00am Continental Breakfast Room: Ponce De Leon 8:00-11:00am Continuation of Breakout Sessions Drug Discovery - Room: Cabot Clinical Issues - Room: Davis Basic Research - Room: Matheson Instrumentation/Animal Model - Room: Munroe Standardization/Education - Room: Osborn 11:00-12:00pm Report Preparation and Checkout 12:00-1:00pm Lunch Room: Salon 3 and 4 1:00-3:30pm Focused Final Presentations by Panel Chairs to Assembly Room: Ponce De Leon

1:00-1:30pm Drug Discovery 1:30-2:00pm Clinical Issues 2:00-2:30pm Basic Research 2:30-3:00pm Instrumentation/Animal Model 3:00-3:30pm Standardization/Education

3:30-4:00pm Wrap-up

Molecular Imaging: Shaping the Future

The Ritz-Carlton, Key Biscayne, Florida July 27-30, 2006

Attendee List William F. Abbott Bracco Diagnostics, Inc. Vice President, Operations General Manager, Nuclear Medicine 107 College Road East Princeton, NJ 08540 609-514-2352 fax: 609-514-2429 [email protected] Dr. Brian Abeysekera MDS Nordion Director, Cyclotron Operations 4004 Wesbrook Mall Vancouver, BC V6T 2A3 Canada 604-228-8952 fax: 604-228-5990 [email protected] Paul D. Acton, PhD Associate Professor, Director of Molecular Imaging Physics Thomas Jefferson University Department of Radiology Thomas Jefferson University 796G main Building 132 South 10th Street Philadelphia, PA 19107 215-955-7238 fax: 215-955-8549 [email protected]

Eric D. Agdeppa, PhD Molecular Imaging Scientist & Reagents Product Manager GE Healthcare, Pre-Clinical Imaging 800 Centennial Ave Box 1327 Piscataway, New Jersey 08855-1327 732-457-8427 fax: 732-457-8166 [email protected] Carolyn J. Anderson, PhD Associate Professor Washington Univ. Med. School 510 S. Kings Hwy Blvd Box 8225 St. Louis, MO 63110 314-362-8427 fax: 314-362-9940 [email protected] Robert W. Atcher, PhD, MBA 2006-07 SNM Vice President-Elect Los Alamos National Lab. Biosciences Division Mail Stop G758 Los Alamos, NM 87545 505-667-0585 [email protected] or [email protected] Malcolm (Calum) J. Avison, PhD Professor Departments of Radiology & Radiological Sciences, Pharmacology Vanderbilt University Institute of Imaging Science Vanderbilt University Medical Center R-1302 MCN 1161 21st Avenue South Nashville, TN 37232-2310 615-322-8359 fax: 615-322-0734 [email protected]

Kathy Bates Director of Development Society of Nuclear Medicine 1850 Samuel Morse Drive Reston, VA 20190 703-326-1194 fax: 703-708-9020 [email protected] Jessica Bede Capintec, Inc. President & CEO 6 arrow Road Ramsey, NJ 07446 201-825-9500 fax: 201-825-4829 [email protected] Terence Beven, MD 3855 Floyd Drive Baton Rouge, LA 70808 225-769-9797 fax: 225-765-1299 [email protected] Steven Bodovitz, PhD Principal BioPerspectives 2040 Hyde Street San Francisco, CA 94109 415-336-2700 [email protected] Kevin Brooks Vice President, Medical Isotopes MDS Nordion 447 March Road Ottawa, ON K2K 1X8 Canada 613-592-3400 x2131 fax: 613-592-0767 [email protected]

Dr. Lynn Buchanan MDS Nordion Chief Scientist, R&D 447 March Road Ottawa, ON K2K 1X8 Canada 613-592-3400 x2150 fax: 613-592-8121 [email protected] Dr. Robert Carretta Mallinckrodt, Inc. Vice President, Medical Affairs PO Box 5840 St. Louis, MO 63134 314-654-3447 fax: 314-654-6433 [email protected] Kam Cheung Biogen Idec Molecular Imaging Discovery Scientist 5300 Research Place San Diego, CA 92122 858-401-5743/617-679-2073 fax: 858-795-9206 Henry M. Chilton Cardinal Health Director, Business Development 32 Palisades Parkway Oak Ridge, TN 37838 865-425-0995 fax: 865-483-1612 [email protected] Sudeep Chandra Philips General Manager for Molecular Imaging 3000 Minuteman Road Andover, MA 01810 Phone 978-659-3291 Fax 978-659-3331 Email [email protected]

Peter S. Conti, MD, PhD 2005-06 Immediate Past President University Southern California 1510 San Pablo Street Suite 350 Los Angeles, CA 90033 323-442-5940 fax: 323-442-5778 [email protected] Mary Anne Dell-Yusko Capintec, Inc. Vice President, Manufacturing 620 Alpha Drive Pittsburgh, PA 15238 412-963-1988 fax: 412-963-0610 [email protected] Louis DePalatis The University of Texas MD Anderson Cancer Center Director, Faculty Business Development 1515 Holcombe Boulevard, #59 Houston, TX 77030 703-563-4875 [email protected] Ward Digby Siemens Molecular Imaging Director, Biomarker Portfolio Management 810 Innovation Drive Knoxville, TN 37932 865-218-2417 fax: 865-218-2752 [email protected] Chaitanya Divgi, MD Chief, Nuclear Medicine & Clinical Molecular Imaging Hospital of the University of Pennsylvania 3400 Spruce Street, Donner 116 Philadelphia, PA 19104. 215-615-3687 fax: 215-349-5843 [email protected]

D. Scott Edwards Bristol-Myers Squibb Medical Imaging Executive Director, R&D 331 Treble Cove Road N. Billerica, MA 01862 978-671-8311 fax: 978-667-3926 [email protected] David Geho, MD, PhD Research Professor George Mason University Center for Applied Proteomics and Molecular Medicine 10900 University Boulevard MS 4E3 Discovery Hall Manassas, VA 20110 703-993-4284 fax: 703-993-4288 [email protected] Juri G. Gelovani, MD, PhD Professor of Radiology and Neurology Director, UT Texas Center for Advanced Biomedical Imaging Research, MD Anderson Cancer Center Chairman, The Department of Experimental Diagnostic Imaging Department of Experimental Diagnostic Imaging, Box 59 713-563-3343 fax: 713-794-5456 [email protected] John C. Gore, PhD Director, Vanderbilt University Institute of Imaging Science Vanderbilt University MCN R1302 Nashville, TN 37232 Ph: 615-322-8357 [email protected] Josh Gurewutz Spectrum Dynamics Vice President, Marketing 2 HaEtgar Street Tirat, HaCarmel, Israel +972-4-858-0774 +972-4-8580776 [email protected]

Steve Gutman, MD FDA Center for Radiological Health Director, Office of In Vitro Diagnostic Device Evaluation and Safety 2098 Gaithers Road Rockville, MD 20850 HSZ-440 240-276-0450x114 [email protected] Elaine Haynes Mallinckrodt, Inc. Group Director Nuclear Medicine Imaging Group PO Box 5840 St. Louis, MO 63134 314-654-8468 fax: 314-654-7281 [email protected] William J. Heetderks, MD, PhD Associate Director for Science Programs National Institute of Biomedical Imaging and Bioengineering National Institutes of Health 6707 Democracy Blvd. Suite 200 Bethesda, MD 20894 301-451-4772 fax: 301-480-1614 [email protected] Peter Herscovitch, MD Chief, PET Department NIH Clinical Center 10 Center Drive MSC1180, Room 1C401 Bethesda, MD 20892-1180 301-451-4248 fax: 301-402-3521 [email protected] Rick Hiatt Siemens Molecular Imaging Vice President, Business Development 810 Innovation Drive Knoxville, TN 37932 865-603-2472 fax: 865-218-2700 [email protected]

Luna Hilaire, PhD GE Healthcare Director, Medical Physics US 101 Carnegie Center Princeton, NJ 08540 609-514-6597 [email protected] D. Scott Holbrook, BS, CNMT, FSNMTS SNMTS President 101 Dilon Court PO Box 8545 Gray, TN 37615 423-477-2440 fax: 423-477-3233 [email protected] Warren Janowitz, MD, JD SNM Board of Directors Baptist Hospital of Miami 8900 N. Kendall Drive Miami, FL 33176 786-596-5917 fax: 305-667-1401 [email protected] Richard Key Bracco Diagnostics, Inc. Director, Nuclear Cardiology 107 College Road East Princeton, NJ 08540 609-514-2571 fax: 609-514-2429 [email protected] Hartmuth Kolb Siemens Molecular Imaging Vice President, Business Development 810 Innovation Drive Knoxville, TN 37932 310-670-2864 [email protected]

Steven M. Larson, MD Chief Nuclear Medicine and Vice Chairman for Research Department of Radiology Memorial Sloan Kettering Cancer Center 1275 York Avenue, NY 10021 212-639-7373 fax: 212-717-3263 [email protected] Cheryl L. Marks, PhD Associate Director, Division of Cancer Biology National Cancer Institute 6130 Executive Blvd., Suite 5000 Bethesda, MD 20892-7380 301 594-8778 fax: 301 496-8656 [email protected] Alexander J.B. (Sandy) McEwan, MD 2006-07 SNM President-Elect Cross Cancer Institute Nuclear Medicine Department 11560 University Avenue Edmonton, AB T6G 1Z2 Canada 780-432-8524 fax: 780-432-8483 [email protected] P. David Mozley, MD Senior Director, Imaging Merck Research Laboratories 770 Sumneytown Pike, WP42-210 West Point, PA 19486-0004 215-652-7525 215-353-8958 cell [email protected] or [email protected] Mike Nelson Chief Operating Officer Society of Nuclear Medicine 1850 Samuel Morse Drive Reston, VA 20190 703-326-1195 fax: 703-708-9020 [email protected]

Adrian D. Nunn, PhD Bracco Research USA, Inc. 305 College Road East Princeton, NJ 08540 609-514-2409 [email protected] Alan B. Packard, PhD Senior Research Associate Division of Nuclear Medicine Children’s Hospital, Boston 300 Longwood Avenue. Boston, MA 02115 617-355-7539 fax: 617-730-0619 Virginia M. Pappas, CAE SNM Chief Executive Officer Society of Nuclear Medicine 1850 Samuel Morse Drive Reston, VA 20190 703-708-9000 703-326-1181 direct fax: 703-708-9020 [email protected] Peter Pattison MDS Nordion Vice President, Pharmaceutical markets 447 March Road Ottawa, ON K2K 1X8 Canada 613-592-3400 x2284 fax: 613-592-8121 [email protected] Richard. G Pestell, MD PhD, FRACP Director, Kimmel Cancer Center Professor, Cancer Biology 233 S. 10th Street, Room 1050 Philadelphia, PA 19107 215-503-5692 fax: 215-503-9334 [email protected]

Todd Peterson, PhD Assistant Professor Vanderbilt University Medical R-1302 Medical Center North Nashville, TN 37232-2310 615-322-2648 [email protected] Martin G. Pomper, MD, PhD Instructor Johns Hopkins University Department of Radiology 600 N. Wolfe Street Phipps B-100 Baltimore, MD 21287-2182 410-955-2789 fax: 410-614-1213 [email protected] Simon P. Robinson Bristol-Myers Squibb Medical Imaging Director, Pre-Clinical Biology 331 Treble Cove Road N. Billerica, MA 01862 978-671-8341 fax: 978-667-3926 [email protected] Anwer Rizvi IBA Molecular President 100 Executive Drive #100 Sterling, VA 20166 703-787-7900 fax: 703-787-4079 [email protected] David Rollo, MD, PhD Philips Chief Medical Officer 540 Alder Drive Milpitas, CA 95070 408-468-3634 fax: 408-321-7435 [email protected]

Martin P. Sandler, MD 2006-07 SNM President Vanderbilt Univ. Medical Center Radiology, CCC-1106 MCN Nashville, TN 37232-2675 615-322-0860 [email protected] Megan Schagrin, CMP Associate Director, Industry & International Relations Society of Nuclear Medicine 1850 Samuel Morse Drive Reston, VA 20190 703-326-1184 fax: 703-709-9274 [email protected] Aldo Serafini, MD Professor of Radiology & Medicine University of Miami Jackson Memorial Medical Center Nucelar Medicine Division (D-57) PO Box 016960 Miami, FL 33101 305-243-6036 fax: 305-243-4913 [email protected] George Sgouros, PhD Dir. Radiopharm Dosimetry Johns Hopkins Medical Institute Dept. of Radiology 720 Rutland Avenue; 220 Ross Rsrch Bldg Baltimore, MD 21205 410-614-0116 fax: 413-487-3753 [email protected] Lalitha K. Shankar, MD, PhD National Cancer Institute Cancer Imaging Program 6130 Executive Boulevard EPN 6048 Bethesda, MD 20892-7412 301-496-9531 [email protected]

Albert J. Sinusas, MD Professor of Medicine and Diagnostic Radiology Yale University 333 Cedar Street, 3FMP P.O. Box 208017 New Haven, CT 06520 203-785-4915 fax: 203-737-1026 [email protected] Walter A. Smith, Jr. Bristol-Myers Squibb Medical Imaging Associate Director, marketing 331 Treble Cove Road N. Billerica, MA 01862 978-671-8471 fax: 978-436-7509 [email protected] Michael G. Stabin, PhD Vanderbilt University Dept of Radiology/Radiological Sciences 1161 21st Avenue South Nashville, TN 37232-2675 615-343-0068 fax: 615-322-3764 [email protected] Mathew Thakur PhD Professor, Departments of Radiology and Radiation Oncology Director, Laboratory of Molecular Imaging and Therapy Thomas Jefferson University 359 Jefferson Alumni Hall 1020 Locust Street Philadelphia, PA 19107 215-503-7874 fax: 215 923-9245 [email protected] Thom Tulip Bristol-Myers Squibb Medical Imaging Vice President, Brand Champion 331 Treble Cove Road N. Billerica, MA 01862 978-671-8352 fax: 978-671-8355 [email protected]

Henry F. VanBrocklin, PhD Lawrence Berkeley Labs 1 Cyclotron Road MS55/121 Berkeley, CA 94720 510 486-4083 fax: 510-486-4768 [email protected] JeanLuc Vanderheyden GE Healthcare Molecular Imaging Leader 3000 N. Grandview Boulevard Waukesha, WI 262-544-3802 fax: 262-871-7070 [email protected] John Viscovic Capintec, Inc. Vice President, National Accounts 6 Arrow Road Ramsey, NJ 07446 201-825-9500 fax: 201-825-4829 [email protected] Lihong Wang, PhD Royce E. Wisenbaker II Endowed Professor of Engineering Texas A&M University 3120 TAMU (337 Zachry Bldg.) College Station, TX 77843-3120 979-847-9040 fax: 979-845-4450 [email protected] Michael J. Welch, PhD Co-Director, Division of Radiological Sciences Washington University School of Medicine Mallinckrodt Institute of Radiology 510 S. Kingshighway Blvd., CB 8225 St. Louis, MO 63110 314-362-8436 fax: 314-362-8399 [email protected]

Joseph C. Wu, MD, PhD System Professor Stanford University School of Medicine Edwards Building, Room R354 Stanford, CA 94305 Ph: (650) 736-2246 Fx: 650-736-0234 [email protected] Michael R. Zalutsky, PhD Professor of Radiology Duke University Medical Ctr. Radiology Dept. Box 3808 Durham, NC 27710 919-684-7708 fax: 919-684-7121 [email protected]

4/10/2007 page 1

AGENDA Molecular Imaging Campaign

Campaign Advisory Board April 6, 2007

Hyatt Hotel (Reston Suite A) - Reston, Virginia Objectives of the Meeting:

Review Campaign Fundraising Progress & Financial Status Approve of Additions to Current Year Budget Review and Endorse Strategic Plan Progress and Deliverables Determine Future Operations of Campaign Advisory Board

Topic Time Discussion Leader

Welcome

1:00 – 1:10 Martin Sandler, M.D.

1. Campaign Advisory Board: Overview and Purpose

1:10 – 1:30 Martin Sandler, M.D.

2. Campaign Report Fundraising Progress

1:30 – 2:00 Peter Conti, M.D., Ph.D. Michael Devous, M.D.

3. Molecular Imaging Center of Excellence –Progress Report Review/Discuss 5 year plan Discussion on Progress of first-year

deliverables Financial Report Additions to Current Year Budget

2:00 – 2:30 Marty Pomper, M.D.

4. Future Plans Discussion of Future Plans – 2nd and 3rd

year deliverables

Marty Pomper, M.D.

5. Other Programs Industry Expert Meeting

Virginia Pappas, CAE

6. Organizational/Administrative Issues Role of Advisory Board/Corporate

Circle Members Structure - Appointment of Chair Procedures Reporting mechanisms Meeting frequency, location, schedule

2:30 – 3:00 Martin Sandler, MD

Adjournment 3:00

Campaign Advisory Board Attendee List

SNM Leadership

Martin P. Sandler, M.D. SNM President Vanderbilt University Medical Center Department of Radiology and Radiological Sciences Nashville TN 37232-2675 Assistant: Janet Staley Phone: (615) 322-0860 Fax: (615) 343-2330 E-mail: [email protected] E-mail: [email protected]

Alexander J. McEwan, M.D. SNM President-Elect Department of Oncologic Imaging 11560 University Avenue Edmonton AB T6G 1Z2 Canada Assistant: Cheryl Loeffler Phone: (780) 432-8524 Fax: (780) 432-8483 E-mail: [email protected] E-mail: [email protected]

Robert W. Atcher, Ph.D., M.B.A. SNM Vice President-Elect UNM/LANL Professor of Pharmacy Program Manager, HHS Programs Mailstop M888 Bioscience Div. Los Alamos National Laboratory Los Alamos, NM 87545 Phone: (505) 667-0585 Fax: (505) 667-8339 Pager: (505) 996-1956 E-mail 1: [email protected] E-mail 2: [email protected]

Peter S. Conti, M.D., Ph.D. SNM Immediate Past President & Bench to Bedside Co-Chair Professor University Southern California 1510 San Pablo Street Suite 350 Los Angeles, CA 90033 Phone: (323) 442-5940 Fax: (323) 442-5778 E-mail: [email protected]

MI Center Leadership Martin G. Pomper, M.D., Ph.D. President SNM Molecular Imaging Center of Excellence Johns Hopkins University Department of Radiology 600 N. Wolfe Street Phipps B-100 Baltimore, MD 21287-2182 Phone: (410) 955-2789 Fax: (410) 614-1213 E-mail: [email protected]

Henry F. VanBrocklin, Ph.D. Vice President SNM Molecular Imaging Center of Excellence University of California San Francisco Dept of Radiology, UCSF 185 Berry Street, Suite 350 San Francisco, CA 94107 Phone: (415) 353-4569 Fax: (415) 353-9421 E-mail: [email protected]

Carolyn J. Anderson, Ph.D. Secretary/Treasurer SNM Molecular Imaging Center of Excellence Washington Univ. Med. School 510 S. Kings Hwy Blvd Box 8225 St. Louis, MO 63110 Phone: (314) 362-8427 Fax: (314) 362-9940 E-mail: [email protected]

Michael D. Devous, Sr., Ph.D. Bench to Bedside Co-Chair University of TX SW Medical Center Nuclear Medicine Center 5323 Harry Hines Boulevard Dallas, TX 75390-9061 Phone: (214) 648-3315 Fax: (214) 648-5641 E-mail: [email protected]

Hadi Moufarrej Bench to Bedside Co-Chair GM Global Molecular ImagingGE Healthcare 3000 N Grandview Blvd., W1250Waukesha, WI 53188Phone: (262) 312-7334 Fax: (262) 548-5197 E-mail: [email protected] Assistant: Carla Palmer E-mail: [email protected]

Corporate Circle

Richard A Frank, M.D., Ph.D., FFPM Vice President, Medical Affairs and Clinical Strategy GE Healthcare 105 Carnegie Center Princeton, NJ Phone: 609-936-6028 *211 6028 Dialcomm Mobile: (609) 933-0007e E-mail: [email protected] Assistant: Lerina Forster Phone: (609) 936-6029 E-mail: [email protected]

Anwer Rizvi Vice President, Sales IBA Molecular 100 Executive Drive Suite 100 Sterling, VA 20166 Phone: (703) 787-7900 E-mail: [email protected]

Matt Shah Director, Strategic Planning Siemens Medical Solutions USA, Inc. Molecular Imaging 2501 North Barrington Road Hoffman Estates, IL 60195 Phone: (847) 304-7370 Mobile: (847) 910-8419 Fax: (847) 304-7707 E-mail: [email protected]

Peter Kingma Vice President, Molecular Imaging Siemens Medical Solutions USA, Inc. 51 Valley Stream Parkway Malvern, PA 19355 Phone: (610) 448-4990 Mobile: (610) 772-1968 E-mail: [email protected]

Thomas H. Tulip, Ph.D. Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road Building 600-1 N. Billerica, MA 01862 Phone: (978) 671-8048 E-mail: [email protected]

SNM Staff

Virginia M. Pappas, CAE Chief Executive Officer SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1241 Fax: (703) 708-9020 E-mail: [email protected]

Michael S. Nelson, CAE Chief Operating Officer SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1024 Fax: (703) 708-9020 E-mail: [email protected]

Megan Schagrin Associate Director, Industry & International Relations SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1214 E-mail: [email protected]

Pandora C. Rivera Program Manager, Leadership SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1027 Fax: (703) 708-9020 E-mail: [email protected]

Kathleen Bates Director, Development SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1028 Fax: (703) 708-9020 E-mail: [email protected]

Marybeth Howlett Director, Molecular Imaging Center of Excellence SNM 1850 Samuel Morse Drive Reston, VA 20190 Phone: (703) 708-9000 ext. 1026 Fax: (703) 708-9020 E-mail: [email protected]

CORPORATE ADVISORY BOARD GUIDELINES Background Advisory boards are used by profit and non-profit organizations to provide senior management with advice and counsel on the execution of its business strategies and objectives. In general, advisory boards include key stakeholders who offer opinions and provide advice from an industry or community perspective. They offer senior management insights into emerging trends and perspectives on the critical issues and concerns of the industry or community they represent. In doing so, they influence management decisions and help the organization deliver a better product, whether it’s a piece of equipment, a social service, or an educational course. Using this concept, the SNM has developed the Bench to Bedside Molecular Imaging Campaign Corporate Advisory Board. As key investors in the Campaign, Corporate Circle industry supporters are invited to help chart the course of the campaign and the activities it funds. Corporate Circle members will serve on the board along with the executive leadership of the SNM, the SNM Molecular Imaging Center of Excellence and the Campaign Co-Chairs. Membership Benefits The SNM is appreciative of the Advisory Board members’ commitment to helping the SNM achieve the goals of the Bench to Bedside Molecular Imaging Campaign and manage the programs as effectively and efficiently as possible. We believe that Corporate Circle advisory board members will also benefit from their service on the board in the following ways:

• Advanced knowledge and preview of Bench to Bedside plans and development • Input and influence into program direction, development and implementation • Opportunity to recommend changes, new ideas • Endorsement of programmatic and financial reports prior to approval by SNM

BOD • Sharing of knowledge and experience among other advisory board members,

leaders of the SNM and of the SNM Molecular Imaging Center of Excellence • Participation in agenda development for the SNM MI Industry Summit • Corporate Circle recognition of support

The following page describes the purpose of the board, board member responsibilities and the operational procedures.

1

CORPORATE ADVISORY BOARD GUIDELINES Purpose: The Corporate Advisory Board has been established to provide oversight, advice and recommendations on the direction, planning and implementation of the Bench to Bedside Molecular Imaging Campaign and the programs it supports. Board Composition:

• Corporate Circle industry representatives • SNM Executive Leadership • Molecular Imaging Center of Excellence Executive Leadership and Campaign Co-

Chairs

Board Term: The Corporate Advisory Board will function over the length of the Campaign.

• Corporate Circle members will serve on the Board as determined by their corporations.

• SNM and Molecular Imaging Center of Excellence leadership and Campaign Co-Chairs will serve while they are in their executive positions.

Chair: The Corporate Advisory Board will determine the chair of the Board and his or her term at its initial meeting. Board Responsibilities: Board members are expected to

• Advise on the campaign’s vision and strategic direction including planning and fund development

• Provide program and financial oversight • Help establish programmatic priorities • Endorse the plan and budget prior to presentation to the SNM Board of Directors

for approval • Monitor outcomes • Evaluate effectiveness of plans and their implementation • Identify emerging trends in industry that will impact molecular imaging • Identify issues and concerns, especially those that are best addressed through

cooperation among campaign stakeholders

Operational Procedures 1. Formal meetings will be conducted twice a year with conference calls arranged as required. 2. SNM staff will manage meeting logistics and develop meeting agendas and materials with input from board members, meeting minutes, action items, reports and operational documents.

2

Corporate Decisions Pending or Additional Contacts Required

• Mallinckrodt-Pending until Covidien is formed• Bracco Diagnostics-Meeting with new Vice President Scott Hollander

must be arranged• Hermes-Second meeting arranged for May-June• Glaxo Smith Kline-Declined support for this year; will continue to

cultivate interst• Merck-Decision pending• Novartis-Meeting with one representative arranged; will continue to

cultivate interest

Current and Planned Solicitations• 130 companies (SNM exhibitors, advertisers, industry coalition members)

received letters in March, with follow up calls to take place beginning mid April.

• Major pharmaceutical companies targeted for direct contacts within the next several months include:

– Sanofi-Aventis– Eli Lilly– Johnson & Johnson

• We are seeking contacts for:– Astra Zeneca – Aventis– Hoffman-La Roche– Pfizer

Molecular Imaging Campaign - Budget 2007 Deliverables Budget Year End Projection I. Creation of a molecular imaging web site that will serve as a central repository and will provide on line information, education, and training in molecular imaging for various audiences.

$30,000 $30,000

II. Create a molecular imaging Speakers Bureau that will provide speakers for scientific or educational meetings, chapter or local meetings. (Will be completed by staff and conference calls–cost reflected in G&A.)

$10,000 0

III. Develop standardized definitions and terminology in molecular imaging that will be the foundation of all communications, advocacy, and education activities. (Completed by conference calls/member work effort–cost in G&A.)

$15,000 0

IV. Recommend new grant and award programs in the area of non-nuclear or multi-modality molecular imaging. (Will be completed by conference calls/member work effort–cost in G&A.)

$15,000 0

V. Create an outline of a curriculum for a resident in molecular imaging. $10,000 $10,000VI. Develop advocacy database of medical associations, pharmaceutical companies, patient advocacy groups and funding agencies for advocacy planning. (Completed by staff and conference calls–cost reflected in G&A.)

$15,000 0

VII. Recruit and staff new SNM positions dedicated to molecular imaging. $150,000 $205,000VIII. Meet and develop relationships with five clinical, five research and five pharmaceutical organizations in Tier 1. (Completed by SNM Leadership, staff, and conference calls–costs reflected in G&A and in SNM Leadership budget.)

$15,000 0

IX. Create a database of funding sources highlighting non-imaging sources of funding for molecular imaging community website.

$15,000 $5,000

X. Convene a workshop(s) to discuss standardized imaging protocols, the next tracers, (and technology assessment).

$20,000 $50,000

XI. Rebrand SNM $50,000 $50,000XII. Develop a major public relations plan. $59,000 $59,000XIII. Publish recommendations from the Industry/Expert Summit in July 2007 $40,000 $14,000TOTAL:

$444,000 $423,000

Draft – For Internal Use Only 4/10/2007 page 1

Deliverables Budget Year End Projection ADDITIONAL ACTIVITIES IDENTIFIED IN STRATEGIC PLAN UNDERWAY

Rebranding – Additional Activities $20,000Create communications vehicles for the Molecular Imaging Center of Excellence that can be used as a foundation for additional community-wide activities in subsequent years. (Welcome Packet with CD of MI References; Quarterly Newsletter)

0 $8,500

Establish and cultivate relationships with NIH, FDA, DOE, NSF, and other federal agencies and Congress that support molecular imaging research to pursue increased support for molecular imaging initiatives. (Extensive Congressional outreach plan to coincide with SNM Annual Meeting.)

0 $50,000

Expansion of the molecular imaging offerings at the 2007 SNM annual and midwinter meetings to inform, education, and train SNM members and meeting participants about molecular imaging.

Complete for 2007. Includes expanded sessions. Planned MI Gateway at the Annual Meeting for outreach/education not in budget.

$7,000

MI Campaign Advisory Board Update Meetings 0 $7,000 Staff Travel/Conference Calls (could be distributed among TFs) 0 $6,000 Subtotal of Additional Items for Year 1 - $98,500New Total Budget - $521,500 ADDITIONAL ACTIVITIES IDENTIFIED IN STRATEGIC PLAN – CONDUCTED WITH EXISTING SNM RESOURCES

Standards Validation Study

SNM Clinical Trials Group budget

$15,000

Red = Communication Green = Education Purple = Advocacy Blue = Science/Research

Draft – For Internal Use Only 4/10/2007 page 2